



(51) International Patent Classification:

C07K 14/005 (2006.01) A61K 38/16 (2006.01)

C07K 14/01 (2006.01) A61K 47/69 (2017.01)

C07K 14/10 (2006.01) A61K 9/51 (2006.01)

C07K 14/155 (2006.01) C07K 14/16 (2006.01)

(21) International Application Number:

PCT/US2021/043151

(22) International Filing Date:

26 July 2021 (26.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/056,125 24 July 2020 (24.07.2020) US

(71) Applicants: **THE GENERAL HOSPITAL CORPORATION** [US/US]; 55 Fruit Street, Boston, MA 02114 (US). **PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, MA 02138-3876 (US).

(72) Inventors: **JOUNG, J., Keith**; 1 Magnolia Way, Winchester, MA 01890 (US). **CABECEIRAS, Peter**; 15 Joy Street, Apartment 6, Boston, MA 02114 (US).

(74) Agent: **DEYOUNG, Janice, Kugler et al.**; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS




FIG. 1

(57) Abstract: Enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise an exogenous gag/pol protein, and methods of use thereof for delivery of the cargo to cells.

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

17 March 2022 (17.03.2022)

ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS

CLAIM OF PRIORITY

This application claims the benefit of U.S. Provisional Patent Application Serial No. 63/056,125, filed on July 24, 2020. The entire contents of the foregoing are hereby incorporated by reference.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government support under Grant No. GM118158 awarded by the National Institutes of Health. The Government has certain rights in the invention.

TECHNICAL FIELD

Described herein are enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise a protein from any human endogenous or exogenous viral gag or pol, and methods of use thereof for delivery of the cargo to cells.

BACKGROUND

Delivery of cargo such as proteins, nucleic acids, and/or chemicals into the cytosol of living cells has been a significant hurdle in the development of biological therapeutics.

SUMMARY

Described herein are enhanced virus-like particles (eVLPs) that are capable of packaging and delivering a wide variety of payloads, e.g., biomolecules including nucleic acids (DNA, RNA) or proteins, chemical compounds including small molecules, and/or other molecules, and any combination thereof, into eukaryotic cells. The non-viral eVLP

systems described herein have the potential to be simpler, more efficient and safer than conventional, artificially-derived lipid/gold nanoparticles and viral particle-based delivery systems, at least because eVLPs have no virus-derived components except for ENV, eVLPs can utilize but do not require chemical-based dimerizers, and eVLPs have the ability to package and deliver specialty single and/or double-stranded DNA molecules (e.g., plasmid, mini circle, closed-ended linear DNA, AAV DNA, episomes, bacteriophage DNA, homology directed repair templates, etc.), single and/or double-stranded RNA molecules (e.g., single guide RNA, prime editing guide RNA, messenger RNA, transfer RNA, long non-coding RNA, circular RNA, RNA replicon, circular or linear splicing RNA, micro RNA, small interfering RNA, short hairpin RNA, piwi-interacting RNA, toehold switch RNA, RNAs that can be bound by RNA binding proteins, bacteriophage RNA, internal ribosomal entry site containing RNA, etc.), proteins, chemical compounds and/or molecules, and combinations of the above listed cargos (e.g. AAV particles) . The eVLPs described herein are different from conventional retroviral particles, virus-like particles (VLPs), exosomes and other previously described extracellular vesicles that can be loaded with cargo because of the membrane configuration, vast diversity of possible cargos that are enabled by novel, innovative loading strategies, the lack of a limiting DNA/RNA length constraint, the lack of proteins derived from any viral gag or pol, and the mechanism of cellular entry.

Described herein are compositions and methods for cargo delivery that can be used with a diverse array of protein and nucleic acid molecules, including genome editing, epigenome modulation, transcriptome editing and proteome modulation reagents, that are applicable to many disease therapies.

Thus, provided herein are eVLPs that include a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins (e.g., as shown in Table 1) on the external side; and optionally a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise any gag and/or pol protein.

Also provided herein are methods for delivering a cargo to a target cell, e.g., a cell *in vivo* or *in vitro*. The methods include contacting the cell with an eVLP as described herein comprising the biomolecule and/or chemical as cargo.

Additionally provided herein are methods for producing an eVLP, e.g., comprising a biomolecular cargo. The methods include providing a cell expressing one or more virally-derived glycoproteins (ENV) (e.g., as shown in Table 1), and a cargo biomolecule and/or chemical, wherein the cell does not express an exogenous gag and/or pol protein; and maintaining the cell under conditions such that the cells produce eVLPs.

In some embodiments, the methods include harvesting and optionally purifying and/or concentrating the produced eVLPs.

In some embodiments, the methods include using cells that have or have not been manipulated to express any exogenous proteins except for an ENV (e.g., as shown in Table 1), and, if desired, a plasma membrane recruitment domain (e.g., as shown in Table 6). In this embodiment, the “empty” particles that are produced can be loaded with cargo by utilizing nucleofection, lipid, polymer, or CaCl₂ transfection, sonication, freeze thaw, and/or heat shock of purified particles mixed with cargo. In all embodiments, producer cells do not express any viral gag protein. This type of loading allows for cargo to be unmodified by fusions to plasma membrane recruitment domains and represents a significant advancement from previous VLP technology.

Also provided herein are cells expressing one or more virally-derived glycoproteins (e.g., as shown in Table 1), and a cargo, wherein the cell does not express an exogenous gag protein. In some embodiments, the cells are primary or stable human cell lines, e.g., Human Embryonic Kidney (HEK) 293 cells or HEK293 T cells.

In some embodiments, the outer surface of the particle could contain scFvs, nanobodies, darpins, and/or other targeting peptides to enable cell-specific entry.

In some embodiments, the biomolecule cargo is a therapeutic or diagnostic protein or nucleic acid encoding a therapeutic or diagnostic protein.

In some embodiments, the cargo is a chemical compound or molecule.

In some embodiments, the chemical molecule is a trigger for protein-protein dimerization or multimerization, such as the A/C heterodimerizer or rapamycin.

In some embodiments, the chemical compound is a DNA PK inhibitor, such as M3814, NU7026, or NU7441 which potentially enhance homology directed repair gene editing.

In some embodiments, the cargo is a gene editing reagent.

In some embodiments, the gene editing reagent comprises a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; a nucleic acid encoding a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; or a
5 ribonucleoprotein complex (RNP) comprising a CRISPR-based genome editing or modulating protein.

In some embodiments, the gene editing reagent is selected from the proteins listed in Tables 2, 3, 4 & 5.

In some embodiments, the gene editing reagent comprises a CRISPR-based
10 genome editing or modulating protein, and the eVLP further comprises one or more guide RNAs that bind to and direct the CRISPR-based genome editing or modulating protein to a target sequence.

In some embodiments, the cargo comprises a covalent or non-covalent connection to a plasma membrane recruitment domain, preferably as shown in Table 6. Covalent
15 connections, for example, can include direct protein-protein fusions generated from a single reading frame, inteins that can form peptide bonds, other proteins that can form covalent connections at R-groups and/or RNA splicing. Non-covalent connections, for example, can include DNA/DNA, DNA/RNA, and/or RNA/RNA hybrids (nucleic acids base pairing to other nucleic acids via hydrogen-bonding interactions), protein domains
20 that dimerize or multimerize with or without the need for a chemical compound/molecule to induce the protein-protein binding, single chain variable fragments, nanobodies, affibodies, proteins that bind to DNA and/or RNA, proteins with quaternary structural interactions, optogenetic protein domains that can dimerize or multimerize in the presence of certain light wavelengths, and/or naturally reconstituting split proteins.

25 In some embodiments, the cargo comprises a fusion to a dimerization domain or protein-protein binding domain that may or may not require a molecule to trigger dimerization or protein-protein binding.

In some embodiments, the producer cells are FDA-approved cells lines, allogenic cells, and/or autologous cells derived from a donor.

30 In some embodiments, the full or active peptide domains of human CD47 may be incorporated in the eVLP surface to reduce immunogenicity.

Examples of AAV proteins included here are AAV REP 52, REP 78, and VP1-3. The capsid site where proteins can be inserted is T138 starting from the VP1 amino acid counting. Dimerization domains could be inserted at this point in the capsid, for instance.

Examples of dimerization domains included here that may or may not need a small molecule inducer are dDZF1, dDZF2, DmrA, DmrB, DmrC, FKBP, FRB, GCN4 scFv, 10x/24x GCN4, GFP nanobody and GFP.

Examples of split inteins included here are Npu DnaE, Cfa, Vma, and Ssp DnaE.

Examples of other split proteins included here that make a covalent bond together are Spy Tag and Spy Catcher.

Examples of RNA binding proteins included here are MS2, Com, and PP7.

Examples of synthetic DNA-binding zinc fingers included here are ZF6/10, ZF8/7, ZF9, MK10, Zinc Finger 268, and Zinc Finger 268/NRE.

Examples of proteins that multimerize as a result of quaternary structure included here are E. coli ferritin, and the other chimeric forms of ferritin.

Examples of optogenetic “light-inducible proteins” included here are Cry2, CIBN, and Lov2-Ja.

Examples of peptides the enhance transduction included here are L17E, Vectofusin, KALA, and the various forms of nisin.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.

DESCRIPTION OF DRAWINGS

FIG 1: Depiction of exemplary T2eVLP/T4eVLP production and transduction for RNP/protein delivery. All eVLP expression constructs are stably integrated in the genome of the producer cell. Construct 1-1 corresponds to the phospholipid bilayer recruitment domain. 1-2 corresponds to the cargo. 2 corresponds to an optional guide RNA. 1-1 and 1-2 is translated in the cytosol where it complexes with guide RNA before it is recruited to the phospholipid bilayer. 3 corresponds to a virally-derived glycoprotein (VSVG). The virally-derived glycoprotein is expressed as a transmembrane protein on the plasma membrane and helps to drive budding of cargo-containing eVLPs from the plasma membrane to extracellular space. These particles are purified and are able to fuse with target cells and deliver cargo by interacting with surface receptors at the target cell surface.

FIG 2: Depiction of purified eVLPs entering a target cell and delivering cargo to the cytosol. Importantly, the phospholipid bilayer recruitment domain allows cargo to enter the target cell nucleus as long as cargo possesses a nuclear localization sequence.

FIG 3: Cas9 RNP was delivered in VSVG-pseudotyped T2eVLPs with or without a PH domain from hPLC δ 1 or hAKT1. The PH domains were fused to the N-terminus of Cas9 via a 10 amino acid glycine/serine polypeptide linker. HepG2, U2OS, HEK293T, CFPAC1, BeWo, Jurkat, K562, and primary T cells were treated with purified and 100x concentrated T2eVLPs for 72 hours. Percent targeted gene modification of VEGF site #3 was determined by amplicon sequencing. The x-axis labels correspond to the contents of each T2eVLP preparation. Cas9 (no fusion) lacked a PH domain fusion. Benzonase (Benz) was used to degrade RNA and DNA outside of VLPs, and a Benzonase treated sample was included as a control.

FIG 4: Depiction of T1eVLP/T3eVLP production. Plasmid DNA constructs involved in the transfection encode cargo, an optional guide RNA and a virally-derived glycoprotein (VSVG). Plasmids, or other types of DNA molecules, will be distributed throughout the production cell, so constructs located in the nucleus will express eVLP components and cargo, and constructs located near the plasma membrane or endosomes will be encapsulated within budding eVLPs.

FIGs. 5A-B: Exemplary T1eVLP-delivered spCas9 genome editing in vitro. A) U2OS eGFP and HEK293 eGFP cell lines transduced with VLPs containing Rous sarcoma virus gag fused to spCas9 and sgRNA, T1eVLPs containing PLC pleckstrin homology (PH) fused to spCas9 and sgRNA, or VLPs containing Rous sarcoma virus gag fused to the SV40 nuclear localization sequence (NLS) and sgRNA. The sgRNA targets GFP. Flow cytometry or T7E1 is performed 72 hours after transduction. The Rous sarcoma virus gag VLPs serve as controls. B) T7E1 analysis of a subpopulation of U2OS or 293 cells from the experiment in FIG 5A. eVLPs and VLPs are pseudotyped with VSVG

FIG 6: Exemplary T1eVLP-delivered spCas9 genome editing in vitro. U2OS cells transduced with T1eVLPs containing PLC PH fused to spCas9 targeted to HEK site #3 or VEGF site #2. eVLPs are pseudotyped with VSVG. Gene modification is measured by amplicon sequencing.

FIG 7: Exemplary T1eVLP-delivered spCas9 genome editing in vitro. U2OS cells transduced with T1eVLPs containing PLC PH or hAkt PH fused to spCas9 targeted to VEGF site #3. eVLPs are pseudotyped with VSVG. Gene modification is measured by amplicon sequencing.

FIG 8: Exemplary T1eVLP-delivered spCas9 base editing in vitro. HEK293T cells transduced with VLPs containing Rous sarcoma virus gag fused to spCas9 BE3 or Gam-BE4 with sgRNA targeted to VEGF site #2, or T1eVLPs containing PLC PH fused to spCas9 BE3 or Gam-BE4 with sgRNA targeted to VEGF site #2. eVLPs and VLPs are pseudotyped with VSVG. Gene modification is measured by amplicon sequencing. The Rous sarcoma virus gag VLP serves as a positive control.

FIG 9: Exemplary T1eVLP-delivered spCas9 base editing in vitro. HEK293T cells transduced with T1eVLPs containing PLC PH fused to codon optimized spCas9 BE4 targeted to HEK site #3. eVLPs are pseudotyped with VSVG. Gene modification is measured by amplicon sequencing.

FIG 10: Exemplary T1eVLP-delivered spCas9 base editing in vitro. HEK293T cells transduced with T1eVLPs containing PLC PH fused to codon optimized spCas9 ABE targeted to VEGF site #3. eVLPs are pseudotyped with VSVG. Gene modification is measured by amplicon sequencing.

FIG 11: Exemplary T1eVLP-delivered spCas9 base editing in vitro. HEK293T cells transduced with T1eVLPs containing PLC PH fused to codon optimized spCas9 ABE targeted to HEK site #3. eVLPs are pseudotyped with VSVG. Gene modification is measured by amplicon sequencing.

FIG 12: Exemplary T1eVLP-delivered asCas12a genome editing in vitro. HEK293 cells transduced with VLPs containing Rous sarcoma virus gag or T1eVLPs containing PLC PH fused to asCas12a. VLPs and eVLPs are targeted to FANCF site #1 by crRNA. Gene modification is measured by T7E1. The Rous sarcoma virus gag VLP serves as a positive control.

FIG 13: Exemplary T1eVLP-delivered spCas9 genome editing in vitro. HEK293 cells transduced with T1eVLPs containing PLC PH fused to RNA binding protein MS2. MS2 binds to MS2 stem loops in the sgRNA, which is complexed with Cas9, and MS2 is fused to a PH domain for efficient eVLP loading. eVLPs are targeted to GFP site #1 by sgRNA. Gene modification is measured by T7E1.

FIG 14: Exemplary T1eVLP-delivered spCas9 genome editing in vitro. HEK293 cells transduced with T1eVLPs containing PLC PH fused to dimerization domain (DmrC). In the presence of A/C Heterodimerizer molecule, DmrC binds to DmrA which is directly fused to Cas9. eVLPs are targeted to GFP site #1 by sgRNA. Gene modification is measured by T7E1.

FIG 15: Exemplary T1eVLP-delivered asCas9 genome editing in vitro. HEK293 cells transduced with T1eVLPs containing PLC PH fused to GNC4 protein domain repeats. An scFv binds to the GCN4 repeats, and scFvs are directly fused to Cas9. eVLPs are targeted to GFP site #1 by sgRNA. Gene modification is measured by T7E1.

FIGS. 16-40: Schematic illustrations of various exemplary eVLP configurations and possible cargo.

DETAILED DESCRIPTION

Therapeutic proteins and nucleic acids hold great promise, but for many of these large biomolecules delivery into cells is a hurdle to clinical development. Genome editing reagents such as zinc finger nucleases (ZFNs) or RNA-guided, enzymatically active/inactive DNA binding proteins such as Cas9 have undergone rapid advancements

in terms of specificity and the types of edits that can be executed, but the hurdle of safe in vivo delivery still precludes efficacious gene editing therapies. Described herein are various embodiments of enhanced virus-like particles (eVLPs), as well as characteristics of various embodiments of eVLPs that provide a novel and optimal platform for the delivery of genome editing reagents, and contrasts eVLPs with canonical delivery modalities.

Retroviral particles, such as lentivirus, have been developed to deliver RNA that is reverse transcribed to DNA that may or may not be integrated into genomic DNA. VLPs have been developed that mimic virus particles in their ability to self-assemble, but are not infectious as they lack some of the core viral genes. Both lentiviral and VLP vectors are typically produced by transiently transfecting a producer cell line with plasmids that encode all components necessary to produce lentiviral particles or VLP. One major flaw that we have discovered regarding lentiviral particles and VSVG-based VLPs that are produced by this conventional transient transfection method is that, in addition to their conventional cargo, these particles package and deliver plasmid DNA that was used in the initial transient transfection. This unintended plasmid DNA delivery can be immunogenic and cause undesirable effects, such as plasmid DNA being integrated into genomic DNA. It is important to specify the type of biomolecules/chemicals that are to be delivered within particles, and eVLPs have been designed to possess this germane capability.

The eVLPs described herein can deliver a wide variety of cargo including DNA only, DNA+RNA+protein, or RNA+protein. Importantly, eVLPs are the first VSVG-based VLP delivery modality that can control the form of the cargo (DNA, protein, and/or RNA). Previously described VSVG-based vesicles and viral particles package and deliver unwanted plasmid DNA (or other types of DNA-based gene expression constructs) introduced into particle producer cells via transient transfection in addition to the intended protein and/or RNA cargo(s).

Another aspect of eVLPs is the ENV protein on the surface of the eVLP. Without wishing to be bound by theory, the ENV protein alone is responsible for eVLP particle generation and the ability of eVLPs to efficiently deliver cargo into cells. Lentivirus and VLPs commonly require GAG and ENV proteins to drive particle formation via budding

off of the plasma membrane of producer cells into the cell culture medium. In addition, the majority of retroviral ENV proteins require post-translational modifications in the form of proteolytic cleavage of the intracellular domain (ICD) of the ENV protein in order to activate the fusogenicity of the ENV protein; this is essential for viral infectivity.

5 The envelope proteins described in Table 1 are all derived from viruses. However, these eVLP ENV proteins do not require exogenous GAG for particle formation and they do not require ICD cleavage for fusogenicity.¹⁻³ The ENV is the only virally-derived component of eVLPs, and these ENV glycoproteins on the external surface of the eVLPs are used to facilitate fusion/entry of eVLPs into the target cell because they are known to
10 be naturally fusogenic. In addition, eVLPs are different from previously described viral particles, VLPs, and extracellular vesicles because eVLPs are composed of a mixture of ectosomes and exosomes which can be separated by purification, if desired. Because of the above mentioned design simplifications and optimizations, eVLPs are particularly suited for delivery of cargo including DNA, RNA, protein, or combinations of
15 biomolecules and/or chemicals, such as DNA-encoded or RNP-based genome editing reagents.

Large biomolecules including proteins and protein complexes such as genome editing reagents, especially CRISPR-CAS, zinc finger, and TAL-nuclease-based reagents, have the potential to become in vivo therapeutics for the treatment of a number of
20 diseases including genetic diseases, but techniques for delivering these reagents into cells are severely limiting or unsafe for patients. Conventional therapeutic monoclonal antibody delivery is successful at utilizing direct injection for proteins. Unfortunately, strategies for direct injection of gene editing proteins, such as Cas9, are hampered by immunogenicity, degradation, ineffective cell specificity, and inability to cross the plasma
25 membrane or escape endosomes/lysosomes.⁴⁻¹⁰ More broad applications of protein therapy and gene editing could be achieved by delivering therapeutic protein cargo to the inside of cells. Cas9, for example, cannot efficiently cross the phospholipid bilayer to enter into cells, and has been shown to have innate and adaptive immunogenic potential.⁴⁻⁸ Therefore, it is not practical or favorable to deliver Cas9 by direct injection
30 or as an external/internal conjugate to lipid, protein or metal-based nanoparticles that

have cytotoxic and immunogenic properties and often yield low levels of desired gene modifications.⁹⁻²⁰

Nanoparticles that encapsulate cargo are another delivery strategy that can be used to deliver DNA, protein, RNA and RNPs into cells.⁹⁻¹⁸ Nanoparticles can be engineered for cell specificity and can trigger endocytosis and subsequent endosome lysis. However, nanoparticles can have varying levels of immunogenicity due to an artificially-derived vehicle shell.⁹⁻²⁰ Many nanoparticles rely on strong opposing charge distributions to maintain particle structural integrity, and the electrostatics can make it toxic and unfit for many in vivo therapeutic scenarios.⁹ Nanoparticles that deliver RNA have had successes in recent clinical trials, but most have only been used to deliver siRNA or shRNA. Toxicity from such nanoparticles is still a major concern.⁹ Nanoparticles that deliver mRNA coding for genome editing RNPs have also been a recent success, but these create a higher number of off-target effects compared to protein delivery and RNA stability is lower than that of protein.¹⁷ Nanoparticles that deliver genome editing RNPs and DNA have been a significant breakthrough because they can leverage both homology directed repair (HDR) and non-homologous end joining (NHEJ), but exhibit prohibitively low gene modification frequencies in vitro and in vivo, and therefore currently have limited applications in vivo as a gene editing therapeutic.¹⁵

Currently, the clinical standard vehicles for delivering genome editing therapeutics are adeno-associated virus (AAV). Although AAV vectors are a promising delivery modality that can successfully deliver DNA into eukaryotic cells, AAV cannot efficiently package and deliver DNA constructs larger than 4.5 kb and this precludes delivery of many CRISPR-based gene editing reagents that require larger DNA expression constructs. CRISPR-based gene editing reagents can be split into multiple different AAV particles, but this strategy drastically reduces delivery and editing efficiency. Depending on the dose required, AAV and adenoviral vectors can have varying levels of immunogenicity. In addition, inverted-terminal repeats (ITRs) in the AAV DNA construct can promote the formation of spontaneous episomes leading to prolonged expression of genome editing reagents and increased off-target effects. ITRs can also promote the undesired integration of AAV DNA into genomic DNA.²¹⁻²⁴

Recently, VLPs have been utilized to deliver mRNA and protein cargo into the cytosol of cells.^{2,3,25-30} VLPs have emerged as a substitute delivery modality for retroviral particles. VLPs can be designed to lack the ability to integrate retroviral DNA, and to package and deliver protein/RNP/DNA. However, most VLPs, including recently conceived VLPs that deliver genome editing reagents known to date, utilize HIV or other virally-derived *gag-pol* protein fusions and viral proteases to generate retroviral-like particles.^{25-27,29,30} Secondly, some VLPs containing RGNs also must package and express guide RNAs from a lentiviral DNA transcript.²⁷ Thirdly, some VLPs require a viral protease in order to form functional particles and release genome editing cargo.^{25-27,29} Since this viral protease recognizes and cleaves at multiple amino acid motifs, it can cause damage to the protein cargo which could be hazardous for therapeutic applications. Fourthly, most published VLP modalities that deliver genome editing proteins to date exhibit low *in vitro* and *in vivo* gene modification efficiencies due to low packaging and transduction efficiency.²⁵⁻²⁷ Fifthly, the complex viral genomes utilized for these VLP components possess multiple reading frames and employ RNA splicing that could result in spurious fusion protein products being delivered.^{25-27,29,30} Sixthly, the presence of reverse transcriptase, integrase, capsid and a virally-derived envelope protein in these VLPs is not ideal for most therapeutic applications because of immunogenicity and off target editing concerns. Lastly, most retroviral particles, such as lentiviral particles, are pseudotyped with VSVG and nearly all described VLPs that deliver genome editing reagents hitherto possess and rely upon VSVG.^{2,3,25-30} We have discovered that VSVG-based particles that are formed by transiently transfecting producer cells package and deliver DNA that was transfected. The current versions of VSVG-based VLPs cannot prevent this inadvertent delivery of DNA and this impedes the use of VLPs in scenarios that necessitate minimal immunogenicity and off target effects.

Extracellular vesicles are another delivery modality that can package and deliver cargo within exosomes and ectosomes.^{31,32} Similar to VLPs, extracellular vesicles are comprised of a phospholipid bilayer from a mammalian cell. Unlike VLPs, extracellular vesicles lack viral components and therefore have limited immunogenicity. Whereas VLPs have a great ability to enter cells due to external fusogenic glycoproteins (VSVG)

extracellular vesicles mainly rely on cellular uptake via micropinocytosis and this limits the delivery efficiency of extracellular vesicles.

eVLPs are a safer and more effective alternative than previously described VLPs, extracellular vesicles, AAVs and nanoparticles-especially for delivery of genome editing reagents-because eVLPs are composed of all human components except for a virally-derived glycoprotein that has been demonstrated to be safe in humans in a clinical trial of a HIV-1 gag vaccine (VSVG),³³ eVLPs lack all other retroviral components besides a safe glycoprotein, eVLPs have the ability to deliver DNA+RNP, or RNP alone while other previously described VLPs cannot prevent transient transfection DNA from being unintentionally packaged and delivered, eVLPs can deliver specialty DNA molecules while previously described VLPs, nanoparticles and AAVs cannot or do not, and eVLPs can be produced with cells that have been derived from patients (autologous eVLPs) and other FDA-approved cell lines (allogenic eVLPs) to further reduce the risks of adverse immune reactions. Here, we describe methods and compositions for producing, purifying, and administering eVLPs for *in vitro* and *in vivo* applications, e.g., of genome editing, epigenome modulation, transcriptome editing and proteome modulation. The desired editing outcome depends on the therapeutic context and will require different gene editing reagents. *Streptococcus pyogenes* Cas9 (spCas9) and *acidaminococcus* sp. Cas12a (functionalize) are two of the most popular RNA-guided enzymes for editing that leverages NHEJ for introducing stop codons or deletions, or HDR for causing insertions.³⁴⁻³⁶ Cas9-deaminase fusions, also known as base editors, are the current standard for precise editing of a single nucleotide without double stranded DNA cleavage.^{37,38} Importantly, these methods address the phenomenon of inadvertent DNA delivery in VLPs and the first to control for the type of biomolecule to be delivered (DNA, RNA, and/or protein) thereby increasing the types of therapeutic *in vivo* genome modifications that are possible and minimizing deleterious off target effects.

Section 1: eVLP-mediated delivery of DNAs, proteins and RNAs

Conventional VLPs that have been engineered to encapsulate and deliver protein-based cargo commonly fuse cargo to the INT or GAG polyprotein.^{25-27,29,30,39,40} After transient transfection of production plasmid DNA constructs, these protein fusions are

translated in the cytosol of conventional VLP production cell lines, the gag matrix is acetylated and recruited to the cell membrane, and the gag fusions are encapsulated (transient transfection DNA is also unintentionally encapsulated) within VLPs as VLPs bud off of the membrane into extracellular space.

5 In contrast, in some embodiments the eVLPs described herein can package protein-based cargo by integrating all production DNA into the genomic DNA of production cell lines. Once cell lines are created, protein delivery eVLPs can be produced in a constitutive or inducible fashion. Proteins are packaged into eVLP by fusing select human-derived phospholipid bilayer recruitment domains to protein-based cargo (e.g., as
10 shown in Table 6). One such human-derived phospholipid bilayer recruitment domain used for this purpose is a human pleckstrin homology (PH) domain. PH domains interact with phosphatidylinositol lipids and proteins within biological membranes, such as PIP2, PIP3, $\beta\gamma$ -subunits of GPCRs, and PKC.^{41,42} Alternatively, the human Arc protein can be fused to protein-based cargo to recruit cargo to the cytosolic side of the phospholipid
15 bilayer.⁴³ These human-derived phospholipid bilayer recruitment domains can be fused to the N-terminus or C-terminus of protein-based cargo via polypeptide linkers of variable length regardless of the location or locations of one or more nuclear localization sequence(s) (NLS) within the cargo. Preferably, the linker between protein-based cargo and the phospholipid bilayer recruitment domain is a polypeptide linker 5-20, e.g., 8-12,
20 e.g., 10, amino acids in length primarily composed of glycines and serines. The human-derived phospholipid bilayer recruitment domain localizes the cargo to the phospholipid bilayer and this protein cargo is packaged within eVLPs that utilize a glycoprotein to trigger budding off of particles from the producer cell into extracellular space (FIG 1). These human-derived domains and proteins can facilitate for localization of cargo to the
25 cytosolic face of the plasma membrane within the eVLP production cells, and they also allow for cargo to localize to the nucleus of eVLP-transduced cells without the utilization of exogenous retroviral gag/pol or chemical and/or light-based dimerization systems (FIG 2). The delivery of Cas9, for example, is significantly more efficient with a fusion to a plasma membrane recruitment domain compared to without a plasma membrane
30 recruitment domain (FIG 3).

In some embodiments, eVLPs can also package and deliver a combination of DNA and RNA if eVLPs are produced via transient transfection of a production cell line. DNA that is transfected into cells will possess size-dependent mobility such that a fraction of the transfected DNA will remain in the cytosol while another fraction of the transfected DNA will localize to the nucleus.⁴⁴⁻⁴⁶ One fraction of the transfected DNA in the nucleus will express components needed to create eVLPs and the other fraction in the cytosol/near the plasma membrane will be encapsulated and delivered in eVLPs (FIG 4).

eVLP “Cargo” refers to any payload that can be delivered, including chemicals, e.g., small molecule compounds, and biomolecules, including DNA, RNA, RNP, proteins, and combinations thereof, including combinations of DNA and RNP, RNP, combinations of DNA and proteins, or proteins, as well as viruses and portions thereof, e.g., for therapeutic or diagnostic use, or for the applications of genome editing, epigenome modulation, and/or transcriptome modulation. In order to simplify these distinctions, a combination of DNA and RNP will be referred to herein as type 1 cargo (T1eVLPs), RNP will be referred to herein as type 2 cargo (T2eVLPs), a combination of DNA and proteins will be referred to herein as type 3 cargo (T3eVLPs), and proteins will be referred to herein as type 4 cargo (T4eVLPs). RNA in this context includes, for example, single guide RNA (sgRNA), Clustered Regularly Interspaced Palindromic Repeat (CRISPR) RNA (crRNA), and/or mRNA coding for cargo.

As used herein, “small molecules” refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons. In general, small molecules useful for the invention have a molecular weight of less than 3,000 Daltons (Da). The small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).

The cargo is limited by the diameter of the particles, e.g., which in some embodiments range from 30nm to 500nm.

Cargo developed for applications of genome editing also includes nucleases and base editors. Nucleases include FokI and AcuI ZFNs and Transcription activator-like effector nucleases (TALENs) and CRISPR based nucleases or a functional derivative thereof (e.g., as shown in Table 2) (ZFNs are described, for example, in United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; and International Publication WO 07/014275) (TALENs are described, for example, in United States Patent Publication US9393257B2; and International Publication WO2014134412A1) (CRISPR based nucleases are described, for example, in United States Patent Publications US8697359B1; US20180208976A1; and International Publications WO2014093661A2; WO2017184786A8).³⁴⁻³⁶ Base editors that are described by this work include any CRISPR based nuclease orthologs (wt, nickase, or catalytically inactive (CI)), e.g., as shown in Table 2, fused at the N-terminus to a deaminase or a functional derivative thereof (e.g., as shown in Table 3) with or without a fusion at the C-terminus to one or multiple uracil glycosylase inhibitors (UGIs) using polypeptide linkers of variable length (Base editors are described, for example, in United States Patent Publications US20150166982A1; US20180312825A1; US10113163B2; and International Publications WO2015089406A1; WO2018218188A2; WO2017070632A2; WO2018027078A8; WO2018165629A1).^{37,38} In addition, prime editors are also compatible with eVLP delivery modalities (Prime editors are described, for example, in PMID: 31634902).

sgRNAs complex with genome editing reagents during the packaging process, and are co-delivered within eVLPs. To date, this concept has been validated *in vitro* by experiments that demonstrate the T1eVLP or T2eVLP delivery of RGN and CI RGN fused to deaminase and UGI (base editor) as protein for the purposes of site specific editing of exogenous and endogenous sites (FIGs. 3, 5, 6, 7, 8, 9, 10, 11 & 12). For example, T1eVLPs have been used to deliver Cas9 RNP to U2OS and HEK293 cells for the purposes of editing exogenous GFP, and endogenous HEK site #3 and VEGF site #2 & #3 (FIGs. 4, 5, 6 & 7). In addition, T1eVLPs have been used to deliver BE3 and BE4 RNP to HEK293T cells for the purpose of base editing endogenous VEGF site #2 & #3 and HEK site #3 (FIGs. 8, 9, 10 & 11). T1eVLPs have also been used to deliver Cas12a RNP to HEK293 cells for the purposes of editing endogenous FANCF site #1 (FIG 12).

Cargo designed for the purposes of epigenome modulation includes the CI CRISPR based nucleases, zinc fingers (ZFs) and TALEs fused to an epigenome modulator or combination of epigenome modulators or a functional derivative thereof connected together by one or more variable length polypeptide linkers (Tables 2 & 4).

5 T1-T4 cargo designed for the purposes of transcriptome editing includes CRISPR based nucleases or any functional derivatives thereof in Table 5 or CI CRISPR based nucleases or any functional derivatives thereof in Table 5 fused to deaminases in Table 3 by one or more variable length polypeptide linkers.

The cargo can also include any therapeutically or diagnostically useful protein,
10 DNA, RNP, or combination of DNA, protein and/or RNP. See, e.g., WO2014005219; US10137206; US20180339166; US5892020A; EP2134841B1; WO2007020965A1. For example, cargo encoding or composed of nuclease or base editor proteins or RNPs or derivatives thereof can be delivered to retinal cells for the purposes of correcting a splice site defect responsible for Leber Congenital Amaurosis type 10. In the mammalian inner
15 ear, eVLP delivery of base editing reagents or HDR promoting cargo to sensory cells such as cochlear supporting cells and hair cells for the purposes of editing β -catenin (β -catenin Ser 33 edited to Tyr, Pro, or Cys) in order to better stabilize β -catenin could help reverse hearing loss.

In another application, eVLP delivery of RNA editing reagents or proteome
20 perturbing reagents could cause a transitory reduction in cellular levels of one or more specific proteins of interest (potentially at a systemic level, in a specific organ or a specific subset of cells, such as a tumor), and this could create a therapeutically actionable window when secondary drug(s) could be administered (this secondary drug is more effective in the absence of the protein of interest or in the presence of lower levels
25 of the protein of interest). For example, eVLP delivery of RNA editing reagents or proteome perturbing reagents could trigger targeted degradation of MAPK and PI3K/AKT proteins and related mRNAs in vemurafenib/dabrafenib-resistant BRAF-driven tumor cells, and this could open a window for the administration of vemurafenib/dabrafenib because BRAF inhibitor resistance is temporarily abolished
30 (resistance mechanisms based in the MAPK/PI3K/AKT pathways are temporarily

downregulated by eVLP cargo). This example is especially pertinent when combined with eVLPs that are antigen inducible and therefore specific for tumor cells.

In some embodiments, eVLPs could be used deliver factors, e.g., including the Yamanaka factors Oct3/4, Sox2, Klf4, and c-Myc, to cells such as human or mouse fibroblasts, in order to generate induced pluripotent stem cells.

In some embodiments, eVLPs could deliver dominant-negative forms of proteins in order to elicit a therapeutic effect.

eVLPs that are antigen-specific (i.e., tumor-antigen specific) could be targeted to cancer cells in order to deliver proapoptotic proteins BIM, BID, PUMA, NOXA, BAD, BIK, BAX, BAK and/or HRK in order to trigger apoptosis of cancer cells. Tumor antigens are known in the art and include

90% of pancreatic cancer patients present with unresectable disease. Around 30% of patients with unresectable pancreatic tumors will die from local disease progression, so it is desirable to treat locally advanced pancreatic tumors with ablative radiation, but the intestinal tract cannot tolerate high doses of radiation needed to cause tumor ablation. Selective radioprotection of the intestinal tract enables ablative radiation therapy of pancreatic tumors while minimizing damage done to the surrounding gastrointestinal tract. To this end, eVLPs could be loaded with dCas9 fused to the transcriptional repressor KRAB and guide RNA targeting *EGLN*. *EGLN* inhibition has been shown to significantly reduce gastrointestinal toxicity from ablative radiation treatments because it causes selective radioprotection of the gastrointestinal tract but not the pancreatic tumor.⁴⁷ Such fusion proteins, eVLPs, and methods of making and using the same are provided herein.

Unbound steroid receptors reside in the cytosol. After binding to ligands, these receptors will translocate to the nucleus and initiate transcription of response genes. eVLPs could deliver single chain variable fragment (scFv) antibodies to the cytosol of cells that bind to and disrupt cytosolic steroid receptors. For example, the scFv could bind to the glucocorticoid receptor and prevent it from binding dexamethasone, and this would prevent transcription of response genes, such as *metallothionein 1E* which has been linked to tumorigenesis.⁴⁸

eVLPs can be indicated for treatments that involve targeted disruption of proteins. For example, eVLPs can be utilized for targeting and disrupting proteins in the cytosol of cells by delivering antibodies/scFvs to the cytosol of cells. Classically, delivery of antibodies through the plasma membrane to the cytosol of cells has been notoriously difficult and inefficient. This mode of protein inhibition is similar to how a targeted small molecule binds to and disrupts proteins in the cytosol and could be useful for the treatment of a diverse array of diseases.⁴⁹⁻⁵¹ Such fusion proteins, eVLPs, and methods of making and using the same are

In addition, the targeting of targeted small molecules is limited to proteins of a certain size that contain binding pockets which are relevant to catalytic function or protein-protein interactions. scFvs are not hampered by these limitations because scFvs can be generated that bind to many different moieties of a protein in order to disrupt catalysis and interactions with other proteins. For example, RAS oncoproteins are implicated across a multitude of cancer subtypes, and *RAS* is one of the most frequently observed oncogenes in cancer. For instance, the International Cancer Genome Consortium found KRAS to be mutated in 95% of their Pancreatic Adenocarcinoma samples. RAS isoforms are known to activate a variety of pathways that are dysregulated in human cancers, like the PI3K and MAPK pathways. Despite the aberrant roles RAS plays in cancer, no efficacious pharmacologic direct or indirect small molecule inhibitors of RAS have been developed and approved for clinical use. One strategy for targeting RAS could be eVLPs that can deliver specifically to cancer cells scFvs that bind to and disrupt the function of multiple RAS isoforms.⁴⁹⁻⁵¹

Section 2: eVLP composition, production, purification and applications

eVLPs can be produced from producer cell lines that are either transiently transfected with at least one plasmid or stably expressing constructs that have been integrated into the producer cell line genomic DNA. In some embodiments, for T1 and T3eVLPs, if a single plasmid is used in the transfection, it should comprise sequences encoding one or more virally-derived glycoproteins (e.g., as shown in Table 1), cargo (e.g., a therapeutic protein or a gene editing reagent such as a zinc finger, transcription activator-like effector (TALE), and/or CRISPR-based genome editing/modulating protein

and/or RNP such as those found in Tables 2, 3, 4 & 5), with or without fusion to a plasma membrane recruitment domain (e.g., as shown in Table 6), and a guide RNA, if necessary. Preferably, two to three plasmids are used in the transfection. These two to three plasmids can include the following (any two or more can be combined in a single plasmid):

1. A plasmid comprising sequences encoding a therapeutic protein or a genome editing reagent, with or without a fusion to a plasma membrane recruitment domain.
2. A plasmid comprising one or more virally-derived glycoproteins (e.g., as listed in Table 1).
3. If the genome editing reagent from plasmid 1 requires one or more guide RNAs, a plasmid comprising one or more guide RNAs apposite for the genome editing reagent in plasmid 1.

If it is desired to deliver a type of DNA molecule other than plasmid(s), the above-mentioned transfection can be performed with double-stranded closed-end linear DNA, episome, mini circle, double-stranded oligonucleotide and/or other specialty DNA molecules. Alternatively, for T2 and T4eVLPs, the producer cell line can be made to stably express the constructs (1 through 3) described in the transfection above.

As stated earlier, in some embodiments, the methods include using cells that have or have not been manipulated to express any exogenous proteins except for a viral envelope (e.g., as shown in Table 1), and, if desired, a plasma membrane recruitment domain (e.g., as shown in Table 6). In this embodiment, the “empty” particles that are produced can be loaded with cargo by utilizing nucleofection, lipid, polymer, or CaCl_2 transfection, sonication, freeze thaw, and/or heat shock of purified particles mixed with cargo. In all embodiments, producer cells do not express any gag protein. This type of loading allows for cargo to be unmodified by fusions to plasma membrane recruitment domains and represents a significant advancement from previous VLP technology.

The plasmids, or other types of specialty DNA molecules known in the art or described above, can also preferably include other elements to drive expression or translation of the encoded sequences, e.g., a promoter sequence; an enhancer sequence, e.g., 5' untranslated region (UTR) or a 3' UTR; a polyadenylation site; an insulator

sequence; or another sequence that increases or controls expression (e.g., an inducible promoter element).

Preferably, appropriate producer cell lines are primary or stable human cell lines refractory to the effects of transfection reagents and fusogenic effects due to virally-derived glycoproteins. Examples of appropriate cell lines include Human Embryonic
5 Kidney (HEK) 293 cells, HEK293 T/17 SF cells kidney-derived Phoenix-AMPHO cells, and placenta-derived BeWo cells. For example, such cells could be selected for their ability to grow as adherent cells, or suspension cells. In some embodiments, the producer cells can be cultured in classical DMEM under serum conditions, serum-free conditions,
10 or exosome-free serum conditions. eVLPs, e.g., T1 and T3eVLPs, can be produced from cells that have been derived from patients (autologous eVLPs) and other FDA-approved cell lines (allogenic eVLPs) as long as these cells can be transfected with DNA constructs that encode the aforementioned eVLP production components by various techniques known in the art.

15 In addition, if it is desirable, more than one genome editing reagent can be included in the transfection. The DNA constructs can be designed to overexpress proteins in the producer cell lines. The plasmid backbones, for example, used in the transfection can be familiar to those skilled in the art, such as the pCDNA3 backbone that employs the CMV promoter for RNA polymerase II transcripts or the U6 promoter for RNA
20 polymerase III transcripts. Various techniques known in the art may be employed for introducing nucleic acid molecules into producer cells. Such techniques include chemical-facilitated transfection using compounds such as calcium phosphate, cationic lipids, cationic polymers, liposome-mediated transfection, such as cationic liposome like LIPOFECTAMINE (LIPOFECTAMINE 2000 or 3000 and TransIT-X2),
25 polyethyleneimine, non-chemical methods such as electroporation, particle bombardment, or microinjection.

A human producer cell line that stably expresses the necessary eVLP components in a constitutive and/or inducible fashion can be used for production of T2 and T4eVLPs. T2 and T4eVLPs can be produced from cells that have been derived from patients
30 (autologous eVLPs) and other FDA-approved cell lines (allogenic eVLPs) if these cells

have been converted into stable cell lines that express the aforementioned eVLP components.

Also provided herein are the producer cells themselves.

Production of Cargo-Loaded eVLPs and Compositions

5 Preferably eVLPs are harvested from cell culture medium supernatant 36-48 hours post-transfection, or when eVLPs are at the maximum concentration in the medium of the producer cells (the producer cells are expelling particles into the media and at some point in time, the particle concentration in the media will be optimal for harvesting the particles). Supernatant can be purified by any known methods in the art, such as
10 centrifugation, ultracentrifugation, precipitation, ultrafiltration, and/or chromatography. In some embodiments, the supernatant is first filtered, e.g., to remove particles larger than 1 μm , e.g., through 0.45 pore size polyvinylidene fluoride hydrophilic membrane (Millipore Millex-HV) or 0.8 μm pore size mixed cellulose esters hydrophilic membrane (Millipore Millex-AA). After filtration, the supernatant can be further purified and
15 concentrated, e.g., using ultracentrifugation, e.g., at a speed of 80,000 to 100,000 $\times g$ at a temperature between 1°C and 5°C for 1 to 2 hours, or at a speed of 8,000 to 15,000 g at a temperature between 1°C and 5°C for 10 to 16 hours. After this centrifugation step, the eVLPs are concentrated in the form of a centrifugate (pellet), which can be resuspended to a desired concentration, mixed with transduction-enhancing reagents, subjected to a
20 buffer exchange, or used as is. In some embodiments, eVLP-containing supernatant can be filtered, precipitated, centrifuged and resuspended to a concentrated solution. For example, polyethylene glycol (PEG), e.g., PEG 8000, or antibody-bead conjugates that bind to eVLP surface proteins or membrane components can be used to precipitate particles. Purified particles are stable and can be stored at 4°C for up to a week or -80°C
25 for years without losing appreciable activity.

Preferably, eVLPs are resuspended or undergo buffer exchange so that particles are suspended in an appropriate carrier. In some embodiments, buffer exchange can be performed by ultrafiltration (Sartorius Vivaspin 500 MWCO 100,000). An exemplary appropriate carrier for eVLPs to be used for *in vitro* applications would preferably be a
30 cell culture medium that is suitable for the cells that are to be transduced by eVLPs.

Transduction-enhancing reagents that can be mixed into the purified and concentrated eVLP solution for in vitro applications include reagents known by those familiar with the art (Miltenyi Biotec Vectofusin-1, Millipore Polybrene, Takara Retronectin, Sigma Protamine Sulfate, and the like). After eVLPs in an appropriate carrier are applied to the cells to be transduced, transduction efficiency can be further increased by centrifugation. Preferably, the plate containing eVLPs applied to cells can be centrifuged at a speed of 1,150 g at room temperature for 30 minutes. After centrifugation, cells are returned into the appropriate cell culture incubator (humidified incubator at 37°C with 5% CO₂).

An appropriate carrier for eVLPs to be administered to a mammal, especially a human, would preferably be a pharmaceutically acceptable composition. A “pharmaceutically acceptable composition” refers to a non-toxic semisolid, liquid, or aerosolized filler, diluent, encapsulating material, colloidal suspension or formulation auxiliary of any type. Preferably, this composition is suitable for injection. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and similar solutions or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions. Another appropriate pharmaceutical form would be aerosolized particles for administration by intranasal inhalation or intratracheal intubation.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or suspensions. The solution or suspension may comprise additives which are compatible with eVLPs and do not prevent eVLP entry into target cells. In all cases, the form must be sterile and must be fluid to the extent that the form can be administered with a syringe. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. An example of an appropriate solution is a buffer, such as phosphate buffered saline.

Methods of formulating suitable pharmaceutical compositions are known in the art, see, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., 2005; and the books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY). For example, solutions or suspensions used for parenteral,

intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients

enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

The compositions comprising cargo-loaded eVLPs can be included in a container, pack, or dispenser together with instructions for administration.

EXAMPLES

The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

Methods

The following methods were used in the Examples below. eVLP particles were produced by HEK293T cells using polyethylenimine (PEI) based transfection of plasmids. PEI is Polyethylenimine 25kD linear (Polysciences #23966-2). To make a stock 'PEI MAX' solution, 1g of PEI was added to 1L endotoxin-free dH₂O that was previously heated to ~80°C and cooled to room temperature. This mixture was neutralized to pH 7.1 by addition of 10N NaOH and filter sterilized with 0.22µm polyethersulfone (PES). PEI MAX is stored at -20°C.

HEK293T cells were split to reach a confluency of 70%–90% at time of transfection and are cultured in 10% FBS DMEM media. Cargo vectors, such as one encoding a CMV promoter driving expression of a hPLCδ1 PH fusion to codon optimized Cas9 were co-transfected with a U6 promoter-sgRNA encoding plasmid and the VSV-G envelope plasmid pMD2.G (Addgene #12259). Transfection reactions were assembled in reduced serum media (Opti-MEM; GIBCO #31985-070). For eVLP particle production on 10 cm plates, 7.5 µg PH-Cas9 expressing plasmid, 7.5 µg sgRNA-expression plasmid and 5 µg pMD2.G were mixed in 1 mL Opti-MEM, followed by addition of 27.5µl PEI MAX. After 20-30 min incubation at room temperature, the transfection reactions were dispersed dropwise over the HEK293T cells.

eVLPs were harvested at 48-72 hours post-transfection. eVLP supernatants were filtered using 0.45 μ m cellulose acetate or 0.8 μ m PES membrane filters and transferred to polypropylene Beckman ultracentrifuge tubes that are used with the SW28 rotor (Beckman Coulter #326823). Each ultracentrifuge tube is filled with eVLP-containing supernatant from 3 10 cm plates to reach an approximate final volume of 35-37.5 ml. eVLP supernatant underwent ultracentrifugation at approximately 100,000 xg, or 25,000 rpm, at 4°C for 2 hours. After ultracentrifugation, supernatants were decanted and eVLP pellets resuspended in DMEM 10% FBS media such that they are now approximately 1,000 times more concentrated than they were before ultracentrifugation. eVLPs were added dropwise to cells that were seeded in a 24-well plate 24 hours prior to transduction. Polybrene (5-10 μ g/mL in cell culture medium; Sigma-Aldrich #TR-1003-G) was supplemented to enhance transduction efficiency, if necessary. Vectofusin-1 (10 μ g/mL in cell culture medium, Miltenyi Biotec #130-111-163) was supplemented to enhance transduction efficiency, if necessary. Immediately following the addition of eVLPs, the 24-well plate was centrifuged at 1,150 xg for 30 min at room temperature to enhance transduction efficiency, if necessary.

Example 1.

Cas9 RNP was delivered in VSVG-pseudotyped VLPs with or without a fusion to a PH domain. T2eVLPs containing Cas9 with or without PH fusion and VEGF-targeting sgRNA were applied to HepG2, U2OS, HEK293T, CFPAC1, BeWo, Jurkat, K562, and primary T cells for 48 hours. Gene modification frequencies of the target site within VEGF were obtained by amplicon sequencing. FIG. 3 demonstrates that fusion to PH domains from hPLC δ 1 or hAKT1 significantly enhanced delivery/editing efficiency of Cas9 in T2eVLPs.

Gag fusions to Cas9 or PH fusions to Cas9 with guide RNA targeting GFP were packaged in VLPs or T1eVLPs, respectively. U2OS or HEK293 cell line stably expressing a single copy of GFP were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, Cas9 fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by PVDF filtration and ultracentrifugation at 100,000xg for

2 hours. Gene modification frequencies were determined by T7E1 and flow cytometry. The results are shown in FIGs. 5A-B.

In FIG. 6, hPLC δ 1 PH fusions to codon optimized Cas9 with guide RNA targeting HEK site #3 or VEGF site #2 were packaged in T1eVLPs. U2OS cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM, 10% FBS) 48 hours after transfection of VSVG, Cas9 fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by amplicon sequencing.

In FIG. 7, hPLC δ 1 (left graph) or hAkt PH (right graph) fusions to codon optimized Cas9 with guide RNA targeting VEGF site #3 were packaged in T1eVLPs. U2OS cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM, 10% FBS) 48 hours after transfection of VSVG, Cas9 fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by amplicon sequencing.

In FIG. 8, gag fusions to the N or C terminus of Cas9-based base editors (BE3 and BE4) or PH fusions to the N or C terminus of BE3 and BE4 with guide RNA targeting VEGF site #2 were packaged in VLPs and eVLPs, respectively. HEK293T cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, base editor fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by amplicon sequencing.

In FIG. 9, hPLC δ 1 fusions to the N terminus of Cas9-based base editors (codon optimized BE4) with guide RNA targeting HEK site #3 were packaged in eVLPs. HEK293T cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, base editor fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by amplicon sequencing.

In FIG. 10, hPLC δ 1 fusions to the N terminus of Cas9-based base editors (codon optimized ABE) with guide RNA targeting VEGF site #3 were packaged in eVLPs. HEK293T cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, base editor fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by amplicon sequencing.

In FIG. 11, hPLC δ 1 fusions to the N terminus of Cas9-based base editors (codon optimized ABE) with guide RNA targeting HEK site #3 were packaged in eVLPs. HEK293T cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, base editor fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by amplicon sequencing.

In FIG. 12, gag fusions to Cas12a or hPLC δ 1 PH fusions to Cas12a with guide RNA targeting FANCF site #1 were packaged in VLPs and eVLPs, respectively. HEK293 cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, Cas12a fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by PVDF filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by T7E1.

In FIG. 13, hPLC δ 1 PH fusions to MS2 with MS2-stem loop guide RNA targeting GFP site #1 were packaged in eVLPs with Cas9. HEK293 cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, Cas9, PH-MS2 fusions and MS2 stem loop guide RNA expressing plasmids. Particle purification and concentration was performed by PVDF filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by T7E1.

In FIG. 14, hPLC δ 1 PH fusions to DmrC with guide RNA targeting GFP site #1 and Cas9 fused to DmrA repeats were packaged in eVLPs. HEK293 cells were treated with these particles that were previously purified from HEK293T cell culture media

(DMEM) 48 hours after transfection of VSVG, DmrA-Cas9, PH-DmrC fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by PVDF filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by T7E1.

In FIG. 15, hPLC81 PH fusions to GCN4 repeats with guide RNA targeting GFP site #1 and Cas9 fused to scFv were packaged in eVLPs. HEK293 cells were treated with these particles that were previously purified from HEK293T cell culture media (DMEM) 48 hours after transfection of VSVG, scFv-Cas9, PH-GCN4 fusions and guide RNA expressing plasmids. Particle purification and concentration was performed by PVDF filtration and ultracentrifugation at 100,000xg for 2 hours. Gene modification frequencies were determined by T7E1.

FIGs. 16-40 show various non-limiting examples of eVLP configurations and possible cargo.

TABLE 1 | Exemplary Virally-derived glycoproteins.

Virally-derived glycoproteins
vesicular stomatitis virus glycoprotein (VSVG)
GP64
GP160
RD114
BaEVTR
BaEVTRless
FuG-E
FuG-E (P440E)
MLV ENV (ecotropic)
MLV ENV (amphotropic)
MLV 10A1

TABLE 2 | Exemplary Potential Cas9 and Cas12a orthologs

DNA-binding Cas ortholog	Enzyme class	Nickase mutation	CI mutations
SpCas9	Type II-A	D10A	D10A, H840A
SaCas9	Type II-A	D10A	D10A
CjCas9	Type II-C	D8A	D8A
NmeCas9	Type II-C	D16A	D16A, H588A
asCas12a	Type II-C		D908A, E993A
IbCas12a	Type II-C		D832A, E925A

Nickase mutation residues represents a position of the enzyme either known to be required for catalytic activity of the conserved RuvC nuclease domain or predicted to be required for this catalytic activity based on sequence alignment to CjCas9 where structural information is lacking. All positional information refers to the wild-type protein sequences acquired from uniprot.org.

TABLE 3 | Exemplary Deaminase domains and their substrate sequence preferences.

Deaminase	Nucleotide sequence preference
hAID	5'-WRC
rAPOBEC1*	5'-TC ≥ CC ≥ AC > GC
mAPOBEC3	5'-TYC
hAPOBEC3A	5'-TCG
hAPOBEC3B	5'-TCR > TCT
hAPOBEC3C	5'-WYC
hAPOBEC3F	5'-TTC
hAPOBEC3G	5'-CCC
hAPOBEC3H	5'-TTCA ~ TTCT ~ TTCG > ACCCA > TGCA
ecTadA	
hAdar1	
hAdar2	

Nucleotide positions that are poorly specified or are permissive of two or more nucleotides are annotated according to IUPAC codes, where W = A or T, R = A or G, and Y = C or T.

TABLE 4 | Exemplary Epigenetic modulator domains.

Epigenetic modulator	Epigenetic modulation
VP16	transcriptional activation
VP64	transcriptional activation
P65	transcriptional activation
RTA	transcriptional activation
KRAB	transcriptional repression
MeCP2	transcriptional repression
Tet1	Methylation
Dnmt3a	Methylation

5

TABLE 5 | Exemplary CRISPR based RNA-guided RNA binding enzymes

RNA-binding Cas ortholog	Enzyme class
LshCas13a	Type-VI
LwaCas13a	Type-VI
PspCas13b	Type-VI
RfxCas13d	Type-VI

10

TABLE 6 | Exemplary plasma membrane recruitment domains

#	Plasma membrane recruitment domain	Substitution(s)
1.	Pleckstrin homology domain of human phospholipase C δ 1 (hPLC δ 1)	
2.	Pleckstrin homology domain of human Akt1 (hAkt1)	
3.	Mutant Pleckstrin homology domain of human Akt1	E17K
4.	Pleckstrin homology domain of human 3-phosphoinositide-dependent protein kinase 1 (hPDK1)	
5.	Human CD9	
6.	Human CD47	
7.	Human CD63	
8.	Human CD81	
9.	Pleckstrin homology domain of Human Dapp1	
10.	Pleckstrin homology domain of Mouse Grp1	
11.	Pleckstrin homology domain of Human Grp1	

#	Plasma membrane recruitment domain	Substitution(s)
12.	Pleckstrin homology domain of Human OSBP	
13.	Pleckstrin homology domain of Human Btk1	
14.	Pleckstrin homology domain of Human FAPP1	
15.	Pleckstrin homology domain of Human CERT	
16.	Pleckstrin homology domain of Human PKD	
17.	Pleckstrin homology domain of Human PHLPP1	
18.	Pleckstrin homology domain of Human SWAP70	
19.	Pleckstrin homology domain of Human MAPKAP1	

Exemplary Relevant Protein Sequences:

***Homo sapiens*: Pleckstrin homology domain of Human Dapp1**

MQTGRTEDDLVP TAPSLGTKEGYLTQGGVKTWKTRWFTLHRNELKYFKDQMSPEP
 5 IRILDLTECSAVQFDYSQERVNCFCLVFPFRTFYLCAGTGV EADEWIKILRWKLSQIRKQ
 LNQGEGTIR (SEQ ID NO:1)

***Mus musculus*: Pleckstrin homology domain of Mouse Grp1**

PFKIPEDDGN DLTH TFFNP DREGWLLKLGGRVKTWKRRWFILTDNCLYYFEYTTDKEP
 10 RGIIPLENLSIREVEDPRKPNCFELYNPSHKGQVIKACKTEADGRVVEGNHVVYRISAPS
 PEEKEEWMKSIKASISRDPFYDMLATRKRRIANKK (SEQ ID NO:2)

***Homo sapiens*: Pleckstrin homology domain of Human Grp1**

NPDREGWLLKLGGGRVKTWKRRWFILTDNCLYYFEYTTDKEPRGIIPLENLSIREVEDP
 15 RKPNCFELYNPSHKGQVIKACKTEADGRVVEGNHVVYRISAPSP EEKEEWMKSIKASIS
 (SEQ ID NO:3)

***Homo sapiens*: Pleckstrin homology domain of Human OSBP**

SGSAREGWLFKWTNYIKGYQRRWFVLSNGLLSYYRSKAEMRH TCRGTINLATANITVE
 20 DSCNFIISNGGAQTYHLKASSEVERQRWWTALELAKAKAVK (SEQ ID NO:4)

***Homo sapiens*: Pleckstrin homology domain of Human Btk1**

MAAVILESIFLKRSQQKKKTSPLNFKKRLFLT VHKLSYYEYDFERGRRGSKKGSIDVEKI
 25 TCVETVVPEKNPPPERQIPRRGEESSEMEQISIERFPYPFQVVYDEGPLYVFSPTTEELR
 KRWIHQLKNVIRYNSDLVQKYHPCFWIDGQYLCCSQ TAKNAMGCQILENRNGSLKP
 (SEQ ID NO:5)

***Homo sapiens*: Pleckstrin homology domain of Human FAPP1**

MEGVLYKWTNYLTGWQPRWFVLDNGILSYYSQDDVCKGSKGSIKMAVCEIKVHSAD
 30 NTRMELIIPGEQHFYMKAVNAAERQRWLVALGSSKACLTDT (SEQ ID NO:6)

Homo sapiens: Pleckstrin homology domain of Human CERT

MSDNQSWNSSGSEEDPETESGPPVERCGVLSKWTNYIHGWQDRWVVLKNNALSYK
SEDETEYGCRGSICLSKAVITPHDFDECRFDSVNSVWYLRAQDPDHRQQWIDAIEQH
KTESGYG (SEQ ID NO:7)

5

Homo sapiens: Pleckstrin homology domain of Human PKD

TVMKEGWMVHYTSKDTLRKRHYWRLDSKCITLFQNDTGSRYEKEIPLSEILSLEPVKTS
ALIPNGANPHCFEITTANVVYYVGENVVNPSSPSPNSVLTSGVGADVARMWEIAIQHA
LM (SEQ ID NO:8)

10

Homo sapiens: Pleckstrin homology domain of Human PHLPP1

RIQLSGMYNVRKGMQLPVNRWTRRQVILCGTCLIVSSVKDSLTKGMHVLPLIGGKVEE
VKKHQHCCLAFSSSGPQSQTYYICFDTFTEYLRWLRQVSKVAS (SEQ ID NO:9)

15

Homo sapiens: Pleckstrin homology domain of Human SWAP70

DVLKQGYMMKKGHRRKNWTERWFVLKPNISYYVSEDLKDKKGDILLDENCCVESLPD
KDGGKCLFLVKCFDKTFEISASDKKKKQEWIQAIIHSTIH (SEQ ID NO:10)

20

Homo sapiens: Pleckstrin homology domain of Human MAPKAP1

DMLSSHYYKSFVSMIHLRFTTDVQLGISGDKVEIDPVTNQAQKSTKFWIKQKPISIDSD
LLCACDLAEEKSPSHAIFKLTYSNHDYKHLVFESDAATVNEIVLKVNYILES (SEQ ID
NO:11)

25

Baboon Endogenous Retrovirus glycoprotein (BaEVTR)

MGFTTKIIFLYNLVLVYAGFDDPRKAIELVQKRYGRPCDCSGGQVSEPPSDRVSQVTCS
GKTAYLMPDQRWKCKSIPKDTSPSGPLQECPCNSYQSSVHSSCYTSYQQCRSGNKTY
YTATLLKTQTGGTSDVQVLGSTNKLQSPCNIGKQSIWSTTAPIHVSDDGGGLDITRI
KSVQRKLEEIHKALYPELQYHPLAIPKVRDNLMDAQTNLNATYNLLLSNTSLVDDC
WLCKLGPPTPLAIPNLLSYVTRSSDNISCLIPPLLVQPMQFSNSSLFSPSYNSTEEI
DLGHVAFSNCTSTNVTGPICAVNGSVFLCGNNMAYTYLPTNWTGLCVLATLLPDIDIIP
GDEPVPIPAIDHFIYRPKRAIQFIPLLAGLGITAAFTTGATGLGVSVTQYTKLSNQLISDVQI
LSSTIQDLQDQVDSLAEVVLQNRRLDLLTAEQGGICLALQEKCCFYVNKSGIVRDKIKT
LQEELERRRKDLASNPLWTGLQGLLPYLLPFLGPLLTLTLLLTIGPCIFNRLVQFVKDRIS
VVQALVLTQQYHQLKPLEYEP (SEQ ID NO:12)

35

Modified Baboon Endogenous Retrovirus glycoprotein (BaEVTRless)

MGFTTKIIFLYNLVLVYAGFDDPRKAIELVQKRYGRPCDCSGGQVSEPPSDRVSQVTCS
GKTAYLMPDQRWKCKSIPKDTSPSGPLQECPCNSYQSSVHSSCYTSYQQCRSGNKTY
YTATLLKTQTGGTSDVQVLGSTNKLQSPCNIGKQSIWSTTAPIHVSDDGGGLDITRI
KSVQRKLEEIHKALYPELQYHPLAIPKVRDNLMDAQTNLNATYNLLLSNTSLVDDC
WLCKLGPPTPLAIPNLLSYVTRSSDNISCLIPPLLVQPMQFSNSSLFSPSYNSTEEI
DLGHVAFSNCTSTNVTGPICAVNGSVFLCGNNMAYTYLPTNWTGLCVLATLLPDIDIIP
GDEPVPIPAIDHFIYRPKRAIQFIPLLAGLGITAAFTTGATGLGVSVTQYTKLSNQLISDVQI
LSSTIQDLQDQVDSLAEVVLQNRRLDLLTAEQGGICLALQEKCCFYVNKSGIVRDKIKT

40

LQEELERRRKDLASNPLWTGLQGLLPYLLPFLGPLLTLLLLLTIGPCIFNRLTAFINDKLNII
HAM (SEQ ID NO:13)

Fusion protein of Vesicular stomatitis Indiana virus and Rabies virus

Glycoproteins (FuG-E)

MVPQVLLFVLLLGFSLCFGKFPIYTIPDELGPWSPIDIHHLSCPNNLVVEDEGCTNLSEFS
YMELKVGYISAIKVNNGFTCTGVVTEAETYTNFVG YVTTTTFKRKHFRTPTDACRAAYNWK
MAGDPRYEESLHNPYPDYHWLRTVRTTKESLIISPSVTDLDPYDKSLHSRVFPGGKCS
GITSSTYCSTNHDYTIWMPENPRPRTPCDIFTNSRGKRASNGNKTCGFVDERGLYKS
LKGACRLKLCGVLGLRLMDGTWVAMQTSDETKWCPPDQLVNLHDFRSDEIEHLVVEE
LVKKREECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLM EADAHYKSVRT
WNEIIPSKGCLKVGGRCPPHVNGVFFNGIILGPDDHVLIPEMQSSLLQQHMELLESSVIP
LMHPLADPSTVFKEGDEAEDFVEVHLPKNPIELVEGW FSSWKSSIASFFFIIGLIIGLFLVL
RVGIHLCKIKHTKKRQIYTDIEMNRLGK (SEQ ID NO:14)

Modified Fusion protein of Vesicular stomatitis Indiana virus and Rabies virus

Glycoproteins (FuG-E (P440E))

MVPQVLLFVLLLGFSLCFGKFPIYTIPDELGPWSPIDIHHLSCPNNLVVEDEGCTNLSEFS
YMELKVGYISAIKVNNGFTCTGVVTEAETYTNFVG YVTTTTFKRKHFRTPTDACRAAYNWK
MAGDPRYEESLHNPYPDYHWLRTVRTTKESLIISPSVTDLDPYDKSLHSRVFPGGKCS
GITSSTYCSTNHDYTIWMPENPRPRTPCDIFTNSRGKRASNGNKTCGFVDERGLYKS
LKGACRLKLCGVLGLRLMDGTWVAMQTSDETKWCPPDQLVNLHDFRSDEIEHLVVEE
LVKKREECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLM EADAHYKSVRT
WNEIIPSKGCLKVGGRCPPHVNGVFFNGIILGPDDHVLIPEMQSSLLQQHMELLESSVIP
LMHPLADPSTVFKEGDEAEDFVEVHLEKNPIELVEGW FSSWKSSIASFFFIIGLIIGLFLVL
RVGIHLCKIKHTKKRQIYTDIEMNRLGK (SEQ ID NO:15)

Amphotrophic Murine Leukemia Virus (MLV ENV (amphotropic))

MARSTLSKPPQDKINPWKPLIVMGVLLGVGMAESPHQVFNVWVRVTNLMTGRTANAT
SLLGTVQDAFPKLYFDLCLDVGEEWDPSDQEPYVGYGCKYPAGRQRTRTDFDYVCPG
HTVKSGCGGPGEGYCGKWGCETTQAYWKPTSSWDLISLKRGNTPWDTGCSKVAC
GPCYDLSKVSNSFQGATRGGRCNPLVLEFTDAGKKANWDGPKSWGLRLYRTGTDPIT
MFSLTRQVLNVGPRVPIGNPVLDPQRLPSSPIEIVPAPQPPSPLNTSYPPSTTSTPSTS
PTSPSPVQPPPGTGDRLLALVKGAYQALNLNPDKTQECWLCLVSGPPYYEGVAVVG
TYTNHSTAPANCTATSQHKLTLSEVTGQGLCMGAVPKTHQALCNTTQSAGSGSYLAA
PAGTMWACSTGLTPCLSTTVLNLTTDYCVLVELWPRVIYHSPDYMYGQLEQRTKYKRE
PVSLLTALLLGGTLMGGIAAGIGTGTTALIKTQQFEQLHAAIQTDLNEVEKSITNLEKSLTS
LSEVVLQNRRLDLLFLKEGGLCAALKECCFYADHTGLVRDSMAKLRERLNQRQKLF
ETGQGWFEGLFNRSWF TTTLISTIMGPLIVLLLLLLFGPCILNRLVQFVKDRISVVQALVLT
QQYHQLKPIEYEP (SEQ ID NO:16)

Ecotrophic Murine Leukemia Virus (MLV ENV (Ecotropic))

MARSTLSKPLKNKVNPRGPLIPLILLMLRGVSTASPGSSPHQVYNITWEVTNGDRETVW
ATSGNHPLWTWWPDLTPDLCMLAHHGPSYWGLEYSQSPFSSPPGPPCCSGGSSPGC
SRDCEEPLTSLTPRCNTAWNRLKLDQTTHKSNEGFYVCPGPHRPRESKSCGGPDSFY
CAYWGCETTGRAYWKPPSSWDFITVNNNLTSQAVQVCKDNKWCNPLVIRFTDAGR

VTSWTTGHWGLRLYVSGQDPGLTFGIRLRYQNLGPRVPIGPNPVLADQQPLSKPKPV
 KSPSVTKPPSGTPLSPTQLPPAGTENRLLNLVDGAYQALNLTSPDKTQECWLCLVAGP
 PYYEGVAVLGTYSNHTSAPANCSVASQHKLTLEVTGQGLCIGAVPKTHQALCNTTQT
 SSRGSYYLVAPTGTMWACSTGLTPCISTTILNLTTDYCVLVELWPRVTYHSPSYVYGLF
 5 ERSNRHKREPVSLTLALLLGGLTMGGIAAGIGTGTTALMATQQFQQLQAAVQDDLREV
 EKSISNLEKSLTSLSEVVLQNRRLDLLFLKEGGLCAALKEECCFYADHTGLVRDSMAK
 LRERLNQRQKLFESTQGWFEGLFNRSPWFTTLLISTIMGPLIVLLMILLFGPCILNRLVQFV
 KDRISVVQALVLTQQYHQLKPIEYEP (SEQ ID NO:17)

Moloney murine leukemia virus 10A1 strain Glycoprotein (MLV 10A1)

MARSTLSKPLKDKINPWKSLMVMGVLLRVGMAESPHQVFNTWVRVTNLMTGRTANAT
 SLLGTVQDAFPRLYFDLCLDVGEEWDPSDQEPYVGYGCKYPGGRKRTRTFDFYVCPG
 HTVKSGCGGPREGYCGEWGCETTQAYWKPTSSWDLISLKRGNTPWDTGCSKMAC
 GPCYDLSKVSNSFQGATRGGRCNPLVLEFTDAGKKANWDGPKSWGLRLYRTGTDPIT
 15 MFSLTRQVLNIGPRIPIGPNPVITGQLPPSRPVQIRLPRPPQPPPTGAASIVPETAPPSQ
 QPGTGDRLLNLVEGAYRALNLTNPDKTQECWLCLVSGPPYEGVAVVGTYTNHSTAP
 ASCTATSQHKLTLEVTGQGLCMGAVPKTHQALCNTTQSAGSGSYLAAPAGTMWAC
 STGLTPCLSTTMLNLTTDYCVLVELWPRIYHSPDYMYGQLEQRKYKREPVSLTLALLL
 GGLTMGGIAAGIGTGTTALIKTQQFEQLHAAIQTDLNEVEKSITNLEKSLTSLSEVVLQNR
 20 RGLDLLFLKEGGLCAALKEECCFYADHTGLVRDSMAKLRELRNQRQKLFESGQGWFE
 GLFNRSPWFTTLLISTIMGPLIVLLLILLFGPCILNRLVQFVKDRISVVQALVLTQQYHQLKPI
 EYEP (SEQ ID NO:18)

***Rattus norvegicus* & synthetic: APOBEC1-XTEN L8-nspCas9-UGI-SV40 NLS**

MSSETGPVAVDPTLRRRIEPHEFEVFFDPRELKRETCCLYEINWGGRHHSIWRHTSQNT
 NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVTFLFIYIARL
 YHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYSNPSNEAHWPYRPHLWVR
 LYVLELYCIILGLPPCLNLRKQKQPLTFFIALQSCHYQRLPPHILWATGLKSGSETPGT
 SESATPESDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFD
 30 SGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEEDKKH
 ERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRILIYALAHMIKFRGHFLIEGDLN
 PDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLLENLIAQLPGEKKN
 GLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDITYDDDLNLLAQIGDQYADLFLAAKN
 LSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSK
 35 NGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHL
 GELHAILRRQEDFYFPLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPW
 NFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMR
 KPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYH
 DLLKIIKDKDFLDNEENEDILEDIVLTTLTFEDREMIEERLKTYAHLFDDKVMKQLKRRRY
 40 TGWGRLSRKLINGIRDKQSGKTILDFLKSDFANRNFMLIHDDSLTFKEDIQKAQVSG
 QGDSLHEHIANLAGSPAIIKQILQTVKVDELVKVMGRHKKPENIVIMARENQTTQKGQ
 KNSRERMKRIEELGKELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRL
 SDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKKNYWRQLLNAKLI
 TQRKFDNLTKAERGGSELDAKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIRE

VKVITLKSCLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVG TALIKKYPKLESEFVYGD
 YKVYDVRKMIKSESEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIV
 WDKGRDFATVRKVL SMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKY
 GGFDSPTVAYSVLVVAKEVGKSKKLKSVKELLGITIMERSSSFENPIDFLEAKGYKEVK
 5 KDLIIKLPKYSLFELNGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED
 NEQKQLFVEQHKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKH RDKPIREQAENIIHLF
 TLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ SITGLYETRIDLSQLGGDSGGSTN
 LSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEY
 KP WALVIQDSNGENKIKMLSGGSPKKRKV (SEQ ID NO:19)

Homo sapiens: AID

MDSLLMNRKFLYQFKNVRWAKGRRETYLCYVVKRRDSATSFS LDFGYLRNKNKGCHV
 ELLFLRYISDWLDPGRCYRVTWFTSWSPCYDCARHVADFLRG NPNL SLRIFTARLYF
 CEDRKAEP EGLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAW EGLHENS VRLS
 15 RQLRRILLPLYEVDDL RDAFRTLGL (SEQ ID NO:20)

Homo sapiens: AIDv solubility variant lacking N-terminal RNA-binding region

LMDPHIFTSN FNNGIGRHKTYLCYEVERLDSATSFS LDFGYLRNKNKGCHV ELLFLRYISD
 WDLDPGRCYRVTWFTSWSPCYDCARHVADFLRG NPNL SLRIFTARLYFCEDRKAEP E
 20 GLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAW EGLHENS VRLS RQLRRILLPL
 YEVDLLRDAFRTLGL (SEQ ID NO:21)

Homo sapiens: AIDv solubility variant lacking N-terminal RNA-binding region and the C-terminal poorly structured region

MDPHIFTSN FNNGIGRHKTYLCYEVERLDSATSFS LDFGYLRNKNKGCHV ELLFLRYISD
 WDLDPGRCYRVTWFTSWSPCYDCARHVADFLRG NPNL SLRIFTARLYFCEDRKAEP E
 25 GLRRLHRAGVQIAIMTFKDYFYCWNTFVENHERTFKAW EGLHENS VRLS RQLRRILLPL
 (SEQ ID NO:22)

Rattus norvegicus: APOBEC1

MSSETGPVAVDPTLRRRIEPHEFEVFFDPREL RKETCLLYEINWGGRH SIWRHTSQNT
 NKHVEVNFIEKFTTERYFCPNTRCSITWFLSWSPCGECSRAITEFLSRYPHVT LFIYIARL
 YHHADPRNRQGLRDLISSGVTIQIMTEQESGYCWRNFVNYS PSNEAHWP RYPHLWVR
 30 LYVLELYC IILGLPPCLNLRKQPQLTFFTIALQSCHYQRLPPHILWATGLK (SEQ
 ID NO:23)

Mus musculus: APOBEC3

MGPFCLGCSHRKCYSPIRN LISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSL
 HHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLAT
 40 HHNLSLDIFSSRLYNVQDPETQQNLCLRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRR
 FRPWKRLLTNFRYQDSKLQEILRRMDPLSEEEFY SQFYNQRVKHL CYYHRMKPYLCYQ
 LEQFNGQAPLKGCLLSEKGKQHA EILFDKIRSMELSQVTITCYLTWSPCPNCAWQLAA
 FKRDRPDLILHIYTSRLYFHWKRPFQKGLCSLWQSGILVDVMDLPQFTDCWTNFVNP

RPFRPWKGLEIISRRTQRRRLRRIKESWGLQDLVNDFGNLQLGPPMSN (SEQ ID NO:24)

***Mus musculus*: APOBEC3 catalytic domain**

MGPFCLGCSHRKCYSPIRNLISQETFKFHFKNLGYAKGRKDTFLCYEVTRKDCDSPVSL
HHGVFKNKDNIHAEICFLYWFHDKVLKVLSPREEFKITWYMSWSPCFECAEQIVRFLAT
HHNLSLDIFSSRLYNVQDPETQQNLCLRLVQEGAQVAAMDLYEFKKCWKKFVDNGGRR
FRPWKRLLTNFRYQDSKLQEILRR (SEQ ID NO:25)

***Homo sapiens*: APOBEC3A**

MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHN
QAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTFISWSPCFSWGCAEVRAFLQ
ENTHVRLRIFAARIYDYPDYKEALQMLRDAGAQSIMTYDEFKHCWDTFVDHQQGCPF
QPWDGLDEHSQALSGRLRAILQNQGN (SEQ ID NO:26)

***Homo sapiens*: APOBEC3G**

MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTGSPSRPPLDAKIFRGQV
YSELKYHPEMRFFHWFWSKWRKLHRDQEYEVWYISWSPCTKCTRDMATFLAEDPKVT
LTIFVARLYYFWDPDYQEALRSLCQKRDGPRATMKIMNYDEFQHCWSKFVYSQRELFE
PWNNLPKYYILLHIMLGEILRHSMDPPTFTFNNEPWWRGRHETYLCYEVERMHNDT
WLLNQRRGFLCNQAPHKHGFLEGRHAELCFDVIPFWKLDLDQDYRVTCFTSWSPC
FSCAQEMAKFISKNHVSLCIFTARIYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCW
DTFVDHQQGCPFQPWDGLDEHSQDLSGRLRAILQNNEN (SEQ ID NO:27)

***Homo sapiens*: APOBEC3G catalytic domain**

PPTFTFNNEPWWRGRHETYLCYEVERMHNDTWLLNQRRGFLCNQAPHKHGFLE
GRHAELCFDVIPFWKLDLDQDYRVTCFTSWSPCFSCAQEMAKFISKNHVSLCIFTAR
IYDDQGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQQGCPFQPWDGLDEHSQD
LSGRLRAILQNNEN (SEQ ID NO:28)

***Homo sapiens*: APOBEC3H**

MALLTAETFRLQFNNKRRLRRPYYPKALLCYQLTPQNGSTPTRGYFENKKKCHAEICF
INEIKSMGLDETQCYQVTCYLTWSPCSCAWELVDFIKAHDHLNLGIFASRLYYHWCKP
QQKGLRLLCGSQVPVEVMGFPAFCWENFVDHEKPLSFNPYKMLEELDKNSRAIKR
RLERIKIPGVRAQGRYMDILCDAEV (SEQ ID NO:29)

***Homo sapiens*: APOBEC3F**

MKPHFRNTVERMYRDTFSYNFYNRPILSRRNTVWLCYEVKTGSPSRPRLDAKIFRGQV
YSQPEHHAEMCFLSWFCGNQLPAYKCFQITWVFSWTPCPDCVAKLAEFLAHPNVTL
TISAARLYYYWERDYRRALCRLSQAGARVKIMDDEEFAYCWENFVYSEGQPFMPWYK
FDDNYAFLHRTLKEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSP
VSWKRGVFRNQVDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGE
VAEFLARHSNVNLTIFTARLYYFWDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFV
YNDDEPFKPWKGLKYNFLFLDSKLQEILE (SEQ ID NO:30)

Homo sapiens: APOBEC3F catalytic domain

KEILRNPMEAMYPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQ
VDPETHCHAERCFLSWFCDDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVN
5 LTIFTARLYYFWDTDYQEGRLRSLSQEGASVEIMGYKDFKYCWENFVYNDDEPFKPKWKG
LKYNFLFLDSKLQEILE (SEQ ID NO:31)

Escherichia coli: TadA

MKRTADGSEFESPCKKKRKVSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNN
10 RVIGEGWNRPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIH
SRIGRVVFGARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRRQ
EIKAQKKAQSSTDGSGSSGSSGSGSETPGTSESATPESSGSSGSSGSSEVEFSHEYWM
RHALTLAKRARDEREVPVGAVLVLNRRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVM
15 QNYRLIDATLYVTLEPCVMCAGAMIH SRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNH
RVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO:32)

Homo sapiens: Adar1

MNPRQGYSLSGYYTHPFQGYEHRQLRYQQPGPGSSPSSFLLKQIEFLKGQLPEAPVIG
KQTPSLPPSLPGLRPRFPVLLASSTRGRQVDIRGVPRGVHLGSQGLQRGFQHPSPRG
20 RSLPQRGVDCLSHFQELSIYQDQEQRILKFLLEELGEGKATTAHDLSGKLGTTPKKEINR
VLYSLAKKGKLQKEAGTPPLWKIAVSTQAWNQHSGVVRPDGHSQGAPNSDPSLEPED
RNSTSVSEDLLEPFIAVSAQAWNQHSGVVRPDSHSQGSPNSDPGLEPEDSNSTSALE
DPLEFLDMAEIKEKICDYLFNVSDSSALNLAKNIGLTKARDINAVLIDMERQGDVYRQGT
TPPIWHLTDKKRERMQIKRNTNSVPETAPAAIPETKRNAEFLTCNIPTSNASNNMVTEK
25 VENGQEPVIKLENRQEARPEPARLKPPVHYNGPSKAGYVDFENGQWATDDIPDDLNSI
RAAPGEFRAIMEMPSFYSHGLPRCSPYKKLTECQLKNPISGLLEYAQFASQTCEFNIE
QSGPPHEPRFKFQVVINGREFPPAEAGSKKQDAAMKAMTILLEAKAKDSGKSEE
SSHYTEKESEKTAESQTPTPSATSFSGKSPVTTLLECMHKLGNSCFRLLSKEGPAH
EPKFQYCVAVGAQTFPSVSAPSKKQVQMAAEEAMKALHGEATNSMASDNQPEGMIS
30 ESLDNLESMMPNKVRKIGELVRYLNTNPVGGLLEYARSHGFAAEFKLVDQSGPPHEPK
FVYQAKVGGRWFPVAVCAHKKQKQKQEAADAALRVLIGENKAERMGFTEVTPVTGAS
LRRTMLLSRSPEAQPKTLPLTGSTFHDQIAMLSHRCFNTLTNSFQPSLLGRKILAAIIMK
KDSIEDMGVVVSLGTGNRCVKGDSLSLKGETVNDCHAEIISRRGFIRFLYSELMKYNSQT
AKDSIFEPAGGGEKLQIKKTVSFHLYISTAPCGDGALFDKSCSDRAMESTESRHYPVFE
35 NPKQGKLRRTKVENGEGTIPVESSDIVPTWDGIRLGERLRTMSCSDKILRWNVLGLQ GAL
LTHFLQPIYLYKSVTLGYLFSQGHLLTRAICCRVTRDGSFEDGLRHPFIVNHPKVGRVSIY
DSKRQSGKTKETSVNWCLADGYDLEILDGTRGTVDGPRNELSRVSKKNIFLLFKKLCSF
RYRRDLLRLSYGEAKKAARDYETAKNYFKKGLKDMGYGNWISKPQEEKNFYLCPV
(SEQ ID NO:33)

Streptococcus pyogenes: spCas9 Bipartite NLS

MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDS
GETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFHRLSEESFLVEE
DKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRILIYLAHMIKFR
45 GHFLIEGDLNPDNSDVKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSR

RLENLIAQLPGEKKNGLFGNLIASLGLTPNFKSNFDLAEDAKLQLSKDITYDDDL
 DNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD
 LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGT
 EELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYFPLKDNREKIE
 5 KILTRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEVVVDKGASAQSFIERM
 TNFDKNLPNEKVLPKHSLLEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIV
 DLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKD
 FLDNEENEDILEDIVLTLTLFEDREMIEERLKYAHLFDDKVMKQLKRRRYTGWG
 RLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMLIHDDSLTFKEDIQKAQVSG
 10 QGDSLHEHIANLAGSPAIKKILQTVKVVDELVKVMGRHKPENIVIAMARENQTT
 QKGQKNSRERMKRIEEGKELGSQILKEHPVENTQLQNEKLYLYLQNGRDMY
 VDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVK
 KMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHV
 AQILDSRMNTKYDENDKLIREVKVITLKSCLVSDFRKDFQFYKVREINNYHHAHD
 15 AYLNNAVVGTAIIKKYPKLESEFVYGDYKVYDVRKMIKSEQEIGKATAKYFFYSN
 IMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSPQVNIVKK
 TEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKEK
 GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLELEN
 GRKRMLASAGELQKGNELALPSKYVNFYLYASHYEKLKGSPEDNEQKQLFVEQ
 20 HKHYLDEIIEQISEFSKRVLADANLDKVL SAYNKHARDKPIREQAENIIHLFTLNL
 GAPAAFKYFDTTIDRKRYTSTKEVL DATLIHQSI TGLYETRIDLSQLGGDGSGGG
 GSGKRTADGSEFEPKKKRKVSSGGDYKDHDGDYKDHDIDYKDDDDK (SEQ ID
 NO:34)

Staphylococcus aureus: saCas9

MKRNYILGLDIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARR
 LKRRRRRHRIQRVKKLLFDYNLLTDHSELGINPYEARVKGLSQKLSEEEFSAALL
 HLAKRGRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGE
 VRGSINRFKTS DYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGE
 30 GSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRD
 ENKLEYEYEFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNL
 KVYHDIKDITARKEIENAEELLDQIAKILTIYQSSEDIQEELTNLSEL TQEEIEQISN
 LKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLV
 DDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIELAREKNSKDAQKMINEMQKRNR
 35 QTNERIEEII RTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVD
 HIIPRSVSFDNSFNKVLVKQEENSKKGNRTPFQYLSSSDSKISYETFKKHILNL
 AKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNNLLRSYFRV
 NNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAE DALIIANADFIKWKKL
 DKAKKVMENQMFEKQAESMPEIETE QEYKEIFITPHQIKHIKDFKDYKYSHRVD
 40 KKP NRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYH

HDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGN
KLNALHDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKENYY
EVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMI
DITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG
(SEQ ID NO:35)

Campylobacter jejuni: cjCas9

MARILAFDIGISSIGWAFSENDELKDCGVRIFTKVENPKTGESLALPRRLARSAR
KRLARRKARLNHLKHLIANEFKLNEDYQSFDESLAKAYKGSLSIPYELRFRALN
ELLSKQDFARVILHIAKRRGYDDIKNSDDKEKGAILKAIKQNEEKLANYSVGEY
LYKEYFQKFENSKEFTNVRNKKESYERCIASFLKDELKLIFKKQREFGFSFSK
KFEEEVLSVAFYKRALKDFSHLVGNCSSFTDEKRAPKNSPLAFMFVALTRIINLL
NNLKNTEGILYTKDDLNALLNEVLKNGTLTYKQTKKLLGLSDDYEFKGEKGTYFI
EFKKYKEFIKALGEHNLSQDDLNEIAKDITLIKDEIKLKKALAKYDLNQNQIDSLSK
LEFKDHLNISFKALKLVTPLMLEGKKYDEACNELNLKVAINEDKKDFLPANETY
YKDEVTNPVVLRAIKEYRKVLNALLKKYGVHKNIELAREVGKNHSQRAKIEKE
QENYKAKKDAELECEKLGLKINSKNILKLRLFKEQKEFCAYSGEKIKISDLQDE
KMLEIDHIYPYSRSFDDSYMNVKLVFTKQNKQEKLNQTPFEAFGNDSAKWQKIEV
LAKNLPTKKQKRILDKNYKDKEQKNFKDRNLNDTRYIARLVNNTKYLDLFLPLS
DDENTKLNDTQKGSKVHVEAKSGMLTSALRHTWGFSKDRNNHLHHAIDAVIIA
YANNSIVKAFSDFKKEQESNSAELYAKKISELDYKNKRKFFEPFSGFRQKVLDKI
DEIFVSKPERKKPSGALHEETFRKEEEFYQSYGGKEGVKALELGKIRKVNKGIV
KNGDMFRVDIFKHKKTNKFYAVPIYTMDFALKVLPNKAVARSKKGEIKDWILMD
ENYEFCSLYKDSLILIQTKDMQEPEFVYYNAFTSSTVSLIVSKHDNKFETLSKN
QKILFKNANEKEVIAKSIGIQNLKVFEKYIVSALGEVTKAEFRQREDFKK (SEQ
ID NO:36)

Neisseria meningitidis: nmeCas9

MAAFKPNSINYILGLDIGIASVGWAMVEIDEEENPIRLIDLGVRFERAEVPKTGD
SLAMARRLARSVRRLTRRRRAHRLRLTRRLLKREGVLQAANFDENGLIKSLPNT
WQLRAAALDRKLTPLEWSAVLLHLIKHRGYLSQRKNEGETADKELGALLKGVA
GNAHALQTGDFRTPAELALNKFEKESGHIRNQRSDYSHTFSRKDLQAEILLFE
KQKEFGNPHVSGGLKEGIETLLMTQRPALSGDAVQKMLGHCTFEPAEPKAAKN
TYTAERFIWLTKLNNLRILEQQSERPLTDTERATLMDEPYRKSCLTYAQARKLLG
LEDTAFFKGLRYGKDNAEASTLMEMKAYHAISRALEKEGLKDKKSPNLSPELQ
DEIGTAFSLFKTDEDITGRLKDRIQPEILEALLKHISFDKFVQISLKALRRIVPLMEQ
GKRYDEACAEIYGDHYGKKNTEEKIYLPPIPADEIRNPVVLRLALSQARKVINGVV
RRYGSPARIHIETAREVGKSFKDRKEIEKRQEENRKDREKAAAKFREYFPNFVG
EPKSKDILKLRLYEQQHGKCLYSGKEINLGRLEKGYVEIDHALPFSRTWDDSF
NNKVLVLGSENQNKGNQTPYEYFNGKDNSREWQEFKARVETSRFPRSKKQRI
LLQKFDEDGFKERNLNDTRYVNRFLCQFVADRMRLTGKGKKRVFASNGQITNL
LRGFWGLRKVRAENDRHHAALDAVVVACSTVAMQQKITRFVRYKEMNAFDGKTI

DKETGEVLHQKTHFPQPWEFFAQEVMIRVFGKPDGKPEFEEADTLEKLRTLLA
 EKLSSRPEAVHEYVTPLFVSRAPNRKMSGQGHMETVKSARKLDEGVSVLRVPL
 TQLKLDLEKVMNRREREPKLYEALKARLEAHKDDPAKAFAPFYKYDKAGNRT
 QQVKAVRVEQVQKTGVWVRNHNGIADNATMVRVDVFEKGDYKLVPIYSWQV
 5 AKGILPDRAVVQGKDEEDWQLIDDSFNFKFSLHPNDLVEVITKKARMFYGFASC
 HRGTGNINIRIHDLDHKIGKNGILEGIVKTALS FQKYQIDELGKEIRPCRLKKRP
 PVR (SEQ ID NO:37)

Acidaminococcus sp.: asCas12a

MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNNDHYKELKPIID
 RIYKTYADQCLQLVQLDWNLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDF
 IGRTDNLTDANKRHAIEYKGLFKAELFNGKVLKQLGTVTTEHENALLRSFDKF
 TTYFSGFYENRKNVFS AEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREH
 FENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLN
 15 EVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQSFCKY
 KTLRNENVLETAELFNLNSIDLTHIFISHKKLETISSALCDHWDTLRNALYER
 RISELTGKITSAKEKVQRSLKHEDINLQEIIAAGKELSEAFKQKTSEILSHAHAA
 LDQPLPTTLKKQEEKEILKSQDLSLLGLYHLLDWFVAVDESNEVDPEFSARLTGIK
 LEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDVNKEKNNGAILF
 20 VKNGLYYL GIMPKQKGRYKALSFEPTKTSEGFDKMYDYFPDAAKMIPKCS
 QLKAVTAHFQTHHTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQ
 KGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHI
 SFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLA
 KTSIKLNGQAELFYRPSRMKMAHRLGEKMLNKKLKDQKTPIDTLYQELYDY
 25 VNHRLSHDLSDEARALLPNVITKEVSHEIKDRRFTSDKFFFHVPITLNYQAANSP
 SKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSNTIQQFDYQK
 KLDNREKERVAAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVLENLN
 FGFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPNYQLTDQFT
 SFAKMGTSQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHESRKHFLGDFDL
 30 HYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAQGTPFIAGK
 RIVPVIEHNRFTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDSDSHAIT
 MVALIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRFQNPWPMDADANG
 AYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRN (SEQ ID NO:38)

Lachnospiraceae bacterium: IbCas12a:

MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVKKLLD
 RYYLSFINDVLHSIKLKNLNNYISLFRKKTRTEKENKELENLEINLRKEIAKAFKGN
 EGYKSLFKKDIETILPEFLDDKDEIALVNSFNGFTTAFTGFFDNRENMFSEEAKS
 TSIAFRGINENLTRYISNMDIFEKVDAIFDKHEVQEIKEILNSDYDVEDFFEGEFF
 40 NFVLTQEGIDVYNAIIGGFVTESGEKIKGLNEYINLYNQKTKQKLPKFKPLYKQVL
 SDRESLSFYGEGYTSDEEVLEVFRNTLNKNSEIFSSIKKLEKLFKNFDEYSSAGI
 FVKNPAISTISKDIFGEWNVIRDKWNAEYDDIHLKKKAVVTEKYEDDRRKSFKK
 IGSFSLEQLQEYADADLSVVEKLKEIIQKVDEIYKVYGSSEKLFDAFVLEKSLKK
 NDAVVAIMKDLLDSVKSFENYIAFFGEGKETNRDESFYGDFVLAYDILLKVDHI
 45 YDAIRNYVTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAI
 MDKKYAKCLQKIDKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYYNPSE

DIQKIYKNGTFKKGDMFNLNDCHKLIDFFKDSISRYPKWSNAYDFNFSETEKYK
DIAGFYREVEEQGYKVSFESASKKEVDKLVVEEGKLYMFQIYNKDFSDKSHGTP
NLHTMYFKLLFDENNHGQIRLSGGAELFMRRASLKKEELVVHPANSPIANKNPD
NPKKTTTTLSYDVYKDKRFSEDQYELHIPIAINKCPKNIFKINTEVRVLLKHDDNPY
5 VIGIDRGERNLLYIVVVDGKGNIVEQYSLNEIINNFNIRIKTDYHSLLDKKEKERF
EARQNWTSIENIKELKAGYISQVVHKICELVEKYDAVIALEDLNSGFKNSRVKVE
KQVYQKFEKMLIDKLNMYMDKKSNPCATGGALKGYQITNKFESFKSMSTQNGFI
FYIPAWLTSKIDPSTGFVNLLKTKYTSIADSKKFISFDRIMYVPEEDLFEFALDYK
NFSRTDADYIKKWKLYSYGNRIRIFRNPKKNVFDWEEVCLTSAYKELFNKYGI
10 NYQQGDIRALLCEQSDKAFYSSFMALMSLMLQMRNSITGRTDVDFLISPVKNSD
GIFYDSRNYEAQENAILPKNADANGAYNIARKVLWAIGQFKKAEDEKLDKVKIAI
SNKEWLEYAQTSVKH (SEQ ID NO:39)

***Leptotrichia shahii*: LshCas13a**

15 MGNLFGHKRWYEVDRDKKDFKIKRKVKVKRNYDGNKYILNINENNNKEKIDNNKFIRKYIN
YKKNNDNILKEFTRKFHAGNILFKLKGKEGIIRIENNDDFLETEEVVLYIEAYGKSEKLKALG
ITKKKIIDEAIRQGITKDDKKIEIKRQENEEIEIDIRDEYTNKTLNDCSILRIIENDELETKKS
IYEIFKNINMSLYKIIKIIENETEKVFENRYEEHLREKLLKDDKIDVILTNFMEIREKIKSNL
EILGFVKFYLVNCGDKKSKNKKMLVEKILNINVDLTVEDIADFVIKELEFWNITKRIEKVK
20 KVNNEFLEKRRNRTYIKSYVLLDKHEKFKIERENKKDKIVKFFVENIKNNSIKEKIEKILAE
FKIDELIKKLEKELKKGNCDEIFGIFKKHYKVNFDSSKFSKKSDEEKELYKIIYRYLKGRI
EKILVNEQKVRLKKMEKIEIEKILNESILSEKILKRVKQYTLHIMYLGKLRHNDIDMTTVNT
DDFSRLHAKEELDLELITFFASTNMELNKIFSRENINNDENIDFFGGDREKNYVLDKKILN
SKIKIIRDLDIFDNKNNITNFIKFTKIGTNERNRILHAISKERDLQGTQDDYNKVINIIQNL
25 KISDEEVSKALNLDVVFCDKKNITKINDIKISEENNDIKYLPFSKVLPEILNLYRNPNPKN
EPFDTIETEKIVLNALIYVNKELYKKLILEDDLEENESKNIFLQELKKTGLNIDEIDENIENY
YKNAQISASKGNNKAIKKYQKKVIECYIGYLRKNYEELDFDSDFKMNIQEIKKQIKDINDN
KTYERITVKTSDKTIVINDDFEYIISIFALLNSNAVINKIRNRFFATSVWLNTSEYQNIIDILD
EIMQLNLTNRNENITENWNLNLEEFIQKMKEIEKDFDDFKIQTKEIFNNYYEDIKNNILTEF
30 KDDINGCDVLEKKLEKIVIFDDETKFEIDKKSNIHQDEQRKLSNINKKDLKKKVDQYIKDK
DQEIKSKILCRIIFNSDFLKKYKKEIDNLIEDMESEENKFKQEIYYPKERKNELYIYKKNLFL
NIGNPNFDKIYGLISNDIKMADAKFLNIDGKNIRKNKISEIDAILKNLNDKLNKYSKEYKE
KYIKKLKENDDDFAKNIQNKNYKSFEKDYNRVSEYKKIRDLVEFNLYLNKIESYLIDINWKL
AIQMARFERDMHYIVNGLRELGLIKLSGYNTGISRAYPKRNGSDGFYTTTAYYKFFDEES
35 YKKFEKICYGFGIDLSENSEINKPENESIRNYISHFYIVRNPFADYSIAEQIDRVSNLLSYS
TRYNNSTYASVFEVFKKDVNLDYDELKKKFKLIGNNDILRLMKPKKVSLELESYNSDY
IKNLIIELLTKIENTNDTL (SEQ ID NO:40)

***Leptotrichia wadeii*: LwaCas13a**

40 MKVTKVDGISHKKYIEEGKLVKSTSEENRTSERLSELLSIRLDIYIKNPDNASEEENRIRR
ENLKKFFSNKVLHLKDSVLYLKNRKEKNAVQDKNYSEEDISEYDLKNKNSFSVLKILLN
EDVNSEELIFRKDVEAKLNKINSLSKYSFEENKANYQKINENNVEKVGKSKRNIIYDYY
RESAKRNDYINNVEAFDKLYKKEDIEKLFFLIENSKKHEKYKIREYYHKIIGRKNNDKENF
AKIIYEEIQNVNNIKELIEKIPDMSELKKSQVFYKYLDKEELNDKNIKYAFCHFVEIEMSQ
45 LLKNYVYKRLSNISNDKIRIFEQNLKKLIENKLLNKLDTYVRNCGKYNYYLQVGEIATS
DFIARNRQNEAFLRNIGVSSVAYFSLRNILETENENGITGRMRGKTVKNNKGEEKYVSG
EVDKIYNENKQNEVKENLKMFSYDFNMDNKNEIEDFFANIDEAIISSIAHGIVHFNLELE
GKDIFAFKNIAPSEISKMFQNEINEKKLKLKIFKQLNSANVFNYEYKDVIIKYLKNTKFNF

VNKNIPFVPSFTKLYNKIEDLRNTLKFFWSVPKDKKEKDAQIYLLKNIYYGEFLNKFVKNS
 KVFFKITNEVIKINKQRNQKTGHYKYQKFENIEKTPVEYLAIQSREMINNQDKEEKNTYI
 DFIQQIFLKGFIIDYLNKNNLKYIESNNNDNDNDIFSKIKIKKDNKEKYDKILKNYEKHNRNK
 EIPHEINEFVREIKLGKILKYTENLNMFYILKLLNHKELTNLKGSLKYQSANKEETFSD
 5 LELINLLNLDNRRVTEDELEANEIGKFLDFNENKIKDRKELKKFDTNKIYFDGENIHKHRA
 FYNIKKYGMLNLEKIADKAKYKISLKEKEYSNKKNEIEKNYTMQQNLHRKYARPKKDE
 KFNDYDYKEYEKAIGNIQKYTHLKNKVEFNELNLLQGILLKILHRLVGYTSIWERDLRFRL
 KGEFPENHYIEEIFNFDNSKNVKYKSGQIVEKYINFYKELYKDNVEKRSIYSDKKVKKLK
 10 QEKDLYIANYIAHFNYIPHAELSLLEVLNLRKLLSYDRKLKNAIMKSIVDILKEYGFVATF
 KIGADKKIEIQTLESEKIVHLKLNKKKKLM TDRNSEELCELVKVMFEYKALE (SEQ
 ID NO:41)

Pleckstrin homology domain of *Homo sapiens* phospholipase Cδ1 (hPLCδ1)
 MDGRDFTLHGLQDDEDLQALLKGSQLLKVKSSSWRRERFYKLQEDCKTIW
 15 QESRKVMRTPESQLFSIEDIQEVRMGHRTEGLEKFARDVPEDRCFSIVFKDQR
 NTLDLIAPSPADAQHWVLGLHKIIHSGSMDQRQKLQHWIHSCLRKADKNKDN
 KMSFKELQNFLKELNIQ (SEQ ID NO:42)

Pleckstrin homology domain of *Homo sapiens* Akt1 (hAkt)
 MSDVAIVKEGWLHKGREYIKTWRPRYFLLKNDGTFIGYKERPDVDQREAPLN
 20 NFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREETTAIQTVA
 DGLKKQEEEEMDFRSGSPSDNSGAEEMEVS LAKPKHRVTMNEFEYLKLLGKG
 TFGKVDPV (SEQ ID NO:43)

Pleckstrin homology domain of *Homo sapiens* PDPK1 (hPDPK1)
 KMGPVDKRKGLFARRRQLLLTEGPHLYYVDPVNKVLKGEIPWSQELRPEAKNF
 25 KTFFVHTPNRTYYLMDPSGNAHKWCRKIQEVWRQRYQSH (SEQ ID
 NO:44)

Herpes simplex virus (HSV) type 1: VP16 Transcription Activation Domain
 30 PTDALDDFDLMDLPADALDDFDLMDLPADALDDFDLDM (SEQ ID NO:45)

Herpes simplex virus (HSV) type 1 & Synthetic: VP64
 35 GRADALDDFDLMDLGSDALDDFDLMDLGSDALDDFDLMDLGSDALDDFDLDM
 L (SEQ ID NO:46)

***Homo sapiens*: P65**

SQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPRRRIAVPSRSSA
 SVPKPAPQYPFTSSLSTINYDEFPTMVFPSPGQISQASALAPAPPQVLPQAPAP
 40 APAPAMVSALAQAAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFD
 DEDLGALLGNSTDPVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAI
 TRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALL (SEQ
 ID NO:47)

Kaposi's Sarcoma-Associated Herpesvirus Transactivator: RTA
 45 RDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLA
 PTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPEETSQAVKALRE

MADTVIPQKEEAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELN
EILDFTFLNDECLLHAMHISTGLSIFDTSLF (SEQ ID NO:48)

Homo sapiens: KRAB

MDAKSLTAWSRTLVTFKDVFDFTREEWKLLDTAQQIVYRNVMLENYKNLVSL
GYQLTKPDVILRLEKGEEP (SEQ ID NO:49)

Homo sapiens: MeCP2

EASVQVKRVLEKSPGKLLVKMPFQASPGGKGEGGGATTSAQVMVIKRPGRKR
KAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPICKRKTR
ETVSIEVKEVVKPLLSTLGEKSGKGLKTKCKSPGRKSKESSPKGRSSSASSPPK
KEHHHHHHHAESPKAPMPLPPPPPPPEPQSSSEDPISPPEPQDLSSSICKEEKM
PRAGSLESDGCPKEPAKTQPMVAAAATTTTTTTTTTVAEKYKHRGEGGERKDIVS
SSMPPRNREEPVDSRTPVTERVS (SEQ ID NO:50)

Homo sapiens: Tet1

LPTCSCLDRIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNIRIEIVVYT
KEGKSSHGCPIAKWVLRSSDEEKVLCLVRQRTGHHCPAVMMVVLIMVWDGIP
LPMADRLYTELTLNLSYNGHPTDRRCTLNENRTCTCQGIDPETCGASFSGC
SWSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAP
VAYQNVQVEYENVARECRLGSKEGRPFSGVTACLDCAHPHRDIHNMNNGSTV
VCTLTREDNRSGLGVIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAP
RRKKRTCFTQPVPRSGKKRAAMMTEVLAHKIRAVEKKPIPRIKRNSTTTNNS
KPSSLPTLGSNTETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPG
FSWSPKTASATPAPLKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGP
GISQLGEVAPLPTLSAPVMEPLINSEPSTGVTEPLTPHQPNHQPSFLTSPQDLA
SSPMEEDEQHSEADEPPSDEPLSDDPLSPAEEKLPHIDEYWSDSEHIFLDANIG
GVAIAPAHGSLVIECARRELHATTPVEHPNRNHPTRLSLVFYQHKNLNKPQHGF
ELNLIKFEAKEAKNKKMKASEQKDQAANEGPEQSSEVNELNQIPSHKALTTHD
NVVTVSPYALTHVAGPYNHWW (SEQ ID NO:51)

Homo sapiens: Dnmt3a

MPAMPSSGPGDTSSSAAEREEDRKDGEEQEEPRGKEERQEPSTTARKVGRP
GRKRKHPPVESGDTPKDPAVISKSPSMAQDSGASELLPNGDLEKRSEPQPEE
GSPAGGQKKGAPAEEGEGAAETLPEASRAVENGCCPTKEGRGAPAEAGKEQK
ETNIESMKMEGSRGRLRGGLGWESSLRQRPMPRLTFQAGDPYYISKRKREDEW
LARWKREAEKKAKVIAGMNAVEENQGPGESQKVEEASPPAVQQPTDPASPTV
ATTPEPVGSDAGDKNATKAGDDEPEYEDGRGFGIGELVWGKLRGFSWWPGRI
VSWWMTGRSRAAEGTRWMMWFGDGKFSVVCVEKLMPLSSFCSAFHQATYN
KQPMYRKAIYEVQLQVASSRAGKLFVCHDSDESDTAKAVEVQNKPMIEWALGG
FQPSGPKGLEPPEEEKNPYKEVYTDMMWEPEAAAYAPPPPAKKPRKSTAEKP
KVKEIIDERTRERLVYEVQRQCRNIEDICISCGSLNVTLEHPLFVGGMCQNCKNC
FLECAYQYDDDDGYQSYCTICCGGREVLNMCNNCCRCFCVECDLLVGPAA
QAAIKEDPWNCYMCYMGHKGTYGLLRRREDWPSRLQMFFANNHDQEFDPKPKVY
PPVPAEKRKPIRVLSLFDGIATGLLVKLDLGIQVDRIYASEVCEDSITVGMVRHQ
GKIMYVGDVRSVTQKHIEWGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFF

EFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFLSNPVMIDAKEV
SAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRS
SIKQKGDKQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLGR
SWSVPVIRHLFAPLKEYFACV (SEQ ID NO:52)

5

**Indiana vesiculovirus, formerly Vesicular stomatitis Indiana virus G
Protein: VSVG**

MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIG
TALQVKMPKSHKAIQADGWMCHASKWTTCDFRWYGPKYITHSIRSFTPSVEQ
CKESIEQTKQGTWLNPGFPPQSCGYATVTDAAEAVIVQVTPHHVLVDEYTGWW
DSQFINGKCSNYICPTVHNSTTWHSYKVKGLCDSNLISMDITFFSEDGELSSL
GKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAAR
FPECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPDLSYL
APKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTTTERELWDDW
APYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHIQDAA
SQLPDDDSLFFGDTGLSKNPIELVEGWFWSSWKSSIASFFFIIGLIIGLFLVLRVGIH
LCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO:53)

10

15

Baculovirus envelope glycoprotein GP64

MVSAIVLYVLLAAAAHSAFAAEHCNAQMKTGPYKIKNLDITPPKETLQKDVEITIV
ETDYNENVIIIGYKGYQAYAYNGGSLDPNTRVEETMKTLNVGKEDLLMWSIRQ
QCEVGEELIDRWGSDSDDCFRDNEGRGQWVKGKELVKRQNNNHFAHHTCNK
SWRCGISTSKMYSRLECQDDTDECQVYILDAEGNPINVTVDTVLHRDGVSMILK
QKSTFTTRQIKAACLLIKDDKNNPESVTREHCLIDNDIYDLSKNTWNCKFNRCIK
RKVEHRVKKRPPTWRHNVRKYTEGDTATKGDLMHIEELMYENDLLKMNIEL
MHAHINKLNNMLHDLIVSAKVDERLIGNLMNNSVSSTFLSDDTFLLMPCTNPP
AHTSNCYNNSIYKEGRWWANTDSSQCIDFSNYKELAIDDDVEFWIPTIGNTTYH
DSWKDASGWSFIAQQKSNLITTMENKFGGVGTSLSDITSMAEGELAAKLTFS
MFGHVNFVILIVILFLYCMIRNRNRQY (SEQ ID NO:54)

20

25

30

Human immunodeficiency virus gp160

MRVKEKYQHLWRWGWRTMMLGMLMICSATEKLWVTVYYGVPVWKEATTT
LFCASDAKAYDTEVHNWATHACVPTDPNPQEVVLNVNVTENFNMWKNDMVE
QMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKN
CSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSFEPI
PIHYCAPAGFAILKCNNKTFNGTGPCNTVSTVQCTHGIRPVVSTQLLLNGSLAEE
EVVIRSVNFTDNAKTIIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFTIGKIGN
MRQAHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCG
GEFFYCNSTQLFNSTWFNSTWSTEGSNNTGSDTITLPCRIKQIINMWQKVGKA
MYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNRSELYKY
KVKIEPLGVAPTAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQ
ARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGI
WGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLEE
SQNQKEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVL
SIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEGGERDRDRSIRLVNGSLALI
WDDLRLSLCLFSYHRLRDLIIIIVTRIVELLGRRGWEALKYWWNLLQYWSQELKN

35

40

45

SAVSLLNATAIAVAEGTDRVIEWVQGACRAIRHIPRRIRQGLERILL (SEQ ID NO:55)

Endogenous feline virus RD114 ENV

5 MKLPTGMVILCSLIIVRAGFDDPRKAIALVQKQHGKPCCECSGGQVSEAPPNSIQ
QVTCPGKTAYLMTNQKWKCRVTPKISPSGGELQNCPCNTFQDSMHSSCYTEY
RQCRRINKTYTATLLKIRSGSLNEVQILQNPQNQLLQSPCRGSINQPVCSATA
PIHISDGGGPLDTRVWTVQKRLEQIHKAMTPELQYHPLALPKVRDDLSDART
FDILNTTFRLLQMSNFSLAQDCWLCLKLGTPTPLAIPTPSLTYSLADSLANASCQI
10 IPPLLQPMQFSNSSCLSSPFINDTEQIDLGAVTFTNCTSVANVSSPLCALNGSV
FLCGNNMAYTYLPQNWTRLCVQASLLPDIDINPGDEPVPIPAIDHYIHRPKRAVQ
FIPLLAGLGITAAFTTGATGLGVSVTQYTKLSHQLISDVQVLSGTIQDLQDQVDSL
AEVVLQNRRLDLLTAEQGGICLALQEKCCFYANKSGIVRNKIRTLQEELQKRR
ESLATNPLWTGLQGFLPYLLPLLGPLLTLLILTIGPCVFSRLMAFINDRLNVVHA
15 MVLAQQYQALKAEAAAQD (SEQ ID NO:56)

***Homo sapiens*: CD9 Complete Protein**

MSPVKGGTKCIKYLFLGFNFIFWLAGIAVLAIGLWLRFDQSQTKSIFEQETNNNS
SFYTGVIYILIGAGALMMLVGFLGCCGAVQESQCMLGLFFGFLLVIFAIEIAAAIWG
20 YSHKDEVIKEVQEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVEQFIS
DICPKKDVLFTTVKSCPDALKEVFDNKFHIGAVGIGIAVVMIFGMIFSMILCCAIR
RNREMV (SEQ ID NO:57)

***Homo sapiens*: CD63 Complete Protein**

25 MAVEGGMKCVKFLLYVLLAFCAVGLIAGVGAQLVLSQTIIQGATPGSLLPV
VIAVGVFLFLVAFVGGCGACKENYCLMITFAIFLSLIMLVEVAAAIAGYVFRDKVM
SEFNNNFRQQMENYPKNNHTASILDRMQADFKCCGAANYTDWEKIPSMSKNR
VPDSCCINVTVGCGINFNEKAIHKEGCVKIGGWLRKNVLVAAAALGIAFVEVL
GIVFACCLVKSIIRSGYEV (SEQ ID NO:58)

***Homo sapiens*: CD81 Complete Protein**

30 MGVEGCTKCIKYLFLVFNFWLAGGVILGVALWLRHDPQTTNLLYLELGDKPA
PNTFYVGIYILIAVGAVMMFVGFLGCYGAIQESQCLLGTFFTCVLIFACEVAAGI
WGFVNKDQIAKDVQFYDQALQQAVVDDANNAKAVVKTFFHETLDCCGSSTL
35 TALTTSVLKNLCPSGSNIISNLFKEDCHQKIDDLFSGKLYLIGIAAIVVAVIMIFEM
ILSMVLCCGIRNSSVY (SEQ ID NO:59)

***Homo sapiens*: CD47 “Self Hairpin” 10 Amino Acids**

40 EVTEL TREGE (SEQ ID NO:60)

***Homo sapiens*: CD47 “Self Hairpin” 21 Amino Acids**

GNYTCEVTEL TREGETIIELEK (SEQ ID NO:61)

***Homo sapiens*: CD47 Complete Protein**

45 MWPLVAALLLSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEV
YVKWKFKGRDIYTFD GALNKSTVPTDFSSAKIEVSQLLKGDA SLKMDKSDAVSH

TGNYTCEVTELTREGETIIEELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLK
YRSGGMDEKTIALLVAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLH
YYVFSTAIGLTSFVIAILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLL
GLVYMKFVE (SEQ ID NO:62)

AAV2: REP52

MELVGWLVDKGITSEKQWQEDQASYISFNAASNSRSQIKAALDNAGKIMSLTK
TAPDYLVGQQPVEDISSNRIYKILELNGYDPQYAASVFLGWATKKFGKRNTIWL
FGPATTGKTNIAEIAHTVPFYGCVNWTNENFPFNDCCVDMVIWWEKGMTAK
VVESAKAILGGSKVRVDQKCKSSAQIDPTPVIVTSNTNMCAVIDGNSTTFEHQQ
PLQDRMFKFELTRRLDHDGFKVTKQEVKDFFRWAKDHVVEVEHEFYVKKGGA
KKRPAPSDADISEPKRVRESVAQPSTSDAEASINYADRYQNKCSRHVGMNLML
FPCRQCERMNQNSNICFTHGQKDCLECFPVSESQPVSVVKKAYQKLCYIHHIM
GKVPDACTACDLVNVDLDDCIFEQ (SEQ ID NO:63)

AAV2: REP78

MPGFYEIVIKVPSDLDEHLPGISDSFVNWVAEKEWELPPDSDMDLNLIEQAPLT
VAEKLQRDFLTEWRRVSKAPEALFFVQFEKGESYFHMHVLEVTTGVKSMVLGR
FLSQIREKLIQRIYRGIEPTLPNWFVAVTKTRNGAGGGNKVVDECYIPNYLLPKTQ
PELQWAWTNMEQYLSACLNLTERRKRLVAQHLTHVSQTQEQNKENQNPNSDAP
VIRSKTSARYMELVGWLVDKGITSEKQWQEDQASYISFNAASNSRSQIKAALD
NAGKIMSLTKTAPDYLVGQQPVEDISSNRIYKILELNGYDPQYAASVFLGWATKK
FGKRNTIWLFGPATTGKTNIAEIAHTVPFYGCVNWTNENFPFNDCCVDMVIW
WEEGKMTAKVVESAKAILGGSKVRVDQKCKSSAQIDPTPVIVTSNTNMCAVIDG
NSTTFEHQQPLQDRMFKFELTRRLDHDGFKVTKQEVKDFFRWAKDHVVEVEH
EFYVKKGGAKKRPAPSDADISEPKRVRESVAQPSTSDAEASINYADRYQNKCS
RHVGMNLMLFPCRQCERMNQNSNICFTHGQKDCLECFPVSESQPVSVVKKAY
QKLCYIHHIMGKVPDACTACDLVNVDLDDCIFEQ (SEQ ID NO:64)

AAV2: VP1

MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPKPAERHKDDSRGLVLPGYKY
LGPFNGLDKGEPVNEADAAALEHDKAYDRQLDSGDNPYLKYNHADADEFQERL
KEDTSFGGNLGRAVFQAKKRVLEPLGLVEEPVKTAPGKKRPVEHSPVEPDSSS
GTGKAGQQPARKRLNFGQTGDADSVDPDQPLGQPPAAPSGLGNTMATGSG
APMADNNEGADGVGNSSGNWHCDSTWMGDRVITTSTRTWALPTYNNHLYKQ
ISSQSGASNDNHYFGYSTPWGYFDFNRHFCHFSRPRDWQRLINNNWGFRPKRL
NFKLFNIQVKEVTQNDGTTTIANNLSTVQVFTDSEYQLPYVLGSAHQGCLPPF
PADVFMVPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDV
PFHSSYAHSQSLDRLMNPLIDQYLYLSRTNTPSGTTTQSRLQFSQAGASDIRD
QSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHLNGRDSLVPNGPAM
ASHKDDEEKFFPQSGVLIFGKQGSEKTNVDIEKVMITDEEEIRTTNPVATEQYGS
VSTNLQRGNRQAATADVNTQGVLPGMVWQDRDVYLQGPWAKIPHTDGHFHP
SPLMGGFGLKHPPPQILIKNTPVPANPSTTFSAAKFASFITQYSTGQVSVEIEWE
LQKENS KRWNPEIQYTSNYNKS VNVDFTVDTNGVYSEPRPIGTRYLTRNL
(SEQ ID NO:65)

AAV2: VP2

APGKKRPVEHSPVEPDSSSGTGKAGQQPARKRLNFGQTGDADSVDPQPPLG
 QPPAAPSGLGNTMATGSGAPMADNNEGADGVGNSSGNWHCDSTWMGDRV
 ITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPWGYFDFNRFHCHFS
 5 PRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDS
 EYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQAVGRSSFYCLEYFP
 SQMLRTGNNFTFSYTFEDVPPFHSSYAHSQSLDRLMNPLIDQYLYLSRTNTPS
 GTTTQSRLQFSQAGASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWT
 GATKYHLNGRDSLVPNGPAMASHKDDEEKFFPQSGVLIFGKQGSEKTNVDIEK
 10 VMITDEEEIRTTNPVATEQYGSVSTNLQRGNRQAATADVNTQGVLPGMVWQD
 RDVYLQGPWIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTFS
 AAKFASFITQYSTGQVSVEIEWELQKENS KRWNPEIQYTSNYNKSVNVDFTVDT
 NGVYSEPRPIGTRYLTRNL (SEQ ID NO:66)

AAV2: VP3

MATGSGAPMADNNEGADGVGNSSGNWHCDSTWMGDRVITTSTRTWALPTYN
 NHLYKQISSQSGASNDNHYFGYSTPWGYFDFNRFHCHFS PRDWQRLINNNWG
 FRPKRLNFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQ
 GCLPPFPADVFMVPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTF
 20 SYTFEDVPPFHSSYAHSQSLDRLMNPLIDQYLYLSRTNTPSGTTTQSRLQFSQA
 GASDIRDQSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHLNGRDSL
 VNPNGPAMASHKDDEEKFFPQSGVLIFGKQGSEKTNVDIEKVMITDEEEIRTTNP
 VATEQYGSVSTNLQRGNRQAATADVNTQGVLPGMVWQDRDVYLQGPWIWAKIP
 HTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPSTTFSAAKFASFITQYSTG
 25 QVSVEIEWELQKENS KRWNPEIQYTSNYNKSVNVDFTVDTNGVYSEPRPIGTR
 YLTRNL (SEQ ID NO:67)

Synthetic: Myc-Tagged Anti CD19 scFv

EQKLISEEDLDIQMTQTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTV
 30 KLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFG
 GGTKLEITGGGGSGGGGSGGGGSEVKLQESGPGLVAPSQSLSVTCTVSGVSL
 PDYGVSWIRQPPRKGLEWLGVWIGSETTYNSALKSRLTIKDNSKSQVFLKMN
 SLQTDDTAIYYCAKHYYGGSYAMDYWGQGTSTVTVSS (SEQ ID NO:68)

Synthetic: dDZF1

FKCEHCRILFLDHVMFTIHMGCCHGFRDPFKCNMCGEKCDGPVGLFVHMARNA
 HGEKPFYCEHCEITFRDVVMYSLHKGYHGFRDPFECNICGYHSQDRYEFSSHI
 VRGEH (SEQ ID NO:69)

Synthetic: dDZF2

HHCQHCDMYFADNILYTIHMGCCHSCDDVFKCNMCGEKCDGPVGLFVHMARNA
 HGEKPTKCVHCGIVFLDEVMYALHMSCHGFRDPFECNICGYHSQDRYEFSSHI
 VRGEH (SEQ ID NO:70)

Synthetic: DmrA

MGRGVQVETISPGDGRTPFKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFFKM
LGKQEVIRGWEEGVAQMSVGQRAKL TISPDYAYGATGHPGIIPPHATLVFDVEL
LKLE (SEQ ID NO:71)

5 **Synthetic: DmrB**

MASRGVQVETISPGDGRTPFKRGQTCVVHYTGMLEDGKKVDSSRDRNKPFFK
MLGKQEVIRGWEEGVAQMSVGQRAKL TISPDYAYGATGHPGIIPPHATLVFDVE
LLKLE (SEQ ID NO:72)

10 **Synthetic: DmrC**

MGSRLWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKET
SFNQAYGRDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRISK (SEQ ID
NO:73)

15 **Homo sapiens/Synthetic: FKBP**

MGVQVETISPGDGRTPFKRGQTCVVHYTGMLEDGKKFDSSRDRNKPFFKMLG
KQEVIRGWEEGVAQMSVGQRAKL TISPDYAYGATGHPGIIPPHATLVFDVELLK
LE (SEQ ID NO:74)

20 **Homo sapiens/Synthetic: FRB**

QGMLEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFN
QAYGRDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRISK (SEQ ID
NO:75)

25 **Synthetic: Anti-GCN4 scFv**

MGPDIVMTQSPSSLSASVGDRVTITCRSSTGAVTTSNYASWWQEKPGKLFKGLI
GGTNNRAPGVPSRFSGSLIGDKATLTISLQPEDFATYFCALWYSNHWVFGQG
TKVELKRGSGSGSGSGSGSGSGSGSGSEVKLLESGGGLVQPGGSLKLSCAV
SGFSLTDYGVNWRQAPGRGLEWIGVIWGDGITDYN SALKDRFIISKDNGKNTV
30 YLQMSKVRSDDTALYYCVTGLFDYWGGGTLVTVSSYPYDVPDYAGGGGGSG
GGSGGGGGSGGGGS (SEQ ID NO:76)

Synthetic: 10x-GCN4 Repeats

EELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLS
35 KNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHL
ENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVA
RLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKG
SGSGEELLSKNYHLENEVARLKKGS (SEQ ID NO:77)

40 **Synthetic: 24x-GCN4 Repeats**

EELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLS
KNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHL
ENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVA
RLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKG
45 SGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGE
ELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSK

NYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLE
 NEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVAR
 LKKGSGSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGS
 GSGEELLSKNYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGSGSGEE
 5 LLSKDYHLENEVARLKKGSGSGEELLSKNYHLENEVARLKKGS (SEQ ID
 NO:78)

Synthetic: GFP-targeting Nanobody

VQLVESGGALVQPGGSLRLSCAASGFPVNRYSMRWYRQAPGKEREWVAGMS
 10 SAGDRSSYEDSVKGRFTISRDDARNTVYLQMNSLKPEDTAVYYSNVNVGFY
 WGQGTQVTVSS (SEQ ID NO:79)

Nostoc punctiforme: Npu DnaE N-terminal Split Intein

CLSYETEILTVEYGLLPKIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEV
 15 FEYCLEDEGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPN
 (SEQ ID NO:80)

Nostoc punctiforme: Npu DnaE C-terminal Split Intein

MIKIATRKYLKGKQNVYDIGVERDHNFLKNGFIASNCFN (SEQ ID NO:81)

Synthetic: Cfa N-Terminal Split Intein

CLSYDTEILTVEYGFLPIGKIVEERIECTVYTVDKNGFVYTQPIAQWHNRGEQEV
 FEYCLEDEGSIIRATKDHKFMTTDGQMLPIDEIFERGLDLKQVDGLP (SEQ ID
 NO:82)

Synthetic: Cfa C-Terminal Split Intein

MVKIISRKSLGTQNVYDIGVEKDHNFLKNGLVASN (SEQ ID NO:83)

Saccharomyces cerevisiae: Vma N-terminal Split Intein

CFAKGTNVLMDGSIECIENIEVGKNKVMGKDGRPREVIKLPRGRETMYSVVQKS
 30 QHRAHKSDSSREVPELLKFTCNATHELVRTPRSVRRLSRTIKGVEYFEVITFE
 MGQKKAPDGRIVELVKEVSKSYPISEGERANELVESYRKASNKAYFEWTIEAR
 DLSLLGSHVRKATYQTYAPILY (SEQ ID NO:84)

Saccharomyces cerevisiae: Vma C-terminal Split Intein

VLLNVLSKCAAGSKKFRPAPAAFARECRGFYFELQELKEDDYYGITLSDDSDHQ
 35 FLLANQVVVHN (SEQ ID NO:85)

Synechocystis sp. PCC 6803: Ssp DnaE N-terminal Split Intein

CLSFGTEILTVEYGPLPIGKIVSEEINCSVYSVDPEGRVYTQAIAQWHDRGEQEV
 40 LEYELEDGSGVIRATSDHRFLTDDYQLLAIEEIFARQLDLLTLENIKQTEEALDNHR
 LPFPLLDAGTIK (SEQ ID NO:86)

Synechocystis sp. PCC 6803: Ssp DnaE C-terminal Split Intein

MVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAAN (SEQ ID NO:87)

Synthetic: Spy Tag

VPTIVMVDAYKRYK (SEQ ID NO:88)

Synthetic: Spy Catcher

5 MVTTLSGLSGEQGPSGDMTTEEDSATHIKFSKRDEDEGRELAGATMELRDSSG
 KTISTWISDGHVKDFLYLPKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGE
 ATKGDAHTGSSGS (SEQ ID NO:89)

Bacteriophage MS2: MS2 RNA Binding Protein

10 MASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKVTCSVRQS
 SAQNRKYTIKVEVPKVATQTVGGVELPVAAWRSYLNMEITPIFATNSDCELVK
 AMQGLLKDGNPIPSAIAANSIGY (SEQ ID NO:90)

Bacteriophage MS2: MS2 (N55K) RNA Binding Protein

15 MASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKVTCSVRQS
 SAQKRKYTIKVEVPKVATQTVGGVELPVAAWRSYLNMEITPIFATNSDCELVK
 AMQGLLKDGNPIPSAIAANSIGY (SEQ ID NO:91)

Bacteriophage MS2: MS2 (N55K)(V29I) RNA Binding Protein

20 MASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQAYKVTCSVRQSS
 AQKRKYTIKVEVPKVATQTVGGVELPVAAWRSYLNMEITPIFATNSDCELVKA
 MQGLLKDGNPIPSAIAANSIGY (SEQ ID NO:92)

Bacteriophage PP7: PP7 RNA Binding Protein

25 KTIVLSVGEATRTLTEIQSTADRQIFEEKVGPLVGRLRLTASLRQNGAKTAYRVN
 LKLDQADVVDGLPKVRYTQVWSHDVTIVANSTEASRKSLYDLTKSLVATSQVE
 DLVVNLVPLGRS (SEQ ID NO:93)

Bacteriophage Mu: COM RNA Binding Protein

30 MKSIRCKNCNKLKFKADSFHDHIEIRCPCKRHIIMLNACEHPTEKHCGKREKITH
 SDETVRY (SEQ ID NO:94)

Synthetic: Zinc Finger ZF6/10

35 STRPGERPFQCRICMRNFSIPNHLARHTRTHTGEKPFQCRICMRNFSQSAHLK
 RHLRTHHTGEKPFQCRICMRNFSQDVSLVRHLKTHLRQKDGERPFQCRICMRNF
 SSAQALARHTRTHTGEKPFQCRICMRNFSQGGNLTRHLRTHHTGEKPFQCRICM
 RNFSQHPLNLRHLKTHLRGS (SEQ ID NO:95)

Synthetic: Zinc Finger ZF8/7

40 SRPGERPFQCRICMRNFSTMAVLRHTRTHTGEKPFQCRICMRNFSRREVLEN
 HLRTHHTGEKPFQCRICMRNFSQTVNLDRHLKTHLRQKDGERPFQCRICMRNFS
 KKDHLHRHTRTHTGEKPFQCRICMRNFSQRPHLTNHLRTHHTGEKPFQCRICMR
 NFSVGASLKRHLKTHLRGS (SEQ ID NO:96)

45 **Synthetic: Zinc Finger ZF9**

SRPGERPFQCRICMRNFSDKTKLRVHTRTHTGEKPFQCRICMRNFSVRHNLTR
HLRTHHTGEKPFQCRICMRNFSQSTSLQRHLKTHLRGF (SEQ ID NO:97)

Synthetic: Zinc Finger MK10

SRPGERPFQCRICMRNFSRRHGLDRHTRTHTGEKPFQCRICMRNFSDHSSLK
RHLRTHHTGSQKPFQCRICMRNFVRHNLTRHLRTHHTGEKPFQCRICMRNFSDH
SNLSRHLKTHHTGSQKPFQCRICMRNFSQRSSLVRHLRTHHTGEKPFQCRICMRN
FSESGHLKRHLRTHLRGS (SEQ ID NO:98)

Synthetic: Zinc Finger 268

YACPVESCDRRFSRDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHHT
GEKPFACDICGRKFARSDERKRHTKIHLRQKD (SEQ ID NO:99)

Synthetic: Zinc Finger NRE

YACPVESCDRRFSQSHDLTKHIRIHTGQKPFQCRICMRNFSDSSKLSRHIRTHHT
GEKPFACDICGRKFARLDNRTAHTKIHLRQKD (SEQ ID NO:100)

Synthetic: Zinc Finger 268/NRE

YACPVESCDRRFSRDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHHT
GEKPFACDICGRKFARSDERKRHTKIHLRQKDGERPYACPVESCDRRFSQSHD
LTKHIRIHTGQKPFQCRICMRNFSDSSKLSRHIRTHHTGEKPFACDICGRKFARLD
NRTAHTKIHLRQKD (SEQ ID NO:101)

Synthetic: Zinc Finger 268//NRE

YACPVESCDRRFSRDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHHT
GEKPFACDICGRKFARSDERKRHTKIHLRQKDGGGSERPYACPVESCDRRFS
QSHDLTKHIRIHTGQKPFQCRICMRNFSDSSKLSRHIRTHHTGEKPFACDICGRKF
ARLDNRTAHTKIHLRQKD (SEQ ID NO:102)

Synthetic: FokI Zinc Finger Nuclease 17-2 Targeting GFP

SRPGERPFQCRICMRNFSTRQNLDTHTRTHTGEKPFQCRICMRNFSRRDTLER
HLRTHHTGEKPFQCRICMRNFSRPDALPRHLKTHLRGSQVLKSELEKKSELRH
KLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIY
TVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKV
YPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGT
LTLEEVRRKFNNGEINF (SEQ ID NO:103)

Synthetic: FokI Zinc Finger Nuclease 18-2 Targeting GFP

SRPGERPFQCRICMRNFSSPSKLIRHTRTHTGEKPFQCRICMRNFSDGSNLAR
HLRTHHTGEKPFQCRICMRNFSRVDNLPRHLKTHLRGSQVLKSELEKKSELRH
KLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIY
TVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKV
YPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGT
LTLEEVRRKFNNGEINF (SEQ ID NO:104)

Synthetic: Left FokI Zinc Finger Nuclease Targeting CCR5

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRVGIHGVPAAMAERPFQCRICM
 RNFSDRSNLSRHIRTHTGEKPFACDICGRKFAISSNLNSHTKIHTGSQKPFQCRI
 CMRNFSDNLSRHIRTHTGEKPFACDICGRKFATSGNLTRHTKIHLRGSQVLK
 SELEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKH
 5 LGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTR
 NKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSV
 EELLIGGEMIKAGTLTLEEVRKFNNGEINF (SEQ ID NO:105)

Synthetic: Right FokI Zinc Finger Nuclease Targeting CCR5

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRVGIHGVPAAMAERPFQCRICM
 RNFSDRSNLSVHIRTHTGEKPFACDICGRKFAQKINLQVHTKIHTGEKPFQCRI
 MRNFSDVLSHIRTHTGEKPFACDICGRKFAQRNHRRTHTKIHLRGSQVLKS
 ELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHL
 GGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRN
 15 KHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVE
 ELLIGGEMIKAGTLTLEEVRKFNNGEINF (SEQ ID NO:106)

Synthetic: FokI Nuclease Domain

QLVKSELEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGY
 20 RGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEE
 NQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGA
 VLSVEELLIGGEMIKAGTLTLEEVRKFNNGEINF (SEQ ID NO:107)

Synthetic: Acul Nuclease Domain

VHDHKLLEAKLIRNYETNRKECLNSRYNETLLRSDYLDPPFELLGWDIKNKAGK
 25 PTNEREVVLEEALCASASEHSKPDYTFRLFSEKFFLEAKKPSVHIESDNETAK
 QVRRYGFTA KLKISVLSNFEYLVIYDTSVKVDGDDTFNKARIKKYHYTEYETHFD
 EICDLLGRESVYSGNFDKEWLSIENKINHFSVDTL (SEQ ID NO:108)

Synthetic: Truncated Acul Nuclease Domain

YNETLLRSDYLDPPFELLGWDIKNKAGKPTNEREVVLEEALCASASEHSKPDY
 30 TRLFSEKFFLEAKKPSVHIESDNETAKQVRRYGFTA KLKISVLSNFEYLVIYDT
 SVKVDGDDT (SEQ ID NO:109)

Escherichia coli: Ferritin

MLKPEMIEKLNEQMNLELYSSLLYQQMSAWCSYHTFEGAAAFRRHAQEEMT
 35 HMQRLFDYLTDTGNLPRINTVESPF AEYSSLDL FQETYKHEQLITQKINELAHA
 AMTNQDYPTFNFLQWYVSEQHEEEKLFSIIDKLSLAGKSGEGLYFIDKELSTLD
 TQN (SEQ ID NO:110)

Escherichia coli: Ferritin (H34L)(T64I)

MLKPEMIEKLNEQMNLELYSSLLYQQMSAWCSYLT FEGAAAFRRHAQEEMTH
 40 MQRLFDYLTDTGNLPRINTVESPF AEYSSLDL FQETYKHEQLITQKINELAHAA
 MTNQDYPTFNFLQWYVSEQHEEEKLFSIIDKLSLAGKSGEGLYFIDKELSTLDT
 45 QN (SEQ ID NO:111)

***Mus musculus* & Synthetic: Light & Heavy Chain Ferritin Chimera**

MTSQIRQNYSTEVEAAVNRLVNLHLRASYTYLSLGFFFD RDDVALEGVGHFFRE
 LAEEKREGAERLLEFQNDRGGRALFQDVQKPSQDEWGKTQEAMEAALAMEK
 NLNQALLDLHALGSARADPHLCDFLESHYLDKEVKLIKMGHNLTNLRVAGPQ
 5 PAQTGAPQGS LG EYLFERLTLKHDARGGGGSDYKDDDDKGGGGS RVMTTAS
 PSQVRQNYHQDAEAAINRQINLELYASYVYLSMSCYFDRDDVALKNFAKYFLH
 QSHEEREHA EKLMKLQNQRGGRIFLQDIKKPDRDDWESGLNAMECALHLEKS
 VNQSLLELHKLATDKNDPHLCDFIETYLLSEQVKS IKELGDHVTNLRKMGAP EA
 GMAEYLFDKHTLGHGDEST R (SEQ ID NO:112)

***Homo sapiens* & Synthetic: Light & Heavy Chain Ferritin Chimera**

SQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVALEGVSHFFRELA
 EEKREGYERLLKMQNQRGGRALFQDIKKPAEDEWGKTPDAMKAAMALEKKLN
 QALLDLHALGSARTDPHLCDFLETHFLDEEVKLIKMGDHLTNLHRLGGPEAGL
 15 GEYLFERLTLKHDARGGGGSDYKDDDDKGGGGS RVMTTASTS QVRQNYHQD
 SEAAINRQINLELYASYVYLSMSYFDRDDVALKNFAKYFLHQSHHEEREHA EK
 MKLQNQRGGRIFLQDIKKPCDDWESGLNAMECALHLEKNVNQSLLELHKLAT
 DKNDPHLCDFIETHYLNQVKA IKELGDHVTNLRKMGAPESGLAEYLFDKHTLG
 DSDNES (SEQ ID NO:113)

***Arabidopsis thaliana*: Cry2**

MKMDKKTIVWFRDLRIEDNPALAAAAHEGSVFPVFIWCPEEEGQFY PGRASR
 WWWKQSLAHLSSQLKALGSDLTIKTHNTISAILDCIRVTGATKVVFNHLYDPVS
 LVRDHTVKEKLVERGISVQSYNGDLLYEPWEIYCEKGKPF TSFN SYWKKCLDM
 25 SIESVMLPPPWR LMPITAAAEI WACSIEELGLENEAEKPSNALLTRAWSPGWS
 NADKLLNEFIEKQLIDYAKNSKKVVG NSTSLLSPYLHFGEISVRHVFQ CARMKQII
 WARDKNSEGEESADLFLRGIGLREYSRYICFNFPF THEQSLLSHLRFPPWDADV
 DKFKAWRQGR TGYP LVDAGMRELWATGWMHNRIRVIVSSFAVKFLLL PWKWG
 MKYFWD TLLDADLECDILGWQYISGSIPDGHELDRLDNPALQGAKYDPEGEYIR
 30 QWLPELARLPTEWIIHPWDAPLTVLKASGVELGTNYAKPIVDIDTARELLAKAIS
 RTREAQIMIGAAPDEIVADSFEALGANTIKEPGLCPSVSSNDQQVPSAVRYNGS
 AAVKPEEEEEERDMKKS RGFDERELFSTAESSSSSVFFVSQSCSLASEGKNLE
 GIQDSSDQITTS LGKNGCK (SEQ ID NO:114)

***Arabidopsis thaliana*: CIBN**

MNGAIGGDL LNFPDMSVLERQRAHLKYL NPTFDSPLAGFFADSSMITGGEMD
 SYLSTAGLNLPMMYGETTVEGDSRLSISPETTLGTGNFKA AKFDTETKDCNEAA
 KKMTMNRDDLVEEGEEEEKSKITEQNNGSTKSIKKMKHKAKKEENNFSNDSSKV
 40 TKELEKTDYI (SEQ ID NO:115)

Synthetic: LoV2-Ja

SLATT LERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGRNCRFLQGPETD
 RATVRKIRDAIDNQTEVT VQLINYTKSGKKFWNL FHLQPMRDQKGDVQYFIGVQ
 LDGTEHVRDAAEREGVMLIKKTAENIDEAAKEL (SEQ ID NO:116)

***Homo sapiens*: Full Length WT ADAR2**

DIEDEENMSSSSSTDVKENRNLDNVSPKDGSTPGPGEGSQLSNGGGGGPGRK
 RPLEEGSNGHISKYRLKKRRKTPGPVLPKNALMQLNEIKPGLQYTLLSQTGPVH
 APLFVMSVEVNGQVFEGSGPTKKKAKLHAAEKALRSFVQFPNASEAHLAMGRT
 LSVNTDFTSDQADFPDTLFGFETPDKAEPFVYVGSNGDDSFSSSGDLSLSAS
 5 PVPASLAQPPLPVLPPFPFPPSGKNPVMILNELRPGLKYDFLSESGESHAKSFVM
 SVVVDGQFFEGSGRNKKLAKARAAQSALAAIFNLHLDQTPSRQPIPISEGLQLHL
 PQVLADAVSRLVLGKFGDLTDNFSSPHARRKVLAVGVMVMTTGTVDKDAKVISVST
 GTKCINGEYMSDRGLALNDCHAEIISRRSLLRFLYTQLELYLNNKDDQKRSIFQK
 SERGGFRLKENVQFHLYISTSPCGDARIFSPHEPILEGSRSYTQAGVQWCNHG
 10 SLQPRPPGLLSDPSTSTFQGAGTTEPADRHPPNRKARGQLRTKIESGEGTIPVRS
 NASIQTWGVLQGERLLTMSCSDKIARWNVVGIIQGSLLSIFVEPIYFSSIIIGSLY
 HGDHLSRAMYQRISNIEDLPPLYTLNKPLLSGISNAEARQPGKAPNFSVNWTVG
 DSAIEVINATTGKDELGRASRLCKHALYCRWVRVHGKVP SHLLRSKITKPNVYH
 ESKLAAKEYQAAKARLFTAFIKAGLGAWVEKPTEQDQFSLTP (SEQ ID
 15 NO:117)

***Homo sapiens*: Full Length WT ADAR2 (E488Q)**

DIEDEENMSSSSSTDVKENRNLDNVSPKDGSTPGPGEGSQLSNGGGGGPGRK
 RPLEEGSNGHISKYRLKKRRKTPGPVLPKNALMQLNEIKPGLQYTLLSQTGPVH
 20 APLFVMSVEVNGQVFEGSGPTKKKAKLHAAEKALRSFVQFPNASEAHLAMGRT
 LSVNTDFTSDQADFPDTLFGFETPDKAEPFVYVGSNGDDSFSSSGDLSLSAS
 PVPASLAQPPLPVLPPFPFPPSGKNPVMILNELRPGLKYDFLSESGESHAKSFVM
 SVVVDGQFFEGSGRNKKLAKARAAQSALAAIFNLHLDQTPSRQPIPISEGLQLHL
 PQVLADAVSRLVLGKFGDLTDNFSSPHARRKVLAVGVMVMTTGTVDKDAKVISVST
 25 GTKCINGEYMSDRGLALNDCHAEIISRRSLLRFLYTQLELYLNNKDDQKRSIFQK
 SERGGFRLKENVQFHLYISTSPCGDARIFSPHEPILEGSRSYTQAGVQWCNHG
 SLQPRPPGLLSDPSTSTFQGAGTTEPADRHPPNRKARGQLRTKIESGEGTIPVR
 SNASIQTWGVLQGERLLTMSCSDKIARWNVVGIIQGSLLSIFVEPIYFSSIIIGSLY
 YHGDHLSRAMYQRISNIEDLPPLYTLNKPLLSGISNAEARQPGKAPNFSVNWTV
 30 GDSAIEVINATTGKDELGRASRLCKHALYCRWVRVHGKVP SHLLRSKITKPNVY
 HESKLAAKEYQAAKARLFTAFIKAGLGAWVEKPTEQDQFSLTP (SEQ ID
 NO:118)

***Homo sapiens*: Truncated WT ADAR2**

35 VLADAVSRLVLGKFGDLTDNFSSPHARRKVLAVGVMVMTTGTVDKDAKVISVSTGT
 KCINGEYMSDRGLALNDCHAEIISRRSLLRFLYTQLELYLNNKDDQKRSIFQKSE
 RGGFRLKENVQFHLYISTSPCGDARIFSPHEPILEGSRSYTQAGVQWCNHGSL
 QPRPPGLLSDPSTSTFQGAGTTEPADRHPPNRKARGQLRTKIESGEGTIPVRSN
 ASIQTWDGVLQGERLLTMSCSDKIARWNVVGIIQGSLLSIFVEPIYFSSIIIGSLYH
 40 GDHLSRAMYQRISNIEDLPPLYTLNKPLLSGISNAEARQPGKAPNFSVNWTVGD
 SAIEVINATTGKDELGRASRLCKHALYCRWVRVHGKVP SHLLRSKITKPNVYHE
 SKLAAKEYQAAKARLFTAFIKAGLGAWVEKPTEQDQFSLTP (SEQ ID
 NO:119)

***Homo sapiens*: Truncated WT ADAR2 (E488Q)**

VLADAVSRLVLGKFGDLTDNFSSPHARRKVLAVVMTTGTDVKDAKVISVSTGT
 KCINGEYMSDRGLALNDCHAEIISRRSLLRFLYTQLELYLNNKDDQKRSIFQKSE
 RGGFRLKENVQFHLIYSTSPCGDARIFSPHEPILEGSRSYTQAGVQWCNHGSL
 QPRPPGLLSDPSTSTFQGAGTTEPADRHPNRKARGQLRTKIESGQGTIPVRSN
 5 ASIQTWDGVLQGERLLTMSCDKIARWNVVGIQGSLLSIFVEPIYFSSIILGSLYH
 GDHLSRAMYQRISNIEDLPPLYTLNKPLLSGISNAEARQPGKAPNFSVNWTVGD
 SAIEVINATTGKDELGRASRLCKHALYCRWVRVHGKVP SHLLRSKITKPNVYHE
 SKLAAKEYQAAKARLFTAFIKAGLGAWVEKPTEQDQFSLTP (SEQ ID
 NO:120)

***Homo sapiens & Synthetic: MS2-ADAR1 Deaminase Domain-Nuclear
 Exclusion Signal***

MASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQAYKVTC SVRQSS
 AQNRKYTIKVEVPKGAWRSYLNMEITPIFATNSDCELVKAMQGLLKDGNPIPS
 15 AIAANSIYGGSGSGAGSGSPAGGGAPGSGGGGSKAERMGFTEVTPVTGASLR
 RTMLLLSRSPEAQPKTLPLTGSTFHDQIAML SHRCFNTLTNSFQPSLLGRKILAA
 IIMKKDSEDMGVVSLGTGNRCVKGDSL KGETVNDCHAEIISRRGFIRFLYSE
 LMKYNSQTAKDSIFEPAGGGEKLQIKKTVSFHLYISTAPCGDGALFDKSCSDRA
 MESTESRHYPVFENPKQKGLRTKVENGE GTIPVESSDIVPTWDGIRLGERLRT
 20 MSCSDKILRWNVLGLQGALLTHFLQPIYLKSVTLGYLFSQGH LTRAICCRVTRD
 GSAFEDGLRHPFIVNHPKVGRVSIYDSKRQSGKTKETSVNWCLADGYDLEILDG
 TRGTVDGPRNELSRVSKKNIFLLFKKLCSFRYRRDLLRLSYGEAKKAARDYETA
 KNYFKKGLKDMGYGNWISKPQEEKNFYLC PVGSGSGSLPPLERLT (SEQ ID
 NO:121)

***Homo sapiens & Synthetic: MS2-ADAR1 Deaminase Domain (E1008Q)-
 Nuclear Exclusion Signal***

MASNFTQFVLVDNGGTGDVTVAPSNFANGIAEWISSNSRSQAYKVTC SVRQSS
 AQNRKYTIKVEVPKGAWRSYLNMEITPIFATNSDCELVKAMQGLLKDGNPIPS
 30 AIAANSIYGGSGSGAGSGSPAGGGAPGSGGGGSKAERMGFTEVTPVTGASLR
 RTMLLLSRSPEAQPKTLPLTGSTFHDQIAML SHRCFNTLTNSFQPSLLGRKILAA
 IIMKKDSEDMGVVSLGTGNRCVKGDSL KGETVNDCHAEIISRRGFIRFLYSE
 LMKYNSQTAKDSIFEPAGGGEKLQIKKTVSFHLYISTAPCGDGALFDKSCSDRA
 MESTESRHYPVFENPKQKGLRTKVENGE GTIPVESSDIVPTWDGIRLGERLRT
 35 MSCSDKILRWNVLGLQGALLTHFLQPIYLKSVTLGYLFSQGH LTRAICCRVTRD
 GSAFEDGLRHPFIVNHPKVGRVSIYDSKRQSGKTKETSVNWCLADGYDLEILDG
 TRGTVDGPRNELSRVSKKNIFLLFKKLCSFRYRRDLLRLSYGEAKKAARDYETA
 KNYFKKGLKDMGYGNWISKPQEEKNFYLC PVGSGSGSLPPLERLT (SEQ ID
 NO:122)

Ruminococcus flavefaciens: RfxCas13d (CasRx)

EASIEKKKSFAGMGVKSTLVSGSKVYMTTFAEGSDARLEKIVEGDSIRSVNEG
 EAFSAEMADKNAGYKIGNAKFSHPKGYAVVANNPLYTG PVQQDMLGLKETLEK
 RYFGESADGNDNICIQVIHNILDIEKILA EYITNAAYAVNNISGLDKDIIGFGKFSTV
 45 YTYDEFKDP EHHRAAFNNNDKLINAIKAQYDEFDNFLDN PRLGYFGQAFFSKEG
 RNYIINYGNECYDILALLSGLRHWV VHNNEEESRISRTWLYNLDKNLDNEYISTL

NYLYDRITNELTNSFSKNSAANVNYIAETLGINPAEFAEQYFRFSIMKEQKNLGF
 NITKLREVMLDRKDMSEIRKNHKVFDSIRTQVYTMMDFVIYRYIEEDAKVAAAN
 KSLPDNEKSLSEKDIFVINLRGSFNDDQKDALYYDEANRIWRKLENIMHNIKEFR
 GNKTREYKKKDAPRLPRILPAGRDVSAFSKLMYALTMFLDGKEINDLLTTLINKF
 5 DNIQSFLKVMPLIGVNAKFVEEYAFFKDSAKIADELRLIKSFARMGEPIADARRA
 MYIDAIRILGTNLSYDELKALADTFSLDENGNKLKKGKHGMRNFIINNVISNKRFB
 YLIRYGDPAHLHEIAKNEAVVKFVLGRIADIQKKQGQNGKNQIDRYYETCIGKDK
 GKSVEKVDALTKIITGMNYDQFDKKRSVIEDTGRENAEREKFKKIISLYLTVIYHI
 LKNIVNINARYVIGFHCVERDAQLYKEKGYDINLKKLEEKGFSSVTKLCAGIDETA
 10 PDKRKDVEKEMAERAKESIDSLESANPKLYANYIKYSDEKKAEEFTRQINREKA
 KTALNAYLRNTKWNVIREDLLRIDNKTCTLFRNKAVHLEVARYVHAYINDIAEVN
 SYFQLYHYIMQRIIMNERYEKSSGKVSEYFDAVNDEKKYNDRLLKLLCVPFGYCI
 PRFKNLSIEALFDRNEAAKFDKEKKKVSGNSGSG (SEQ ID NO:123)

***Ruminococcus flavefaciens* & Synthetic: dead RfxCas13d (dCasRx)**

EASIEKKKSFAKGMGVKSTLVSGSKVYMTTFAEGSDARLEKIVEGDSIRSVNEG
 EAFSAEMADKNAGYKIGNAKFSHPKGYAVVANNPLYTGPVQQDMLGLKETLEK
 RYFGESADGNDNICIQVIHNILDIEKILAEYITNAAYAVNNISGLDKDIIGFGKFSTV
 YTYDEFKDPPEHHRAAFNNNDKLINAIAQYDEFDNFLDNPRLG YFGQAFFSKEG
 20 RNYIINYGNECYDILALLSGLAHWVANNNEESRISRTWLYNLDKNLDNEYISTL
 NYLYDRITNELTNSFSKNSAANVNYIAETLGINPAEFAEQYFRFSIMKEQKNLGF
 NITKLREVMLDRKDMSEIRKNHKVFDSIRTQVYTMMDFVIYRYIEEDAKVAAAN
 KSLPDNEKSLSEKDIFVINLRGSFNDDQKDALYYDEANRIWRKLENIMHNIKEFR
 GNKTREYKKKDAPRLPRILPAGRDVSAFSKLMYALTMFLDGKEINDLLTTLINKF
 25 DNIQSFLKVMPLIGVNAKFVEEYAFFKDSAKIADELRLIKSFARMGEPIADARRA
 MYIDAIRILGTNLSYDELKALADTFSLDENGNKLKKGKHGMRNFIINNVISNKRFB
 YLIRYGDPAHLHEIAKNEAVVKFVLGRIADIQKKQGQNGKNQIDRYYETCIGKDK
 GKSVEKVDALTKIITGMNYDQFDKKRSVIEDTGRENAEREKFKKIISLYLTVIYHI
 LKNIVNINARYVIGFHCVERDAQLYKEKGYDINLKKLEEKGFSSVTKLCAGIDETA
 30 PDKRKDVEKEMAERAKESIDSLESANPKLYANYIKYSDEKKAEEFTRQINREKA
 KTALNAYLRNTKWNVIREDLLRIDNKTCTLFANKAVALEVARYVHAYINDIAEVN
 SYFQLYHYIMQRIIMNERYEKSSGKVSEYFDAVNDEKKYNDRLLKLLCVPFGYCI
 PRFKNLSIEALFDRNEAAKFDKEKKKVSGNSGSGPKKKRKVAAAYPYDVPDYA
 (SEQ ID NO:124)

***Prevotella* sp. P5-125: PspCas13b**

MNIPALVENQKKYFGTYSVMAMLNAQTVLDHIQKVADIEGEQNNENNENLWFHP
 VMSHLYNAKNGYDKQPEKTMFIERLQSYFPFLKIMAENQREYSNGKYKQNRV
 EVNSNDIFEVLKRAFGVLKMYRDLTNHYKTYEEKLNDGCEFLTSTEQPLSGMIN
 40 NYYTVALRNMNERYGYKTEDLAFIQDKRFKFKVVDAYGKKKSQVNTGFFLSLQD
 YNGDTQKKLHLSGVGIALICLFLDKQYINIFLSRLPIFSSYNAQSEERRIIRSFGI
 NSIKLPKDRIHSEKSNKSVAMDMLNEVKRCPDELFTTLSAEKQSRFRIISDDHNE
 VLMKRSSDRFVPLLLQYIDYGKLFDFHVFHVMGKLRYLLKADKTCIDGQTRVR
 VIEQPLNGFGRLEEAEATMRKQENGTFGNSGIRIRDFENMKRDDANPANYPYIVD
 45 TYTHYLENNKVEMFINDKEDSAPLLPVEDDRYVVKTIPTSCRMSTLEIPAMAFHM
 FLFGSKKTEKLIVDVHNRYKRLFQAMQKEEVTAENIASFGIAESDLPQKILDLISG

NAHGKDVDAFIRLTVDDMLTDTERRIKRFKDDRKSIRSADNKMKGKRGFKQISTG
 KLADFLAKDIVLFQPSVNDGENKITGLNYRIMQSAIAVYDSGDDYEAKQQFKLMF
 EKARLIGKGTTEPHFPLYKVFAARSIPANAVEFYERYLIERKFYLTGLSNEIKKGNR
 VDVPFIRRDQNKWKTPAMKTLGRIYSEDLPVELPRQMFDNEIKSHLKSPLQME
 5 GIDFNNANVTYLIAEYMKRVLDDDFQTFYQWNRNYRYMDMLKGEYDRKGSLQ
 HCFTSVEEREGLWKERASRTERYRKQASNKIRSNRQMRNASSEEIETILDKRLS
 NSRNEYQKSEKVIRRYRVQDALLFLLAKKTLTELADFDGERFKLKEIMPDAEKGI
 LSEIMPMSFTFEKGGKKYTITSEGMKLKNYGDFVFLASDKRIGNLLELVGSDIVS
 KEDIMEEFNKYDQCRPEISSIVFNLEKWAFDTYPELSARVDREEKVDFFKSILKILL
 10 NKNINKEQSDILRKIRNAFDHNNYPDKGVVEIKALPEIAMSIIKAFGEYAIMKGS
 LQ (SEQ ID NO:125)

Synthetic: L17E

IWLTALKFLGKHAAKHEAKQQLSKL (SEQ ID NO:126)

Synthetic: L17E-Transmembrane

IWLTALKFLGKHAAKHEAKQQLSKLNAVGGQDTQEIVVPHSLPFKVVISAILALV
 VLTIIISLIILIMLWQKKPR (SEQ ID NO:127)

Synthetic: KALA

WEAKLAKALAKALAKHLAKALAKALKACEA (SEQ ID NO:128)

Synthetic: KALA-Transmembrane

WEAKLAKALAKALAKHLAKALAKALKACEANAVGGQDTQEIVVPHSLPFKVVIS
 25 AILALVVLTIISLIILIMLWQKKPR (SEQ ID NO:129)

Synthetic: Vectofusin

KKALLHAALAHLLALAHLLALLKKA (SEQ ID NO:130)

Synthetic: Vectofusin-Transmembrane

KKALLHAALAHLLALAHLLALLKKANAVGGQDTQEIVVPHSLPFKVVISAILAL
 30 VLTIIISLIILIMLWQKKPR (SEQ ID NO:131)

Synthetic: Transmembrane Domain

NAVGGQDTQEIVVPHSLPFKVVISAILALVLTIIISLIILIMLWQKKPR (SEQ ID
 35 NO:132)

Lactococcus lactis: Nisin A

ITSISLCTPGCKTGALMGCMKTATCHCSIHVSK (SEQ ID NO:133)

Lactococcus lactis NIZO 22186: Nisin Z

ITSISLCTPGCKTGALMGCMKTATCNCSEHVSK (SEQ ID NO:134)

Lactococcus lactis subsp. lactis F10: Nisin F

ITSISLCTPGCKTGALMGCMKTATCNCSEHVSK (SEQ ID NO:135)

Lactococcus lactis 61-14: Nisin Q

ITSISLCTPGCKTGVLMSGCNLKTATCNCSVHVSK (SEQ ID NO:136)

Streptococcus hyointestinalis: Nisin H

FTSISMCTPGCKTGALMTCNYKTATCHCSIKVSK (SEQ ID NO:137)

Streptococcus uberis: Nisin U

ITSKSLCTPGCKTGILMTCPLKTATCGCHFG (SEQ ID NO:138)

Streptococcus uberis: Nisin U2

VTSKSLCTPGCKTGILMTCPLKTATCGCHFG (SEQ ID NO:139)

Streptococcus galloyticus subsp. pasteurianus: Nisin P

VTSKSLCTPGCKTGILMTCPIKTATCGCHFG (SEQ ID NO:140)

***L. lactis* NZ9800: Nisin A S29A**

ITSISLCTPGCKTGALMSGCNMKTATCHCAIHVSK (SEQ ID NO:141)

***L. lactis* NZ9800: Nisin A S29D**

ITSISLCTPGCKTGALMSGCNMKTATCHCDIHVSK (SEQ ID NO:142)

***L. lactis* NZ9800: Nisin A S29E**

ITSISLCTPGCKTGALMSGCNMKTATCHCEIHVSK (SEQ ID NO:143)

***L. lactis* NZ9800: Nisin A S29G**

ITSISLCTPGCKTGALMSGCNMKTATCHCGIHVSK (SEQ ID NO:144)

***L. lactis* NZ9800: Nisin A K22T**

ITSISLCTPGCKTGALMSGCNMTTATCHCSIHVSK (SEQ ID NO:145)

***L. lactis* NZ9800: Nisin A N20P**

ITSISLCTPGCKTGALMSGCPMKTATCHCSIHVSK (SEQ ID NO:146)

***L. lactis* NZ9800: Nisin A M21V**

ITSISLCTPGCKTGALMSGCNVKTATCHCSIHVSK (SEQ ID NO:147)

***L. lactis* NZ9800: Nisin A K22S**

ITSISLCTPGCKTGALMSGCNMSTATATCHCSIHVSK (SEQ ID NO:148)

***L. lactis* NZ9800: Nisin Z N20K**

ITSISLCTPGCKTGALMSGCKMKTATCNCSIHVSK (SEQ ID NO:149)

***L. lactis* NZ9800: Nisin Z M21K**

ITSISLCTPGCKTGALMSGCNKKTATCNCSIHVSK (SEQ ID NO:150)

Relevant RNA Sequences (5'-3')**Synthetic: MS2 Stem Loop spCas9 Scaffold RNA for sgRNA with Terminator Example 1**

5 GUUUUAGAGCUAGGCCAACAUAGAGGAUCACCCAUGUCUGCAGGGCCUAG
 CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGCCAACAUAGAGGAUCA
 CCAUGUCUGCAGGGCCAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ
 ID NO:151)

Synthetic: MS2 Stem Loop spCas9 Scaffold RNA for sgRNA with Terminator Example 2

10 GUUUUAGAGCUAGGCCAACAUAGAGGAUCACCCAUGUCUGCAGGGCCUAG
 CAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGCCAACAUAGAGGAUCA
 CCAUGUCUGCAGGGCCAAGUGGCACCGAGUCGGUGCGGGAGCACAUGA
 15 GAUCACCCAUGUGCGACUCCACAGUCACUGGGGAGUCUUCCCUUUUU
 UU (SEQ ID NO:152)

Synthetic: MS2 Stem Loop spCas9 Scaffold RNA for sgRNA with Terminator Example 3

20 GUUUUAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAAUAAGGCUAGUC
 CGUUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCGGGAGCACAUGAG
 GAUCACCCAUGUGCGACUCCACAGUCACUGGGGAGUCUUCCCUUUUUU
 U (SEQ ID NO:153)

Synthetic: 4xMS2 Stem Loop RNA Scaffold Example

25 UUCUAGAUAUCGAAACAUGAGGAUCACCCAUAUCUGCAGUCGACAUCGA
 AACAUAGAGGAUCACCCAUGUCUGCAGUCGACAUCGAAACAUGAGGAUCAC
 CCAUGUCUGCAGUCGACAUCGAAACAUGAGGAUCACCCAUGUCUGCAGU
 CGACAUCGAAAUUCGAUAAGCUUCAGAUCAGAUCCUAG (SEQ ID NO:154)

Synthetic: MS2 Stem Loop Example 1

30 ACAUGAGGAUCACCCAUGU (SEQ ID NO:155)

Synthetic: MS2 Stem Loop Example 2

35 ACAUGAGGAUCACCCAUAU (SEQ ID NO:156)

Synthetic: MS2 Stem Loop Example 3

CCACAGUCACUGGG (SEQ ID NO:157)

Synthetic: 2xMS2 Stem Loop Example

40 ACAUGAGGAUCACCCAUGUCUGCAGGGCCUAGCAAGUUAAAAUAAGGCUA
 GUCCGUUAUCAACUUGGCCAACAUAGAGGAUCACCCAUGU (SEQ ID
 NO:158)

Synthetic: 2xPP7 Stem Loop spCas9 Scaffold RNA for sgRNA with Terminator Example

GUUUUAGAGCUAGGCCGGAGCAGACGAUAUGGCGUCGCUCCGGCCUAGC
AAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGGCCGGAGCAGACGAUAU
GGCGUCGCUCCGGCCAAGUGGCACCGAGUCGGUGCUUUUUUU (SEQ ID
NO:159)

5

Synthetic: PP7 Stem Loop Example

GCCGGAGCAGACGAUAUGGCGUCGCUCCGGCC (SEQ ID NO:160)

Synthetic: COM Stem Loop spCas9 Scaffold RNA for sgRNA with Terminator Example

10

GUUUUAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAAUAAGGCUAGUC
CGUUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCCUGAAUGCCUGCG
AGCAUCUUUUUUU (SEQ ID NO:161)

15

Synthetic: COM Stem Loop Example

CUGAAUGCCUGCGAGCAUC (SEQ ID NO:162)

Synthetic ZKSCAN1 Circular Splice RNA: Upstream Intron

20

AGUGACAGUGGAGAUUGUACAGUUUUUCCUCGAUUUGUCAGGAUUUUU
UUUUUUUUGACGGAGUUUAACUUCUUGUCUCCAGGUAGGAAGUGCAGUG
GCGUAAUCUCGGCUCACUACAACCUCACCUCUGGGUUCAAGCGUUUC
UCCUGCCUCAGCUUUCCGAGUAGCUGGGAUUACAGGCGCCUGCCACCAU
GCCUGCUGACUUUUUGUAUUUUUAGUAGAGACGGGGUUUCACCAUGUUG
GCCAGGCUGGUCUUGAACUCCUGACCGCAGGCGAUUGGCCUGCCUCGGC
25 CUCCCAAAGUGCUGAGAUUACAGGCGUGAGCCACCACCCCGGCCUCAG
GAGCGUUCUGAUAGUGCCUCGAUGUGCUGCCUCCUAUAAAGUGUUAGCA
GCACAGAUACAUUUUUUGUAAAGGUACGUACUAAUGACUUUUUUUUUAUAC
UUCAGG (SEQ ID NO:163)

30

Synthetic ZKSCAN1 Circular Splice RNA: Downstream Intron

35

UAAGAAGCAAGGUUUCAUUUAGGGGAAGGGAAAUGAUUCAGGACGAGAG
UCUUUGUGCUGCUGAGUGCCUGUGAUGAAGAAGCAUGUUAGUCCUGGGC
AACGUAGCGAGACCCCAUCUCUACAAAAAUAGAAAAUUAGCCAGGUAU
AGUGGCGCACACCUUGUGAUUCCAGCUACGCAGGAGGCUGAGGUGGGAGG
AUUGCUUGAGCCCAGGAGGUUGAGGCUGCAGUGAGCUGUAAUCAUGCCA
CUACUCCAACCUGGGCAACACAGCAAGGACCCUGUCUCAAAGCUACUUA
CAGAAAAGAAUUAAGGCUCGGCACGGUAGCUCACACCUUGUAAUCCAGCAC
UUUGGGAGGCUGAGGCGGGCAGAUACAUUGAGGUCAGGAGUUUGAGACC
AGCCUGGCCAACAUUGGUGAAACCUUGUCUCUACUAAAAUAUGAAAAUUA
40 GCCAGGCAUGGUGGCACAUUCCUGUAAUCCAGCUACUCGGGAGGCUGA
GGCAGGAGAAUCACUUGAACCCAGGAGGUGGAGGUUGCAGUAAGCCGAG
AUCGUACCACUGUGCUCUAGCCUUGGUGACAGAGCGAGACUGUCUUA
AAAAAAAAAAAAAAAAAAGAAUUAUUAUUUUUUUUUUUUUUUUUUUUUU
AAGCUGCAUGCUUGUUUUUUUGUUUUUAGUUUUUUCUACAUUGUUGUCAUU
45 AUUACCAAUAUUGGGGAAAAUACAACUACAGACCAAUCUCAGGAGUUA

AAUGUUACUACGAAGGCAAUGAACUAUGCGUAAUGAACCUAGGUAGGCAU
UAG (SEQ ID NO:164)

Homo sapiens Beta-globin and Immunoglobulin Heavy Chain Genes: Linear Splice RNA Intron

GUAAGUAUCAAGGUUACAAGACAGGUUUAAGGAGACCAUAGAAACUGGG
CUUGUCGAGACAGAGAAGACUCUUGCGUUUCUGAUAGGCACCUAUUGGU
CUUACUGACAUCACUUUGCCUUUCUCUCCACAG (SEQ ID NO:165)

Relevant DNA Sequences (5'-3')

Synthetic: Zinc Finger ZF6/10 Binding Site

GAAGAAGCTGCAGGAGGT (SEQ ID NO:166)

Synthetic: Zinc Finger ZF8/7 Binding Site

GCTGGAGGGGAAGTGGTC (SEQ ID NO:167)

Synthetic: Zinc Finger ZF6/10 & ZF8/7 Binding Site

GAAGAAGCTGCAGGAGGTGCTGGAGGGGAAGTGGTC (SEQ ID NO:168)

Synthetic: Zinc Finger ZF6/10 & ZF8/7 Binding Site 8x Repeat Example

TGAAGAAGCTGCAGGAGGTGCTGGAGGGGAAGTGGTCCGGATCTTGAAGA
AGCTGCAGGAGGTGCTGGAGGGGAAGTGGTCCGGATCTTGAAGAAGCTGC
AGGAGGTGCTGGAGGGGAAGTGGTCCGGATCTTGAAGAAGCTGCAGGAGG
TGCTGGAGGGGAAGTGGTCCGGATCTTGAAGAAGCTGCAGGAGGTGCTGG
AGGGGAAGTGGTCCGGATCTTGAAGAAGCTGCAGGAGGTGCTGGAGGGGA
AGTGGTCCGGATCTTGAAGAAGCTGCAGGAGGTGCTGGAGGGGAAGTGGT
CCGGATCTTGAAGAAGCTGCAGGAGGTGCTGGAGGGGAAGTGGTCC (SEQ
ID NO:169)

Synthetic: Zinc Finger ZF9 Binding Site

GTAGATGGA (SEQ ID NO:170)

Synthetic: Zinc Finger MK10 Binding Site

CGGCGTAGCCGATGTCGCGC (SEQ ID NO:171)

Synthetic: Zinc Finger 268 Binding Site

AAGGGTTCA (SEQ ID NO:172)

Synthetic: Zinc Finger NRE Binding Site

GCGTGGGCG (SEQ ID NO:173)

Synthetic: Zinc Finger 268/NRE or 268//NRE Binding Site Example 1

AAGGGTTCAGCGTGGGCG (SEQ ID NO:174)

Synthetic: Zinc Finger 268/NRE or 268//NRE Binding Site Example 2

AAGGGTTCAGGCGTGGGCG (SEQ ID NO:175)

Synthetic: Zinc Finger 268/NRE or 268//NRE Binding Site Example 3

AAGGGTTCAGTGCGTGGGCG (SEQ ID NO:176)

Synthetic: FokI Zinc Finger Nuclease 17-2 & 18-2 Binding Site in GFP

GATCCGCCACAACATCGAGGACGGCA (SEQ ID NO:177)

Human codon optimized *Streptococcus pyogenes* Cas9 (spCas9) NLS

ATGGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG
 CTGGGCCGTGATCACCGACGAGTACAAGGTGCCAGCAAGAAATTCAAGGT
 GCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCC
 TGCTGTTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACC
 GCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAG
 ATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTG
 GAAGAGTCCTTCTGGTGGAAAGAGGATAAGAAGCACGAGCGGCACCCCAT
 CTTCCGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCAACCAT
 CTACCACCTGAGAAAGAACTGGTGGACAGCACCGACAAGGCCGACCTGC
 GGCTGATCTATCTGGCCCTGGCCACATGATCAAGTTCCGGGGCCACTTCC
 TGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTT
 ATCCAGCTGGTGCAGACCTACAACCAGCTGTTTCGAGGAAAACCCCATCAAC
 GCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAG
 CAGACGGCTGGAAAATCTGATCGCCAGCTGCCCGGCGAGAAGAAGAATG
 GCCTGTTTCGAAACCTGATTGCCCTGAGCCTGGGCCTGACCCCAACTTCA
 AGAGCAACTTCGACCTGGCCGAGGATGCCAACTGCAGCTGAGCAAGGAC
 ACCTACGACGACGACCTGGACAACCTGCTGGCCAGATCGGCGACCAAGTA
 CGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAG
 CGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCTGAGCGCCT
 CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCTGCTGAAAG
 CTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACC
 AGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAA
 GAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAG
 GAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGAC
 CTTTCGACAACGGCAGCATCCCCACCAGATCCACCTGGGAGAGCTGCACG
 CCATTCTGCGGCGGCAGGAAGATTTTACCCATTCTGAAGGACAACCGGG
 AAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTC
 TGGCCAGGGGAAACAGCAGATTTCGCTGGATGACCAGAAAGAGCGAGGAA
 ACCATCACCCCTGGAACCTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC
 CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGA
 GAAGGTGCTGCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAA
 CGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTT
 CCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCA
 ACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCG
 AGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCT
 CCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCC

TGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGA
CACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCC
ACCTGTTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACC
GGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGC
5 AGTCCGGCAAGACAATCCTGGATTTCTGAAGTCCGACGGCTTCGCCAACA
GAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACA
TCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATT
GCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGT
GAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCGCGCACAAGCCCCGAGA
10 ACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAG
AAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGGCATCAAAGAGCT
GGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGA
ACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGG
ACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCG
15 TGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCA
GAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTC
GTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATT
ACCCAGAGAAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAG
CGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGC
20 AGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGT
ACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCTGAAGT
CCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCG
AGATCAACAACTACCACCACGCCCCACGACGCCTACCTGAACGCCGTCGTGG
GAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACG
25 GCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAG
GAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAAT
TTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTC
TGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGG
GATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCAAGTGAATATCGTG
30 AAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCC
AAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAA
GAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGG
TGGCCAAAGTGGAAGGGCAAGTCCAAGAACTGAAGAGTGTGAAAGAGC
TGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCG
35 ACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCA
AGCTGCCTAAGTACTCCCTGTTTCGAGCTGGAAAACGGCCGGAAGAGAATGC
TGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCC
AAATATGTGAACTTCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGC
TCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCAC
40 TACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATC
CTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGG
GATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTG
ACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGAC
CGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCA
45 CCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGG
GAGGCGACGGATCCCCCAAGAAGAAGAGGAAAGTCTCGAGCGACTACAAA

GACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATG
ACAAGGCTGCAGGATGA (SEQ ID NO:178)

Human codon optimized *Streptococcus pyogenes* Cas9 (spCas9) Bipartite (BP) NLS

5 ATGGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGG
CTGGGCCGTGATCACCGACGAGTACAAGGTGCCAGCAAGAAATTCAAGGT
GCTGGGCAACACCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCC
10 TGCTGTTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACC
GCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAG
ATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTG
GAAGAGTCCTTCTGCTGGTGAAGAGGATAAGAAGCACGAGCGGCACCCCAT
CTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCACCAT
CTACCACCTGAGAAAGAACTGGTGGACAGCACCGACAAGGCCGACCTGC
15 GGCTGATCTATCTGGCCCTGGCCACATGATCAAGTTCCGGGGCCACTTCC
TGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTT
ATCCAGCTGGTGCAGACCTACAACCAGCTGTTTCGAGGAAAACCCCATCAAC
GCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAG
CAGACGGCTGGAAAATCTGATCGCCAGCTGCCCGGCGAGAAGAAGAATG
20 GCCTGTTTCGGAACCTGATTGCCCTGAGCCTGGGCCTGACCCCAACTTCA
AGAGCAACTTCGACCTGGCCGAGGATGCCAACTGCAGCTGAGCAAGGAC
ACCTACGACGACGACCTGGACAACCTGCTGGCCAGATCGGCGACCAAGTA
CGCCGACCTGTTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAG
CGACATCCTGAGAGTGAACACCGAGATCACCAAGGCCCCCTGAGCGCCT
25 CTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAG
CTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACC
AGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAA
GAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAG
GAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGAC
30 CTTGACAACGGCAGCATCCCCACCAGATCCACCTGGGAGAGCTGCACG
CCATTCTGCGGCGGCAGGAAGATTTTACCCATTCTGAAGGACAACCGGG
AAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTC
TGGCCAGGGGAAACAGCAGATTTCGCTGGATGACCAGAAAGAGCGAGGAA
ACCATCACCCCTGGAACCTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGC
35 CCAGAGCTTCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGA
GAAGGTGCTGCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAA
CGAGCTGACCAAAGTGAATACGTGACCGAGGGAATGAGAAAGCCCGCCTT
CCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCA
ACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCG
40 AGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAAGATCGGTTCAACGCCT
CCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCC
TGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGA
CACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCC
ACCTGTTTCGACGACAAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACC
45 GGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGC
AGTCCGGCAAGACAATCCTGGATTTCTGAAGTCCGACGGCTTCGCCAACA

GAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACA
TCCAGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATT
GCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGT
5 GAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCGGCGACAAGCCCGAGA
ACATCGTGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAG
AAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGGCATCAAAGAGCT
GGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGA
ACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGG
10 ACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCG
TGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCA
GAAGCGACAAGAACCAGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTC
GTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATT
ACCCAGAGAAAAGTTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAG
CGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGC
15 AGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGT
ACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCTGAAGT
CCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCG
AGATCAACAACCTACCACCACGCCCCACGACGCCTACCTGAACGCCGTCTGTGG
GAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACG
20 GCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAG
GAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACT
TTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTC
TGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGG
GATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCAAGTGAATATCGTG
25 AAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCC
AAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAA
GAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGG
TGGCCAAAGTGGAAGGGCAAGTCCAAGAACTGAAGAGTGTGAAAGAGC
TGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCG
30 ACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCA
AGCTGCCTAAGTACTCCCTGTTTCGAGCTGGAAAACGGCCGGAAGAGAATGC
TGGCCTCTGCCGGCGAACTGCAGAAAGGGAAACGAACTGGCCCTGCCCTCC
AAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGC
TCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAAGCAC
35 TACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATC
CTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGG
GATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTG
ACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGAC
CGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCA
40 CCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGG
GAGGCGACGGATCCGGCGGAGGCGGAAGCGGGAAAAGAACCGCCGACGG
CAGCGAATTCGAGCCCAAGAAGAAGAGGAAAGTCTCGAGCGGAGGCGACT
ACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGA
CGATGACAAGTGA (SEQ ID NO:179)

45

Human codon optimized *Streptococcus pyogenes* Cas9 (spCas9) BE4

ATGAAACGGACAGCCGACGGAAGCGAGTTCGAGTCACCAAAGAAGAAGCG
 GAAAGTCTCCTCAGAGACTGGGCCTGTCGCCGTCGATCCAACCCTGCGCC
 GCCGGATTGAACCTCACGAGTTTGAAGTGTTCTTTGACCCCCGGGAGCTGA
 5 GAAAGGAGACATGCCTGCTGTACGAGATCAACTGGGGAGGCAGGCACTCC
 ATCTGGAGGCACACCTCTCAGAACACAAATAAGCACGTGGAGGTGAACTTC
 ATCGAGAAGTTTACCACAGAGCGGTACTTCTGCCCAATAACCAGATGTAGC
 ATCACATGGTTTCTGAGCTGGTCCCCTTGCGGAGAGTGTAGCAGGGCCATC
 ACCGAGTTCCTGTCCAGATATCCACACGTGACACTGTTTATCTACATCGCCA
 10 GGCTGTATCACCACGCAGACCCAAGGAATAGGCAGGGCCTGCGCGATCTG
 ATCAGCTCCGGCGTGACCATCCAGATCATGACAGAGCAGGAGTCCGGCTA
 CTGCTGGCGGAACCTTCGTGAATTATTCTCCTAGCAACGAGGCCCACTGGCC
 TAGGTACCCACACCTGTGGGTGCGCCTGTACGTGCTGGAGCTGTATTGCAT
 CATCCTGGGCCTGCCCCCTTGTCTGAATATCCTGCGGAGAAAGCAGCCCCA
 15 GCTGACCTTCTTTACAATCGCCCTGCAGTCTTGTCACTATCAGAGGCTGCCA
 CCCCACATCCTGTGGGCCACAGGCCTGAAGTCTGGAGGATCTAGCGGAGG
 ATCCTCTGGCAGCGAGACACCAGGAACAAGCGAGTCAGCAACACCAGAGA
 GCAGTGGCGGCAGCAGCGGCGGCAGCGACAAGAAGTACAGCATCGGCCT
 GGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTACA
 20 AGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGC
 ATCAAGAAGAACCTGATCGGAGCCCTGCTGTTTCGACAGCGGCGAAACAGC
 CGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGA
 AGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGG
 TGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGG
 25 ATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTG
 GCCTACCACGAGAAGTACCCACCATCTACCACCTGAGAAAGAACTGGTG
 GACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCA
 CATGATCAAGTTCCGGGGGCCACTTCTGATCGAGGGCGACCTGAACCCCG
 ACAACAGCGACGTGGACAAGCTGTTTCATCCAGCTGGTGCAGACCTACAACC
 30 AGCTGTTTCGAGGAAAACCCCATCAACGCCAGCGGCGTGACGCCAAGGCC
 ATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAATCTGATCGCC
 CAGCTGCCCCGGCGAGAAGAAGAATGGCCTGTTTCGGAACCTGATTGCCCT
 GAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGG
 ATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAAC
 35 CTGCTGGCCCAGATCGGCGACCACTACGCCGACCTGTTTCTGGCCGCCAA
 GAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGA
 GATACCAAGGCCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCA
 CCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTG
 AGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCT
 40 ACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCA
 TCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGA
 GAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCA
 CCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGGCGGCAGGAAGATT
 TTTACCCATTCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCT
 45 TCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTC
 GCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACCTCGA

GGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGA
CCAACCTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCC
TGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGT
GACCGAGGGAATGAGAAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGG
5 CCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAAGTGACCGTGAAGCAGC
TGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTC
CGGCGTGGAAAGATCGGTTCAACGCCTCCCTGGGCACATAACCACGATCTGCT
GAAAATTATCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACAT
TCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGAT
10 CGAGGAACGGCTGAAAACCTATGCCACCTGTTTCGACGACAAAAGTGATGAA
GCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAG
CTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTC
CTGAAGTCCGACGGCTTCGCCAACAGAACTTCATGCAGCTGATCCACGAC
GACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGGCCA
15 GGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCA
TTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAA
GTGATGGGCCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGA
GAACCAGACCACCCAGAAGGGACAGAAGAAGACGCCGCGAGAGAATGAAGC
GGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACAC
20 CCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTG
CAGAATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCT
GTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTTTCTGAAGGACGA
CTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCAGGGGCAAGA
GCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAATACTGG
25 CGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTTCGACAATCTG
ACCAAGGCCGAGAGAGGGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCAT
CAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGA
TCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGACAAGCTGATCC
GGGAAGTGAAAGTGATCACCTGAAGTCCAAGCTGGTGTCCGATTTCCGGA
30 AGGATTTCCAGTTTTTACAAAGTGCGCGAGATCAACAATACTACCACCACGCC
ACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACC
CTAAGCTGGAAAGCGAGTTTCGTGTACGGCGACTACAAGGTGTACGACGTGC
GGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAG
TACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGG
35 CCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACC
GGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGT
GCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAG
GCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGA
TCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGC
40 CCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAGGGGCAA
GTCCAAGAACTGAAGAGTGTGAAAGAGCTGCTGGGGATCACCATCATGGA
AAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTA
CAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTC
GAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCA
45 GAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCT
GGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGA

AACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGC
 AGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACA
 AAGTGCTGTCCGCCTACAACAAGCACCAGGATAAGCCCATCAGAGAGCAG
 GCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCC
 5 GCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACC
 AAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTA
 CGAGACACGGATCGACCTGTCTCAGCTGGGAGGTGACAGCGGCGGGAGC
 GGCGGGAGCGGGGGGAGCACTAATCTGAGCGACATCATTGAGAAGGAGAC
 TGGGAAACAGCTGGTCATTTCAGGAGTCCATCCTGATGCTGCCTGAGGAGGT
 10 GGAGGAAGTGATCGGCAACAAGCCAGAGTCTGACATCCTGGTGCACACCG
 CCTACGACGAGTCCACAGATGAGAATGTGATGCTGCTGACCTCTGACGCCC
 CCGAGTATAAGCCTTGGGCCCTGGTCATCCAGGATTCTAACGGCGAGAATA
 AGATCAAGATGCTGAGCGGAGGATCCGGAGGATCTGGAGGCAGCACCAAC
 CTGTCTGACATCATCGAGAAGGAGACAGGCAAGCAGCTGGTCATCCAGGA
 15 GAGCATCCTGATGCTGCCCCGAAGAAGTCGAAGAAGTGATCGGAAACAAGCC
 TGAGAGCGATATCCTGGTCCATACCGCCTACGACGAGAGTACCGACGAAAA
 TGTGATGCTGCTGACATCCGACGCCCCAGAGTATAAGCCCTGGGCTCTGGT
 CATCCAGGATTCCAACGGAGAGAACAATAATCAAAATGCTGTCTGGCGGCTC
 AAAAAGAACCGCCGACGGCAGCGAATTCGAGCCCAAGAAGAAGAGGAAAG
 20 TCTAA (SEQ ID NO:180)

Human codon optimized *Streptococcus pyogenes* Cas9 (spCas9) ABE

ATGAAACGGACAGCCGACGGAAGCGAGTTTCGAGTCACCAAGAAGAAGCG
 GAAAGTCTCTGAAGTCGAGTTTAGCCACGAGTATTGGATGAGGCACGCACT
 25 GACCCTGGCAAAGCGAGCATGGGATGAAAGAGAAGTCCCCGTGGGCGCCG
 TGCTGGTGCACAACAATAGAGTGATCGGAGAGGGATGGAACAGGCCAATC
 GGCCGCCACGACCCTACCGCACACGCAGAGATCATGGCACTGAGGCAGGG
 AGGCCTGGTCATGCAGAATTACCGCCTGATCGATGCCACCCTGTATGTGAC
 ACTGGAGCCATGCGTGATGTGCGCAGGAGCAATGATCCACAGCAGGATCG
 30 GAAGAGTGGTGTTCGGAGCACGGGACGCCAAGACCGGCGCAGCAGGCTC
 CCTGATGGATGTGCTGCACCACCCCGGCATGAACCACCGGGTGGAGATCA
 CAGAGGGAATCCTGGCAGACGAGTGCGCCGCCCTGCTGAGCGATTTCTTTA
 GAATGCGGAGACAGGAGATCAAGGCCCAGAAGAAGGCACAGAGCTCCACC
 GACTCTGGAGGATCTAGCGGAGGATCCTCTGGAAGCGAGACACCAGGCAC
 35 AAGCGAGTCCGCCACACCAGAGAGCTCCGGCGGCTCCTCCGGAGGATCCT
 CTGAGGTGGAGTTTTCCACGAGTACTGGATGAGACATGCCCTGACCCTGG
 CCAAGAGGGCACGCGATGAGAGGGAGGTGCCTGTGGGAGCCGTGCTGGT
 GCTGAACAATAGAGTGATCGGCGAGGGCTGGAACAGAGCCATCGGCCTGC
 ACGACCCAACAGCCCATGCCGAAATTATGGCCCTGAGACAGGGCGGCCTG
 40 GTCATGCAGAACTACAGACTGATTGACGCCACCCTGTACGTGACATTGAG
 CCTTGCGTGATGTGCGCCGGCGCCATGATCCACTCTAGGATCGGCCGCGT
 GGTGTTTGGCGTGAGGAACGCAAAAACCGGCGCCGCAAGGCTCCCTGATGG
 ACGTGCTGCACTACCCCGGCATGAATCACCGCGTCGAAATTACCGAGGGAA
 TCCTGGCAGATGAATGTGCCGCCCTGCTGTGCTATTTCTTTTCGGATGCCTA
 45 GACAGGTGTTCAATGCTCAGAAGAAGGCCCAGAGCTCCACCGACTCCGGA
 GGATCTAGCGGAGGCTCCTCTGGCTCTGAGACACCTGGCACAAGCGAGAG

CGCAACACCTGAAAGCAGCGGGGGCAGCAGCGGGGGGTCAGACAAGAAG
TACAGCATCGGCCTGGCCATCGGCACCAACTCTGTGGGCTGGGCCGTGAT
CACCGACGAGTACAAGGTGCCAGCAAGAAATTCAAGGTGCTGGGCAACA
CCGACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTTCGAC
5 AGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAA
GATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCA
ACGAGATGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCT
TCCTGGTGGAAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAAC
ATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCACCATCTACCACCTG
10 AGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTA
TCTGGCCCTGGCCACATGATCAAGTTCGGGGGCCACTTCCTGATCGAGGG
CGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTTCATCCAGCTGGT
GCAGACCTACAACCAGCTGTTTCGAGGAAAACCCCATCAACGCCAGCGGCG
TGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTG
15 GAAAATCTGATCGCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTTCGG
AAACCTGATTGCCCTGAGCCTGGGCCTGACCCCAACTTCAAGAGCAACTT
CGACCTGGCCGAGGATGCCAACTGCAGCTGAGCAAGGACACCTACGACG
ACGACCTGGACAACCTGCTGGCCAGATCGGCGACCACTACGCCGACCTG
TTTCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTG
20 AGAGTGAACACCGAGATCACCAAGGCCCCCTGAGCGCCTCTATGATCAAG
AGATACGACGAGCACCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCG
GCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA
CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACA
AGTTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCG
25 TGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAAC
GGCAGCATCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCG
GCGGCAGGAAGATTTTTACCCATTCTGAAGGACAACCGGGAAAAGATCGA
GAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGG
GAAACAGCAGATTTCGCTGGATGACCAGAAAGAGCGAGGAAACCATCACCC
30 CCTGGAACCTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCAGAGCTTC
ATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTG
CCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACC
AAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGG
CGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGT
35 GACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGA
CTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCA
CATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGA
GGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGA
GGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCACCTGTTTGA
40 CGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCA
GGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAAG
ACAATCCTGGATTTCTGAAGTCCGACGGCTTCGCCAACAGAACTTCATG
CAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCC
CAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGC
45 CGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGG
ACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATC

GAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCG
 CGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGA
 TCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGT
 ACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGGAAGTGG
 5 ACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCT
 TTCTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGA
 ACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGTTCGTGAAGAAGATG
 AAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCCAGAGAAAAG
 TTCGACAATCTGACCAAGGCCGAGAGAGGGCGGCCTGAGCGAACTGGATAA
 10 GGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGC
 ACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATG
 ACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGT
 CCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTA
 CCACCACGCCCACGACGCCTACCTGAACGCCGTTCGTGGGAACCGCCCTGA
 15 TCAAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGG
 TGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAG
 GCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCG
 AGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACA
 AACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCAC
 20 CGTGCGGAAAGTGCTGAGCATGCCCAAGTGAATATCGTGAAAAAGACCGA
 GGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACA
 GCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGC
 GGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGCCAAAGT
 GGAAAAGGGCAAGTCCAAGAACTGAAGAGTGTGAAAGAGCTGCTGGGGA
 25 TCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGG
 AAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTA
 AGTACTCCCTGTTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTG
 CCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTG
 AACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAG
 30 GATAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAAGCACTACCTGGAC
 GAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGAC
 GCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCCGGGATAAGCCC
 ATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTG
 GGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAG
 35 GTACACCAGCACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCA
 TCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAGCTGGGAGGTGAC
 TCTGGCGGCTCAAAAAGAACCGCCGACGGCAGCGAATTCGAGCCCAAGAA
 GAAGAGGAAAGTCTAA (SEQ ID NO:181)

Human codon optimized VSVG

ATGAAATGTCTGCTGTACCTGGCTTTCCTGTTTCATCGGCGTGAAGTGAAGT
 TCACCATCGTGTTCCTCACAACCAGAAGGGCAACTGGAAAAATGTGCCTA
 GCAACTACCACTACTGTCTAGCTCTAGCGACCTTAATTGGCATAACGACCT
 GATCGGCACAGCCCTGCAGGTGAAGATGCCTAAGAGCCACAAGGCCATCC
 45 AGGCCGACGGATGGATGTGCCACGCCAGCAAGTGGGTACAACTGTGAC
 TTCAGATGGTACGGCCCTAAATACATTACCCACTCTATCAGAAGCTTCACCC

CTTCTGTGGAACAATGTAAAGAGTCCATTGAGCAGACAAAGCAGGGCACCT
 GGCTGAACCCCGGCTTCCCCCCCCAGAGCTGCGGCTACGCCACCGTTACC
 GATGCCGAGGGCGTGATCGTGACAGGTGACACCTCACCACGTGCTGGTCGA
 TGAGTACACCGGCGAATGGGTGGACAGCCAATTTATCAACGGCAAATGCAG
 5 CAATTACATCTGCCCCACCGTGCACAACAGCACCACTGGCACAGCGATTA
 CAAGGTGAAAGGCCTGTGCGACAGCAACCTGATCTCTATGGACATCACCTT
 CTTCAGCGAGGACGGCGAGCTGTCTAGTCTGGGCAAGGAAGGCACAGGTT
 TTCGGAGCAACTACTTCGCCTACGAGACTGGCGGCAAGGCCTGCAAGATG
 CAGTACTGCAAGCACTGGGGCGTTAGACTGCCTTCAGGCGTGTGGTTCGAG
 10 ATGGCCGATAAGGACCTGTTGCGCGCTGCCAGATTCCCAGAGTGCCCTGA
 GGGCAGCTCCATCAGCGCCCCCTTCCCAGACCTCCGTGGATGTGTCCCTGAT
 CCAGGACGTGGAAAGAATCCTGGACTACAGCCTCTGTCAGGAGACATGGTC
 CAAAATCAGAGCCGGACTCCCCATTAGCCCTGTGGACCTGAGCTACCTGGC
 CCCCAGAATCCTGGAACCGGCCCCGCCTTCACAATCATTACGGCACCCCT
 15 GAAATACTTCGAGACCAGATACATCCGGGTGGACATCGCCGCTCCTATCCT
 GTCAAGAATGGTGGGCATGATTTCTGGCACAACAACAGAGAGGGAAGTGTG
 GGACGACTGGGCCCCCTTACGAGGATGTGGAAATCGGCCCAAACGGCGTGC
 TGCGGACCAGCTCAGGCTATAAGTTCCCCCTGTACATGATCGGCCACGGCA
 TGCTGGATTCTGACCTGCACCTGAGCAGCAAGGCCAGGTCTTTGAGCACC
 20 CTCATATCCAAGACGCCGCCAGCCAGCTGCCTGATGACGAGAGCCTGTTTT
 TTGGAGATACAGGACTGAGCAAGAACCCCATCGAGCTGGTGGAAAGGCTGG
 TTTAGCAGCTGGAAGTCCAGCATAGCTAGCTTCTTCTTCATCATCGGCCTGA
 TCATCGGACTGTTCTGCTGAGAGTGGGGATCCACCTGTGCATCAAGC
 TGAAGCACACCAAAAAGAGACAGATCTACACCGACATCGAGATGAACCGGC
 25 TGGGGAAGTGA (SEQ ID NO:182)

Literature Cited

1. Parseval, N. et al. Survey of human genes of retroviral origin: identification and
 30 transcriptome of the genes with coding capacity for complete envelope proteins. *Journal*
of Virology 77, 10414–10422, (2003).
2. Okimoto, T. et al. VSV-G envelope glycoprotein forms complexes with plasmid
 DNA and MLV retrovirus-like particles in cell-free conditions and enhances DNA
 transfection. *Molecular Therapy* 4, 232-238, (2001).
- 35 3. Mangeot, P. et al. Protein transfer into human cells by VSV-G-induced
 nanovesicles. *Molecular Therapy* 19, 1656–1666, (2011).
4. Wagner, D. et al. High prevalence of *Streptococcus pyogenes* Cas9-reactive T
 cells within the adult human population. *Nature Medicine* 25, 242-248 (2019)
5. Kim, S. et al. CRISPR RNAs trigger innate immune responses in human cells.
 40 *Genome Research* 28, 1-7 (2018).

6. Charlesworth, C. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. *Nature Medicine* 25, 249–254 (2019)
7. Ferdosi, S. et al. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. *Nature Communications* 10, Article number: 1842 (2019).
- 5 8. Wang, D. et al. Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. *Human Gene Therapy* 26, 432-442 (2015).
9. Devanabanda, M. et al. Immunotoxic effects of gold and silver nanoparticles: Inhibition of mitogen-induced proliferative responses and viability of human and murine
10 lymphocytes *in vitro*. *Journal of Immunotoxicology* 13, 1547-6901 (2016).
11. Mout, R. et al. Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing. *ACS Nano* 11, 2452-2458 (2017).
12. Yin, H. et al. structure-guided chemical modification of guide RNA enables potent non-viral *in vivo* genome editing. *Nature Biotechnology* 35, 1179-1187 (2017).
- 15 13. Qiao, J. et al. Cytosolic delivery of CRISPR/Cas9 ribonucleoproteins for genome editing using chitosan-coated red fluorescent protein. *Chemical Communications* 55, 4707-4710 (2019).
14. Li, L. et al. A rationally designed semiconducting polymer brush for NIR-II imaging guided light-triggered remote control of CRISPR/Cas9 genome editing.
20 *Advanced Materials* 1901187, 1-9 (2019).
15. Gao, X. et al. Treatment of autosomal dominant hearing loss by *in vivo* delivery of genome editing agents. *Nature* 553, 217-221 (2018)
16. Lee, K. et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA *in vivo* induces homology-directed DNA repair. *Nature Biomedical Engineering* 1, 889–
25 901 (2017).
17. Staahl, B. et al. Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. *Nature Biotechnology* 35, 431-433 (2017).
18. Zuris, J. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing *in vitro* and *in vivo*. *Nature Biotechnology* 33, 73-79
30 (2015).

18. Finn, J. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. *Cell Reports* 22, 2227-2235 (2018).
19. Wang, H. et al. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide. *PNAS* 115, 4903-4908 (2018).
20. Del'Guidice, T. et al. Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells. *PLOS ONE* 13, e0195558 (2018).
21. Colella, P. et al. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. *Molecular Therapy: Methods & Clinical Development* 8, 87-104 (2018).
22. Naso, F. et al. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. *BioDrugs* 31, 317-334 (2017).
23. Handel, E. et al. Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors. *Human Gene Therapy* 23, 321-329 (2012).
24. Chadwick, A. et al. Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3. *Circulation* 137, 975-977 (2018).
25. Schenkwein, D. et al. Production of HIV-1 Integrase Fusion Protein-Carrying Lentiviral Vectors for Gene Therapy and Protein Transduction. *Human Gene Therapy* 21, 589-602 (2010).
26. Cai, Y. et al. Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases. *eLife* 3, e01911 (2014).
27. Choi, J. et al. Lentivirus pre-packed with Cas9 protein for safer gene editing. *Gene Therapy* 23, 627-633 (2016).
28. Meyer, C. et al. Pseudotyping exosomes for enhanced protein delivery in mammalian cells. *International Journal of Nanomedicine* 12, 3153-3170 (2017).
29. Mangeot, P. et al. Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. *Nature Communications* 10, Article number: 45 (2019).

30. Lu, B. et al. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing. *Nucleic Acids Research* 47, e44 (2019).
31. Wang, Q. et al. ARMMs as a versatile platform for intracellular delivery of macromolecules. *Nature Communications* 9, 1-7 (2018).
32. Lainscek, D. et al. Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation. *ACS Synthetic Biology* 7, 2715-2725 (2018).
33. Fuchs, J. et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). *Open Forum Infectious Diseases* 2, 1-9, (2015).
34. Cong, L. et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science* 339, 819–823, (2013).
35. Ran, F. et al. *In vivo* genome editing using *Staphylococcus aureus* Cas9. *Nature* 520, 186-191, (2015).
36. Zetsche, B. et al. Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. *Cell* 163, 759-771, (2015).
37. Komor, A. et al. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 533, 420-424, (2016).
38. Gaudelli, N. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. *Nature* 551, 464-471, (2017).
39. Voelkel, C. et al. Protein transduction from retroviral Gag precursors. *Proc Natl Acad Sci USA* 107, 7805-7810, (2010).
40. Kaczmarczyk, S. et al. Protein delivery using engineered virus-like particles. *Proc Natl Acad Sci USA* 108, 16998–17003, (2011).
41. Ebner, M. et al. PI(3,4,5)P₃ Engagement Restricts Akt Activity to Cellular Membranes. *Mol Cell* 65, 416-431, (2017).
42. Urano, E. et al. Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-d1 pleckstrin homology domain results in infectious pseudovirion production. *J. Gen Virology* 89, 3144–3149, (2008).

43. Pastuzyn, E. et al. The Neuronal Gene Arc Encodes a Repurposed Retrotransposon Gag Protein that Mediates Intercellular RNA Transfer. *Cell* 172, 275-288, (2018).
44. Lukacs, G. et al. Size-dependent DNA Mobility in Cytoplasm and Nucleus. *Journal of Biological Chemistry* 275, 1625-1629, (1999).
45. Kreiss, P. et al. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. *Nucleic Acids Research* 27, 3792–3798 (1999).
46. Nafissi, N. et al. DNA Ministrings: Highly Safe and Effective Gene Delivery Vectors. *Molecular Therapy—Nucleic Acids* 3, e165, (2014).
47. Fujimoto, T. et al. Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. *Cancer Research* 79, 2327-2338 (2019).
48. Tai, S. et al. Differential Expression of Metallothionein 1 and 2 Isoforms in Breast Cancer Lines with Different Invasive Potential: Identification of a Novel Nonsilent Metallothionein-1H Mutant Variant. *American Journal of Pathology* 163, 2009-2019 (2003).
49. Caussinus, E. et al. Fluorescent fusion protein knockout mediated by anti-GFP nanobody. *Nature Structural & Molecular Biology* 19, 117-121, (2012).
50. Zhao, W. et al. Quantitatively Predictable Control of Cellular Protein Levels through Proteasomal Degradation. *ACS Synthetic Biology* 7, 540-552, (2018).
51. Clift, D. et al. A Method for the Acute and Rapid Degradation of Endogenous Proteins. *Cell* 171, 1692-1706, (2017).

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

WHAT IS CLAIMED IS:

1. An enhanced virus-like particle (eVLP), comprising:
a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins, optionally a glycoprotein as shown in Table 1, on the external side; and
a cargo disposed in the core of the eVLP on the inside of the membrane,
wherein the eVLP does not comprise an exogenous gag and/or pol protein.
2. The eVLP of claim 1, wherein the cargo is a therapeutic or diagnostic protein or nucleic acid encoding a therapeutic or diagnostic protein, or a chemical, optionally a small molecule therapeutic or diagnostic.
3. The eVLP of claim 1, wherein the cargo is a gene editing reagent.
4. The eVLP of claim 1, wherein the gene editing reagent comprises a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; a nucleic acid encoding a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; or a ribonucleoprotein complex (RNP) comprising a CRISPR-based genome editing or modulating protein.
5. The eVLP of claim 4, wherein the gene editing reagent is selected from the proteins listed in Tables 2, 3, 4 & 5.
6. The eVLP of claim 4, wherein the gene editing reagent comprises a CRISPR-based genome editing or modulating protein, and the eVLP further comprises one or more guide RNAs that bind to and direct the CRISPR-based genome editing or modulating protein to a target sequence.
7. The eVLP of claims 1-6, wherein the cargo comprises a fusion to a plasma membrane recruitment domain, preferably as shown in Table 6.

8. A method of delivering a cargo to a target cell, optionally a cell *in vivo* or *in vitro*, the method comprising contacting the cell with the eVLP of claims 1-7 comprising the cargo.
9. A method of producing an eVLP comprising a cargo, the method comprising:
providing a cell expressing one or more virally-derived glycoproteins (optionally as shown in Table 1), and a cargo, wherein the cell does not express an exogenous gag and/or pol protein; and
maintaining the cell under conditions such that the cells produce eVLPs.
10. The method of claim 9, further comprising harvesting and optionally purifying and/or concentrating the produced eVLPs.
11. The method of claim 9, wherein the cargo is a therapeutic or diagnostic protein or nucleic acid encoding a therapeutic or diagnostic protein, or a small molecule, optionally a therapeutic or diagnostic small molecule.
12. The method of claim 9, wherein the cargo is a gene editing reagent.
13. The method of claim 9, wherein the gene editing reagent comprises a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; a nucleic acid encoding a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; or a ribonucleoprotein complex (RNP) comprising a CRISPR-based genome editing or modulating protein.
14. The method of claim 13, wherein the gene editing reagent is selected from the proteins listed in Tables 2, 3, 4 & 5.
15. The method of claim 13, wherein the gene editing reagent comprises a CRISPR-based genome editing or modulating protein, and the eVLP further comprises one or more guide RNAs that bind to and direct the CRISPR-based genome editing or modulating protein to a target sequence.

16. The method of claim 9-15, wherein the cargo comprises a fusion to a plasma membrane recruitment domain, preferably as shown in Table 6.
17. A cell expressing one or more virally-derived glycoproteins (optionally as shown in Table 1), and a cargo, wherein the cell does not express an exogenous gag protein.
18. The cell of claim 17, wherein the cargo is a therapeutic or diagnostic protein or nucleic acid encoding a therapeutic or diagnostic protein, or a small molecule, optionally a therapeutic or diagnostic small molecule.
19. The cell of claim 17, wherein the cargo is a gene editing reagent.
20. The cell of claim 17, wherein the gene editing reagent comprises a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; a nucleic acid encoding a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; or a ribonucleoprotein complex (RNP) comprising a CRISPR-based genome editing or modulating protein.
21. The cell of claim 20, wherein the gene editing reagent is selected from the proteins listed in Tables 2, 3, 4 & 5.
22. The cell of claim 20, wherein the gene editing reagent comprises a CRISPR-based genome editing or modulating protein, and the eVLP further comprises one or more guide RNAs that bind to and direct the CRISPR-based genome editing or modulating protein to a target sequence.
23. The cells of claims 17-22, wherein the cargo comprises a fusion to a plasma membrane recruitment domain, preferably as shown in Table 6.
24. The cells of claims 17-23, wherein the cells are primary or stable human cell lines.
25. The cells of claim 24, which are Human Embryonic Kidney (HEK) 293 cells or HEK293 T cells.




FIG. 1




FIG. 2




FIG. 3





FIG. 4






FIG. 6




FIG. 7




FIG. 8

HEK site #3




FIG. 9

VEGF site #3




FIG. 10

HEK site #3




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40